WO2003041715A1 - Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer - Google Patents

Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer

Info

Publication number
WO2003041715A1
WO2003041715A1 PCT/US2002/036208 US0236208W WO03041715A1 WO 2003041715 A1 WO2003041715 A1 WO 2003041715A1 US 0236208 W US0236208 W US 0236208W WO 03041715 A1 WO03041715 A1 WO 03041715A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
chloro
alkyl
diazepin
benzo
Prior art date
Application number
PCT/US2002/036208
Other languages
French (fr)
Inventor
Tianbao Lu
Louis V. Lafrance, Iii
Daniel J. Parks
Karen L. Milkiewicz
Raul R. Calvo
Maxwell David Cummings
Alexander J. Kim
Bruce L. Grasberger
Theodore E. Carver, Jr.
Original Assignee
3-Dimensional Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2003543602A priority Critical patent/JP4497921B2/en
Priority to SI200230733T priority patent/SI1443937T1/en
Application filed by 3-Dimensional Pharmaceuticals, Inc. filed Critical 3-Dimensional Pharmaceuticals, Inc.
Priority to EP02778828A priority patent/EP1443937B1/en
Priority to DE60227185T priority patent/DE60227185D1/en
Priority to IL16169202A priority patent/IL161692A0/en
Priority to UA20040604569A priority patent/UA76798C2/en
Priority to DK02778828T priority patent/DK1443937T3/en
Priority to HU0402003A priority patent/HUP0402003A3/en
Priority to AU2002340464A priority patent/AU2002340464B2/en
Priority to NZ532463A priority patent/NZ532463A/en
Priority to CA002466055A priority patent/CA2466055A1/en
Priority to BR0214048-9A priority patent/BR0214048A/en
Priority to MXPA04004500A priority patent/MXPA04004500A/en
Publication of WO2003041715A1 publication Critical patent/WO2003041715A1/en
Priority to HR20040415A priority patent/HRP20040415A2/en
Priority to NO20042146A priority patent/NO20042146L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention is in the area of novel 1,4-benzodiazepines and salts thereof, their syntheses, and their use as inhibitors of MDM2 and HDM2 oncoproteins.
  • This invention relates to compounds that bind to the human protein HDM2 and interfere with its interaction with other proteins, especially the tumor suppressor protein p53.
  • HDM2 is the expression product of hdm2, an oncogene that is overexpressed in a variety of cancers, especially soft tissue sarcomas (Momand, J., et al, Nucl. Acids Res. 26:3453-3459 (1998)).
  • p53 is a transcription factor that plays a pivotal role in the regulation of the balance between cell proliferation and cell growth arrest/apoptosis. Under normal conditions, the half-life of p53 is very short, and consequently the level of p53 in cells is low.
  • p53 In response to cellular DNA damage, cellular stress, or other factors, levels of p53 increase. This increase in p53 levels in turn increases the transcription of a number of genes which induces the cell to either arrest growth or undergo apoptosis (i.e., controlled cell death). The function of p53 is to prevent the uncontrolled proliferation of cells and thus protect the organism from the development of cancer (for a review, see Levine, A.J., Cell SS:323-331 (1997)).
  • p53 is a latent and short-lived transcription factor which is induced by, and is an integration point for, a range of cellular stresses including DNA damage, UN damage, spindle damage, hypoxia, inflammatory cytokines, viral infection, activated oncogenes, and ribonucleotide depletion.
  • Activation of p53 mediates a change in the balance of gene expression such that expression of many genes involved in proliferation is repressed while a range of genes involved in growth arrest (such as p21WAFl and GADD45), repair (such as p53RE) and apoptosis (such as Bax, Killer/DR5 and PIGs) is activated.
  • p53 activation is dependent on several factors including the type and strength of the inducing stress, and the type of cell or tissue.
  • p53 and MDM2 exist in a negative regulatory feedback loop in which p53 stimulates transcription of the mdm2 gene while MDM2 binds to p53 and targets it for degradation by the 26S proteosome.
  • the key element in the p53 induction process is disruption of the p53-MDM2 complex which permits p53 to accumulate in the nucleus. This mechanism appears to be common to all of the pathways by which p53 becomes activated, although recent evidence has indicated that there is considerable variation in the molecular events by which this is actually achieved.
  • Inactivation of the p53 tumor suppressor is a frequent event in human neoplasia.
  • the inactivation can occur by mutation of the p53 gene or through binding to viral or cellular oncogene proteins, such as the SN40 large T antigen and MDM2. While the mechanism through which wild-type p53 suppresses tumor cell growth is as yet poorly defined, it is clear that one key feature of the growth suppression is the property of p53 to act as a transcription factor (Farmer, G., et al, Nature 358: 83-86 (1992); Funk, W. D. et al, Mol. Cell. Biol. 12: 2866- 2871 (1992); Kern, S. E., et al, Science 256:827-830 (1992)).
  • GADD 45 Kelman, M. B., et al, Cell 77:587- 597(1992)
  • WAF1 or CTP1 El-Beiry, W. S., et al, Cell 75:817-825 (1993); Harper, J. W., et al, Cell 75:805-816 (1993)
  • mdm2 a known oncogene, was originally found on mouse double minute chromosomes (Cahilly-Snyder., L., et al, Somatic Cell Mol Genet. 73:235-244 (1987)).
  • Reporter constructs employing this p53 DNA binding site revealed that they were inactivated when wild-type p53 was co-expressed with MDM2.
  • This inhibition of the transcriptional activity of p53 may be caused by MDM2 blocking the activation domain of p53 and/or the DNA binding site. Consequently, it was proposed that mdm2 expression is autoregulated, via the inhibitory effect of MDM2 protein on the transcriptional activity of wild-type p53.
  • This p53-mdm2 autoregulatory feedback loop provided a novel insight as to how cell growth might be regulated by p53.
  • p53 is a transcription factor for a number of proteins that cause cell cycle arrest or cell death by apoptosis. The level and transcriptional activity of p53 are increased by damage to cellular DNA.
  • the MDM2 protein inhibits p53 function by binding to an amphipathic N-terminal helix of p53, abrogating the interaction of p53 with other proteins and its transactivation activity. The interaction with MDM2 also targets p53 for ubiquitin dependent protein degradation.
  • MDM2 exhibits p53 independent effects on cell cycling as well, possibly by direct interaction with some of the downstream effectors such as pRB and EF2 (Reviewed in Zhang, R. and Wang, H., Cur. Pharm. Des. 6:393- 416 (2000)).
  • Blocking HDM2 from binding p53 would be therapeutically useful in restoring cell cycle control to cells that overexpress HDM2 as a front line cancer treatment. More generally, inhibition of HDM2 may increase the effectiveness of chemotherapy and radiation in p53 normal cancers by enhancing apoptosis and growth arrest signaling pathways.
  • a first aspect of the present invention is directed to novel compounds of Formula /.
  • a second aspect of the present invention is directed to pharmaceutical compositions comprising at least one compound of Formula I, or a salt thereof, and one or more pharmaceutically acceptable excipients.
  • a third aspect of the present invention is directed to a method of inhibiting the binding of a protein encoded by hdm2 to p53 protein, comprising contacting p53 or one or more proteins encoded by mdm2, with one or more compounds of Formula /.
  • a fourth aspect of the invention is directed to a method of inducing apoptosis, comprising contacting an animal with a composition comprising a pharmaceutically effective amount of at least one compound of Formula /, or a salt thereof, and one or more pharmaceutically-acceptable excipients.
  • a fifth aspect of the present invention is directed to a method of treating cancer. The method comprises contacting an animal with (a) a pharmaceutically effective amount of an antineoplastic agent and (b) a pharmaceutically effective amount of at least one compound of Formula /, or a salt thereof, and one or more pharmaceutically-acceptable excipients.
  • a sixth aspect of the present invention is directed to a method of treating cancer, comprising contacting an animal with a composition comprising (a) a pharmaceutically effective amount of at least one compound of Formula /, or a salt thereof, (b) one or more agents that induce or cause DNA damage, and (c) one or more pharmaceutically-acceptable excipients.
  • a seventh aspect of the present invention is directed to a method of synthesizing compounds of Formula 1.
  • Compounds of the present invention include compounds of Formula I:
  • X and Y are independently -C(O)-, -CH 2 - or -C(S)-;
  • R 1 , R 2 , R 3 , and R 4 are independently hydrogen, halo, alkyl, alkenyl, alkynyl, cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, alkoxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, cyano, amino, alkanoylamino, nitro, hydroxy, carboxy, or alkoxycarbonyl; or R 1 and R 2 , or R 2 and R 3 , or R 3 and R 4 are taken together to form
  • R 5 is hydrogen, alkyl, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl or alkylaminocarbonylalkyl;
  • R 6 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted;
  • R 7 and R 8 are independently hydrogen or alkyl;
  • R 9 is cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle,
  • R b is hydrogen, alkyl, optionally substituted cycloalkyl, or optionally substituted, saturated or partially unsaturated heterocycle;
  • M is a cation
  • R c and R d are independently hydrogen, alkyl, hydroxyalkyl, carboxyalkyl, aminoalkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, and an optionally substituted, saturated or partially unsaturated heterocycle; and n is 0-8, m is 0-8, i is 1-8 and j is 0-8.
  • Preferred compounds include compounds of Formula I, or salts thereof, wherein:
  • R 1 , R 2 , R 3 , and R 4 are independently hydrogen, halo, alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, C 3 - cycloalkyl, optionally substituted Ce- t o aryl, optionally substituted C 6 .; ⁇ o ar(C 1 - 6 )alkyl, optionally substituted heteroaryl, optionally substituted heteroar(C 1 - 6 )alkyl, C ⁇ . ⁇ alkoxy, optionally substituted C 6 -; ⁇ o aryloxy, optionally substituted heteroaryloxy, cyano, amino, alkanoylamino, nitro, hydroxy, carboxy, or - ⁇ alkoxycarbonyl; or R 1 and R 2 , or R 2 and R 3 , or R 3 and R 4 are taken together to form
  • R 5 is hydrogen, C ⁇ _ 6 ⁇ alkyl, C 3 . 7 cycloalkyl, optionally substituted C 6 - 10 aryl, optionally substituted heteroaryl, optionally substituted C ⁇ -io ar(C ! - 6 )alkyl, optionally substituted heteroar(C 1 .
  • R 6 is C 3 - 7 cycloalkyl, C 6 -io aryl, heteroaryl, a saturated or partially unsaturated heterocycle, C 3 - 7 cycloalkyl(Ci. 6 )alkyl, C 6 - ⁇ ) ar(C 1 .
  • R 7 is hydrogen or Q- 6 alkyl
  • R 8 is hydrogen or Q- 6 alkyl
  • R 9 is C 3 - cycloalkyl, a saturated or partially unsaturated heterocycle, C 6 .io aryl, heteroaryl, C 3 - cycloalkyl(C 1 - 6 )alkyl, C 6 - ! o ar(C 1 . 6 )alkyl or heteroaryl(Q.
  • R 10 is -(CH 2 ) n — CO 2 R , -(CH 2 ) m — CO 2 M, -(CH 2 )i-OH or -(CH 2 ) j — CONR c R d , where
  • R b is hydrogen, Q. 6 alkyl, optionally substituted C 3 - 7 cycloalkyl, or an optionally substituted, saturated or partially unsaturated heterocycle; M is a cation; R c and R d are independently hydrogen, Q- 6 alkyl, Q- 6 hydroxyalkyl, Q- 6 carboxyalkyl, aminoalkyl, optionally substituted C 3 - 7 cycloalkyl, optionally substituted C 6 - ⁇ o aryl, optionally substituted C 6 - 10 ar(C 1 - 6 )alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl(C 1 - 6 )alkyl, or an optionally substituted, saturated or partially unsaturated heterocycle; and n is 0-4, m is 0-4, i is 1-4 and j is 0-4. In one preferred embodiment: R 1 and R 4 are both hydrogen;
  • R 2 is hydrogen, halo, Q- 6 alkyl, Q- 6 hydroxyalkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, C 3 - 7 cycloalkyl, acetylamino, cyano, amino, Q- 6 alkoxy, phenyl, thienyl, furanyl, and pyrrolyl, wherein said phenyl, thienyl and furanyl are optionally substituted by one or more substituents independently selected from the group consisting of halo, Q. 4 alkoxy, Q- 4 alkyl, amino, methylenedioxy, and ethylenedioxy;
  • R 5 is hydrogen; Q- 6 alkyl; Q- 6 hydroxyalkyl; carboxy(Q- 6 )alkyl; Q- 6 alkylcarbamoyl(Q. 6 )alkyl; Q- 6 alkoxycarbonylamino(C 1 - 6 )alkyl; C 3 - 7 cycloalkyl(C 1 - 6 )alkyl; C 6 - 10 aryl, optionally substituted by Q- 4 alkyl or halo;
  • R 6 is C 6 - ⁇ o aryl, thienyl, benzothienyl, furanyl, benzofuranyl, indolyl, pyridyl, quinolinyl, C 3 - 7 cycloalkenyl or cubanyl, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halo, Q- alkyl, C 2 - alkenyl, Q- 4 alkoxy, halo(Q.
  • R 7 is hydrogen or Q- 6 alkyl
  • R 8 is hydrogen or Q- 6 alkyl
  • R 9 is C 3 . 7 cycloalkyl, C 6 . ⁇ o aryl, heteroaryl, C 3 . 7 cycloalkyl(C 1 - 6 )alkyl,
  • R 10 is -(CH 2 ) n — CO 2 R b or -(CH 2 ) m — CO 2 M, where R b is hydrogen, Q- 6 alkyl, optionally substituted C 3 - cycloalkyl, or optionally substituted heterocycloalkyl, M is a cation n and m are independently 0, 1, 2, 3 or 4; or
  • R 10 is-(CH 2 )i-OH or -(CH 2 ) j — CONR c R d , where R c and R d are independently hydrogen, hydroxy, C 3 . cycloalkyl, Q. 6 alkyl, Q- 6 hydroxyalkyl, Q- 6 carboxyalkyl, Q- 6 aminoalkyl, optionally substituted phenyl, or optionally substituted benzyl; and i is 1, 2, 3, or 4, andj is 0, 1, 2, 3 or 4.
  • Preferred compounds include those wherein R 1 is hydrogen.
  • R 4 is hydrogen.
  • Useful values of R include hydrogen, halo, Q. 4 alkyl, C 3 - 7 cycloalkyl, C2- 6 alkenyl, C 2 . 6 alkynyl, acetylamino, Q- 6 alkoxy, phenyl, halophenyl, hydroxyphenyl, Q- 6 alkoxyphenyl, Q- 6 alkylphenyl, aminophenyl, Q- 6 alkylenedioxyphenyl, hydroxycarbonylphenyl, thienyl, Q- 6 alkylthienyl, furanyl, pyrrolyl, amino, Q- 6 hydroxyalkyl and cyano.
  • Useful values of R also include hydrogen, iodo, fluoro, chloro, bromo, methyl, ethyl, propyl, isopropyl, t-butyl, sec-butyl, cyclopropyl, ethynyl, acetylamino, methoxy, phenyl, 3-chlorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 3-methoxyphenyl, 4-methylphenyl, 3-methylphenyl,
  • More preferred compounds include those wherein R 2 is iodo.
  • R 3 Useful values of R 3 include hydrogen, phenyl, fluoro, chloro, iodo and methyl. Preferred compounds are those wherein R 3 is hydrogen.
  • R 5 Useful values of R 5 include hydrogen, Q- 6 alkyl, Q- 6 hydroxyalkyl, carboxy (Q. 6 )alkyl, Q-e alkylphenyl, Q. 6 alkylbenzyl, phenethyl, phenyl(C 1 - 6 )alkyl, naphthyl(Q. 6 )alkyl, C 3 - 7 cycloalkyl(Q. 6 )alkyl, pyridyl(C 1 - 6 )alkyl, Ci-6 alkoxycarbonylamino(C 1 - 6 )alkyl, and Q. 6 alkylcarbamoyl(C 1 . 6 )alkyl.
  • R 5 also include hydrogen, methyl, carboxymethyl, 3-methylbutyl, 2-methylpropyl, isopropyl, 2-methylphenyl, 3-methylphenyl,
  • Preferred compounds include those wherein R 5 is hydrogen.
  • Useful values of R 6 include optionally substituted C 6 - ! o aryl.
  • Useful values of R 6 also include trifluoromethylphenyl, halophenyl, Q. 6 alkylphenyl, Q- 6 alkoxyphenyl, halo(Q-4)alkoxyphenyl, naphthyl, benzyloxyphenyl, phenoxyphenyl, dihydrobenzodioxinyl, trifluoromethyl- halophenyl, pyridyl, thienyl, Q- 6 alkylthienyl, halothienyl, bithienyl, Q- 6 alkylbenzothienyl, (halophenyl)furanyl, quinolinyl, biphenyl, indolyl, (trifluoromethylsulfanyl)phenyl, (trifluoromethylphenyl)furanyl,
  • R 6 Useful values of R 6 also include 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-chlorophenyl,
  • 4-trifluoromethoxyphenyl 4-isopropylphenyl, phenyl, 4-methoxy-phenyl, naphthalen-2-yl, 4-tert-butylphenyl, 4-benzyloxyphenyl, 4-phenoxyphenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl, 2,3-dihydrobenzo[l,4]dioxin-6-yl, 4-bromo-2-fluorophenyl, 2-fluoro-4-trifluoromethylphenyl, 3-fluoro- 4-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 4-chloro-
  • Preferred compounds include those wherein R 6 is 4-chlorophenyl, 4-bromophenyl, 4-trifluoromethylphenyl or 4-trifluoromethoxyphenyl. More preferred compounds include those wherein R 6 is 4-chlorophenyl.
  • R 7 Useful values of R 7 include hydrogen and methyl. Preferred compounds include those wherein R 7 is hydrogen.
  • R Useful values of R include hydrogen and methyl. Preferred compounds include those wherein R 8 is hydrogen.
  • Useful values of R 9 include optionally substituted C 6 - ⁇ o aryl and optionally substituted C 6 -; ⁇ o ar(Q. 6 )alkyl.
  • R 9 Useful values of R 9 also include phenyl, 4-chlorophenyl, 4-chlorobenzyl, benzyl, cyclohexyl, cyclohexylmethyl, 4-hydroxyphenyl, pyridylmethyl, 4-fluorophenyl, 4-trifluoromethylphenyl, 4-iodobenzyl,
  • Preferred compounds include those wherein R 9 is halophenyl or halobenzyl. More preferred compounds include those wherein R 9 is phenyl or
  • R 10 Useful values of R 10 include -COOR b and -CH 2 -COOR b , where R is hydrogen or Q. 6 alkyl; and -COOM and -CH 2 -COOM, where M is Na + or K + .
  • Preferred compounds include those wherein R 10 is -COOR b or -CH 2 -
  • R b is hydrogen, methyl, ethyl, propyl or tert-butyl.
  • Preferred compounds also include those wherein R 10 is -COOH or -COOM, where M is Na + or K + .
  • R 10 also include -CH 2 OH and -CH 2 CH 2 OH;
  • R c and R d are independently hydrogen, methyl, ethyl, propyl, t-butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, aminomethyl, aminoethyl, aminopropyl, carboxymethyl, carboxyethyl, carboxypropyl, cyclopentyl, cyclohexyl, phenyl or benzyl.
  • Preferred compounds include those wherein R 10 is -CH 2 -CONR c R d or
  • R c and R d are independently hydrogen, methyl, hydroxyethyl, 3-carboxypropyl, l-carboxy-2-methylpropyl, hydroxy,
  • X and Y are independently -C(O)-, -CH 2 - or -C(S)-, more preferably -C(O)- or -C(S)-, most preferably -C(O)-.
  • a second aspect of the present invention is directed to pharmaceutical compositions comprising a) at least one compound of Formula / or a pharmaceutically acceptable salt thereof; and b) one or more pharmaceutically-acceptable excipients.
  • the pharmaceutical composition is sterile.
  • a third aspect of the present invention is directed to a method of inhibiting the binding of a protein encoded by mdm2 to p53 protein, comprising contacting p53 or one or more proteins encoded by mdm2 with one or more compounds of Formula /, wherein R ⁇ R 10 are defined as above.
  • a fourth aspect of the invention is directed to a method of inducing apoptosis, comprising contacting an animal with a composition comprising a pharmaceutically effective amount of at least one compound of Formula J, or a salt thereof, wherein R ⁇ R 10 are defined as above, and optionally one or more pharmaceutically-acceptable excipients.
  • a fifth aspect of the present invention is directed to a method of treating cancer, comprising contacting an animal with (a) a pharmaceutically effective amount of an antineoplastic agent, and (b) a pharmaceutically effective amount of at least one compound of Formula /, or a salt thereof, wherein R 1 - R 10 , are defined as above, and optionally one or more pharmaceutically-acceptable excipients, in combination with (a), (b), or (a) and (b).
  • a sixth aspect of the present invention is directed to a method of treating cancer, comprising contacting an animal with a composition comprising (a) a pharmaceutically effective amount of at least one compound of Formula J, or a salt thereof, (b) one or more agents that induce or cause DNA damage, and optionally (c) one or more pharmaceutically-acceptable excipients.
  • a seventh aspect of the present invention is directed to a method of making compounds of Formula /.
  • the invention disclosed herein is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result for example from the oxidation, reduction, hydrolysis, amidation, esterification and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof.
  • Such products typically are identified by preparing a radiolabeled compound of the invention, administering it parenterally in a detectable dose to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur and isolating its conversion products from the urine, blood or other biological samples.
  • Some of the compounds disclosed herein may contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms.
  • the present invention is also meant to encompass all such possible forms as well as their racemic and resolved forms and mixtures thereof.
  • the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended to include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present invention as well.
  • stereoisomers is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another
  • chiral center refers to a carbon atom to which four different groups are attached, or a sulfur atom to which three different groups are attached, where the sulfur atom and its attached groups form a sulfoxide, sulfinic ester, sulfonium salt or sulfite.
  • enantiomer or “enantiomeric” refers to a molecule that is nonsuperimposable on its mirror image and hence optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image rotates the plane of polarized light in the opposite direction.
  • racemic refers to a mixture of equal parts of enantiomers and which is optically inactive.
  • resolution refers to the separation or concentration or depletion of one of the two enantiomeric forms of a molecule.
  • enantiomeric excess refers to a mixture wherein one enantiomer is present is a greater concentration than its mirror image molecule.
  • the compounds of Formula / may also be solvated, especially hydrated. Hydration may occur during manufacturing of the compounds or compositions comprising the compounds, or the hydration may occur over time due to the hygroscopic nature of the compounds.
  • Certain compounds within the scope of Formula J are derivatives referred to as "prodrugs.”
  • the expression "prodrug” denotes a derivative of a known direct acting drug, which derivative has enhanced delivery characteristics and therapeutic value as compared to the drug, and is transformed into the active drug by an enzymatic or chemical process.
  • Prodrugs are derivatives of the compounds of the invention which have metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo.
  • ester derivatives of compounds of this invention are often active in vivo, but not in vitro.
  • Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but the acid derivative form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985).
  • Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine. Simple aliphatic or aromatic esters derived from acidic groups pendent on the compounds of this invention are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters. Useful prodrugs are those where R b is alkyl, alkenyl, alkynyl, or arylalkyl.
  • alkyl refers to both straight and branched chain radicals of up to 10 carbons, unless the chain length is otherwise limited, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, or decyl.
  • alkenyl is used herein to mean a straight or branched chain radical of 2-10 carbon atoms, unless the chain length is otherwise limited, wherein there is at least one double bond between two of the carbon atoms in the chain, including, but not limited to, ethenyl, 1-propenyl, 2-propenyl, 2- methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like.
  • the alkenyl chain is 2 to 8 carbon atoms in length, most preferably from 2 to 4 carbon atoms in length.
  • alkynyl is used herein to mean a straight or branched chain radical of 2-10 carbon atoms, unless the chain length is otherwise limited, wherein there is at least one triple bond between two of the carbon atoms in the chain, including, but not limited to, ethynyl, 1-propynyl, 2-propynyl, and the like.
  • the alkynyl chain is 2 to 8 carbon atoms in length, most preferably from 2 to 4 carbon atoms in length.
  • the unsaturated linkage i.e., the vinyl or ethenyl linkage, is preferably not directly attached to a nitrogen, oxygen or sulfur moiety.
  • alkoxy refers to any of the above alkyl groups linked to an oxygen atom. Typical examples are methoxy, ethoxy, isopropyloxy, sec- butyloxy, and t-butyloxy.
  • aryl as employed herein by itself or as part of another group refers to monocyclic or bicyclic aromatic groups containing from 6 to 12 carbons in the ring portion, preferably 6-10 carbons in the ring portion. Typical examples include phenyl, biphenyl, naphthyl or tetrahydronaphthyl.
  • aralkyl or "arylalkyl” as employed herein by itself or as part of another group refers to Q- 6 alkyl groups as discussed above having an aryl substituent, such as benzyl, phenylethyl or 2-naphthylmethyl.
  • heteroaryl refers to groups having 5 to 14 ring atoms; 6, 10 or 14 pi electrons shared in a cyclic array; and containing carbon atoms and 1, 2, 3, or 4 oxygen, nitrogen or sulfur heteroatoms (where examples of heteroaryl groups are: thienyl, benzo[b]thienyl, naphtho[2,3- b]thienyl, thianthrenyl, furyl, pyranyl, isobenzofuranyl, benzoxazolyl, chromenyl, xanthenyl, phenoxathiinyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl,
  • saturated or partially unsaturated heterocycle refers to a saturated or partially unsaturated ring system having 5 to 14 ring atoms selected from carbon atoms and 1, 2, 3, or 4 oxygen, nitrogen, or sulfur heteroatoms.
  • Typical saturated examples include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidyl, piperazinyl, quinuclidinyl, morpholinyl, and dioxacyclohexyl.
  • Typical partially unsaturated examples include pyrrolinyl, imidazolinyl, pyrazolinyl, dihydropyridinyl, tetrahydropyridinyl, and dihydropyranyl. Either of these systems can be optionally fused to a benzene ring.
  • heteroarylalkyl or “heteroaralkyl” as employed herein both refer to a heteroaryl group attached to an alkyl group.
  • Typical examples include 2-(3-pyridyl)ethyl, 3-(2-furyl)-.z-propyl, 3-(3-thienyl)-/ ⁇ -propyl, and 4-( 1 -isoquinolinyl)- ⁇ -butyl .
  • cycloalkyl as employed herein by itself or as part of another group refers to cycloalkyl groups containing 3 to 9 carbon atoms.
  • Typical examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and cyclononyl.
  • cycloalkylalkyl or "cycloalkyl(alkyl)" as employed herein, by itself or as part of another group, refers to a cycloalkyl group attached to an alkyl group. Typical examples are 2-cyclopentylethyl, cyclohexylmethyl, cyclopentylmethyl, 3-cyclohexyl-n-propyl, and 5-cyclobutyl- ⁇ -pentyl.
  • cycloalkenyl as employed herein, by itself or as part of another group, refers to cycloalkenyl groups containing 3 to 9 carbon atoms and 1 to 3 carbon-carbon double bonds.
  • Typical examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cyclooctenyl, cyclooctadienyl, cyclooctatrienyl, cyclononenyl, and cyclononadienyl.
  • halogen or "halo" as employed herein by itself or as part of another group refers to chlorine, bromine, fluorine or iodine.
  • dialkylamine or "dialkylamino” as employed herein by itself or as part of another group refers to the group NH wherein both hydrogens have been replaced by alkyl groups, as defined above.
  • hydroxyalkyl refers to any of the above alkyl groups wherein one or more hydrogens thereof are substituted by one or more hydroxyl moieties.
  • haloalkyl refers to any of the above alkyl groups wherein one or more hydrogens thereof are substituted by one or more halo moieties. Typical examples include fluoromethyl, difluoromethyl, trifluoromethyl, trichloroethyl, trifluoroethyl, fluoropropyl, and bromobutyl.
  • carboxyalkyl refers to any of the above alkyl groups wherein one or more hydrogens thereof are substituted by one or more carboxylic acid moieties.
  • heteroatom is used herein to mean an oxygen atom ("O"), a sulfur atom (“S”) or a nitrogen atom (“N”). It will be recognized that when the heteroatom is nitrogen, it may form an NR a R b moiety, wherein R a and R b are, independently from one another, hydrogen or Q to C 8 alkyl, or together with the nitrogen to which they are bound form a saturated or unsaturated 5-, 6-, or 7-membered ring.
  • phrases "optionally substituted" when not explicitly defined refers to a group or groups being optionally substituted with one or more substituents independently selected from the group consisting of hydroxy, nitro, trifluoromethyl, halogen, Q. 6 alkyl, Q- 6 haloalkyl, Q- 6 alkoxy, Q- 6 alkylenedioxy, Q- 6 aminoalkyl, Q. 6 hydroxyalkyl, C 2 - 4 alkenyl, C 2 - 4 alkynyl,
  • Preferred optional substituents include one or more substituents independently selected from the group consisting of nitro, hydroxy, carboxy,
  • MDM2 is used herein to mean the murine double minute 2 gene, and homologous genes found in other animals.
  • MDM2 is used herein to mean a protein obtained as a result of expression of the mdm2 oncogene. Within the meaning of this term, it will be understood that MDM2 encompasses all proteins encoded by mdm2, mutants thereof, alternative splice proteins thereof, and phosphorylated proteins thereof. Additionally, as used herein, it will be understood that the term “MDM2” includes MDM2 homologues of other animals (e.g. , HDM2).
  • hdm2 is used herein to mean the human gene which is homologous to the mouse mdm2.
  • HDM2 is used herein to mean a protein obtained as a result of expression of the hdm2 oncogene. Within the meaning of this term, it will be understood that HDM2 encompasses all proteins encoded by the hdm2, mutants thereof, alternative splice proteins thereof, and phosphorylated proteins thereof.
  • antineoplastic agent is used herein to mean any agent that is used to treat or prevent cancer or other conditions comprising uncontrolled proliferation and growth of cells.
  • Antineoplastic agents include anticancer agents.
  • contacting one or more proteins is used herein to mean placing a compound of the present invention in a solution with one or more proteins of interest.
  • a compound of Formula J and one or more proteins of interest may be in solution together in an aqueous solution, non-aqueous solution, or combination of an aqueous solution and non-aqueous solution.
  • Other proteins may be present in solution along with the compound of Formula J and the protein of interest.
  • Other inorganic or organic molecules may be present in the solution. Such inorganic and organic molecules include, but are not limited to, NaCl, HEPES, and octyl glucoside.
  • the solution may be within an animal cell or outside of an animal cell.
  • inhibitors the binding is used herein to mean preventing or reducing the direct or indirect association of one or more molecules, peptides, proteins, enzymes, or receptors; or preventing or reducing the normal activity of one or more molecules, peptides, proteins, enzymes, or receptors.
  • inducing apoptosis is used herein to mean causing directly or indirectly a cell of animal origin to undergo apoptosis, a process of controlled, or programmed, cellular death.
  • HDM2 inhibitor is used herein to describe an agent which inhibits the function of HDM2 in the assay described in Example 217.
  • the pharmaceutically-acceptable salts of the compounds of Formula J include the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases.
  • acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, > hydrobromide, hydroiodide,
  • 2-hydroxyethanesulfonate lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, tosylate, and undecanoate.
  • Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen- containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides like benzyl and phenethyl bromides and others.
  • Preferred acids for forming acid addition salts include HCl, acetic acid, trifluoroacetic acid and fumaric acid.
  • compositions of the present invention include pharmaceutical compositions comprising a compound of Formula /, wherein R'-R 10 are defined above, and one or more pharmaceutically acceptable excipients.
  • compositions of the present invention are pharmaceutical compositions comprising a compound selected from a preferred group of compounds of Formula J as defined above, and one or more pharmaceutically acceptable excipients.
  • compositions of the invention can be administered to any animal that can experience the beneficial effects of the compounds of the invention. Foremost among such animals are humans, although the invention is not intended to be so limited.
  • the pharmaceutical compositions of the present invention can be administered by any means that achieve their intended purpose.
  • administration can be by subcutaneous, intravenous, intramuscular, intraperitoneal, buccal, or ocular routes, rectally, parenterally, intrasystemically, intravaginally, topically (as by powders, ointments, drops or transdermal patch), or as an oral or nasal spray.
  • administration can be by the oral route.
  • the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
  • the new pharmaceutical preparations can contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically.
  • compositions of the present invention are manufactured in a manner that is, itself, known, for example, by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes.
  • pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as saccharides, for example, lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, as well as binders, such as, starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
  • fillers such as saccharides, for example, lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, as well as binders, such as, starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, traga
  • disintegrating agents can be added, such as, the above-mentioned starches and also carboxymethyl-starch, cross- linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as, sodium alginate.
  • Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as, magnesium stearate or calcium stearate, and/or polyethylene glycol.
  • Dragee cores are provided with suitable coatings that, if desired, are resistant to gastric juices.
  • concentrated saccharide solutions can be used, which can contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol, and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • suitable cellulose preparations such as, acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used.
  • Dye stuffs or pigments can be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
  • Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as, glycerol or sorbitol.
  • the push-fit capsules can contain the active compounds in the form of granules that may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds are preferably dissolved or suspended in suitable liquids, such as, fatty oils or liquid paraffin.
  • stabilizers may be added.
  • Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water- soluble salts, alkaline solutions and cyclodextrin inclusion complexes.
  • Especially preferred alkaline salts are ammonium salts prepared, for example, with Tris, choline hydroxide, Bis-Tris propane, N-methylglucamine, or arginine.
  • One or more modified or unmodified cyclodextrins can be employed to stabilize and increase the water solubility of compounds of the present invention.
  • Useful cyclodextrins for this purpose are disclosed in U.S. Patent ⁇ os. 4,727,064, 4,764,604, and 5,024,998.
  • suspensions of the active compounds as appropriate oily injection suspensions can be administered.
  • suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400 (the compounds are soluble in PEG-400).
  • Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
  • the suspension may also contain stabilizers.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzy
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
  • Topical administration includes administration to the skin or mucosa, including surfaces of the lung and eye.
  • Compositions for topical administration, including those for inhalation may be prepared as a dry powder which may be pressurized or non-pressurized.
  • the active ingredients in finely divided form may be used in admixture with a larger-sized pharmaceutically acceptable inert carrier comprising particles having a size, for example, of up to 100 micrometers in diameter.
  • suitable inert carriers include sugars such as lactose.
  • at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
  • the composition may be pressurized and contain a compressed gas, such as nitrogen or a liquefied gas propellant.
  • the liquefied propellant medium and indeed the total composition are preferably such that the active ingredients do not dissolve therein to any substantial extent.
  • the pressurized composition may also contain a surface-active agent.
  • the surface- active agent may be a liquid or solid non-ionic surface-active agent or may be a solid anionic surface-active agent. It is preferred to use the solid anionic surface-active agent in the form of a sodium salt.
  • a further form of topical administration is to the eye.
  • the compounds and compositions of the present invention are delivered in a pharmaceutically acceptable ophthalmic vehicle, such that the compounds are maintained in contact with the ocular surface for a sufficient time period to allow the compounds to penetrate the corneal and internal regions of the eye, as for example the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/ciliary, lens, choroid/retina and sclera.
  • the pharmaceutically acceptable ophthalmic vehicle may, for example, be an ointment, vegetable oil or an encapsulating material.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the drugs.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the drugs.
  • compositions of the present invention can also be administered in the form of liposomes.
  • liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used.
  • the present compositions in liposome form can contain, in addition to the compounds of the present invention, stabilizers, preservatives, excipients, and the like.
  • the preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art (see, for example, Prescott, Ed., Meth. Cell Biol. 14:33 (1976)).
  • Compounds of the present invention may be used alone or in combination with one or more additional antineoplastic agents.
  • the compound of the present invention may be formulated with the other antineoplastic agent or agents so that a pharmaceutical composition comprising a compound of Formula / and one or more additional antineoplastic agents is administered to an animal.
  • the compound of Formula / can be administered as a separate pharmaceutical composition from the composition comprising the one or more additional antineoplastic agents.
  • Antineoplastic agents that may be used in combination with the compounds of the present invention include compounds selected from the following compounds and classes of antineoplastic agents: 1. fluoropyrimidines, such as 5-FU (5-fluorouracil),
  • pyrimidine nucleosides such as Deoxycytidine, Cytosine Arabinoside, Cytarabine, Azacitidine, 5-Azacytosine, Gencitabine, and 5-Azacytosine-Arabinoside;
  • purines such as 6-Mercaptopurine, Thioguanine, Azathioprine, Allopurinol, Cladribine, Fludarabine, Pentostatin, and 2-Chloroadenosine;
  • platinum analogues such as Cisplatin, Carboplatin, Oxaliplatin, Tetraplatin, Platinum-DACH, Ormaplatin, and CI-973, JM-216; 5. anthracyclines/anthracenediones, such as Doxorubicin,
  • epipodophyllotoxins such as Etoposide, and Teniposide
  • camptothecins such as Irinotecan, Topotecan, 9-Amino Camptothecin, 10,H-Methylenedioxy Camptothecin, 9-Nitro Camptothecin, and TAS 103; 8.
  • hormones and hormonal analogues such as diethylstilbestrol, Tamoxifen, Toremefine, Tolmudex, Thymitaq, flutamide, fluoxymesterone, bicalutamide, Finasteride, estradiol, Trioxifene, dexamethasone, leuproelin acetate, estramustine, Droloxifene, medroxyprogesterone, megesterol acetate, aminoglutethimide, testolactone, testosterone, diethylstilbestrol, and hydroxyprogesterone;
  • hormones and hormonal analogues such as diethylstilbestrol, Tamoxifen, Toremefine, Tolmudex, Thymitaq, flutamide, fluoxymesterone, bicalutamide, Finasteride, estradiol, Trioxifene, dexamethasone, leuproelin acetate, estramustine, Droloxifene, medr
  • enzymes, proteins and antibodies such as Asparaginase, Interleukins, Interferons, Leuprolide, and Pegaspargase;
  • vinca alkaloids such as Nincristine, Ninblastine, Ninorelbine, and Nindesine;
  • Taxanes such as Paclitaxel, Taxotere and Docetaxel.
  • Antineoplastic agents that may be used in combination with compounds of the invention also include compounds selected from the following Mechanism-Based Classes: 1. Antihormonals-See classification for Hormones and Hormonal
  • Antifolates such as methotrexate, leucovorin, aminopterin, trimetrexate, Trimethoprim, pyritrexim, pyrimethamine, Edatrexate, and
  • MDAM 3. Antimicrotubule Agents, such as Taxanes, Ninca Alkaloids, and Ninorelbine;
  • Alkylating Agents Classical and Non-Classical
  • Nitrogen Mustards Mechanismlorethamine, Chlorambucil, Melphalan, Uracil Mustard
  • Oxazaphosphorines Ifosfamide, Cyclophosphamide, Perfosfamide, Trophosphamide
  • Alkylsulfonates Busulfan
  • Nitrosoureas Carmustine
  • Antimetabolites such as Purines, pyrimidines and nucleoside analogs, listed above;
  • Antibiotics such as Anthracyclines/Anthracenediones, Bleomycin, Dactinomycin, Mitomycin, Plicamycin, Pentostatin, and
  • Topoisomerase Inhibitors such as Camptothecins (Topo I), Epipodophyllotoxins, AMSA, NP-16 and Ellipticines (Topo II);
  • Antivirals such as AZT, acyclovir, penciclovir, famcyclovir, didehydrodideoxythymidine, dideoxycytidine, -SddC, ganciclovir, dideoxyinosine, and viral-specific protease inhibitors;
  • Miscellaneous Cytotoxic Agents such as Hydroxyurea, Mitotane, Fusion Toxins, PZA, Bryostatin, Retinoids, Butyric Acid and derivatives, Pentosan, Fumagillin, Mitoxantrone, Bone Marrow Growth Factors, and Procarbazine.
  • Compounds of the present invention are useful for the treatment of uncontrolled proliferation of cells and/or cancer.
  • the compounds of the present invention may produce beneficial cytostatic and/or cytotoxic effects.
  • the cytostatic effects include the inhibition of further cell growth and/or cell division.
  • the cytotoxic effects include the induction of cell death by mechanisms that include apoptosis and cellular necrosis.
  • the compounds of the present invention are useful in treating the following cancers: breast cancer, ovarian cancer, cervical carcinoma, endometrial carcinoma, choriocarcinoma, soft tissue sarcomas, osteosarcomas, rhabdomyosarcomas, leiomyomas, leiomyosarcomas, head and neck cancers, lung and bronchogenic carcinomas, brain tumors, neuroblastomas, esophogeal cancer, colorectal adenocarcinomas, bladder cancer, urothelial cancers, leukemia, lymphoma, malignant melanomas, oral squamous carcinoma, hepatoblastoma, glioblastoma, astrocytoma, medulloblastoma, Ewing's sarcoma, lipoma, liposarcoma, malignant fibroblast histoma, malignant Schwannoma, testicular cancers, thyroid cancers, Wilms' tumor,
  • the present invention is used to treat the cancers selected from the group consisting of breast cancer, choriocarcinoma, soft tissue sarcomas, osteosarcomas, rhabdomyosarcomas, lipoma and liposarcoma.
  • cancers and diseases listed above are merely meant to be illustrative and are by no means meant to be a limiting or exhaustive list. Additionally, the compounds and compositions described herein are useful to treat any undesired or detrimental condition that results from the
  • the compounds of the present invention are also useful at inhibiting the interaction between p53 and HDMX and/or MDMX.
  • MDMX also known as MDM4
  • MDM4 is a cellular protein involved in the regulation of the cell cycle.
  • the compounds of the present invention are also useful for the treatment and prevention of inflammatory conditions.
  • the compounds of the present invention can be administered as anti-inflammatory agents that reduce the degree of or eliminate inflammation of tissues.
  • the compounds of the present invention are also useful for the treatment of autoimmune diseases and conditions.
  • the compounds of the present invention can be administered to reduce or eliminate the symptoms of an autoimmune disease.
  • Autoimmune diseases include any disease in which an animal's immune system reacts adversely to a self-antigen.
  • a self-antigen is any antigen that is normally found in the animal's body.
  • autoimmune diseases include Hashimoto's thyroiditis, Grave's disease, multiple sclerosis, pernicious anemia, Addison's disease, insulin-dependent diabetes mellitus, rheumatoid arthritis, systemic lupus erythematosus (SLE or lupus), dermatomyositis, Crohn's disease, Wegener's granulomatosis, Anti- Glomerular Basement Membrane Disease, Antiphospholipid Syndrome, Dermatitis Herpetiformis, Allergic Encephalomyelitis, Glomerulonephritis,
  • the present invention is used to treat rheumatoid arthritis or systemic lupus erythematosus.
  • Inhibitors of the interaction of HDM2 and/or MDM2 and p53 are also useful for treating cancer, inhibiting cell growth/replication, and inducing cellular apoptosis and necrosis, when administered along with agents that cause or induce DNA damage (see Chen et al. Proc. Nail. Acad. Sci.
  • Compounds of the present invention may be used to treat cancer, inhibit cell growth/replication, and induce cellular apoptosis and necrosis, by administering a compound of the present invention along with agents that cause or induce DNA damage.
  • Agents that induce DNA damage include radiation and chemical agents. The radiation can be administered either internally or externally.
  • Chemical agents include any compounds or elements that cause or induce damage to DNA.
  • the compounds of the present invention may be administered in an effective amount within the dosage range of about 0.01 mg/kg to about 300 mg/kg, preferably between 1.0 mg/kg to 100 mg/kg body weight.
  • Compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • the present invention is also concerned with the syntheses of substituted l,4-benzodiazepin-2,5-dione carboxylic acids.
  • the compounds of the present invention can be prepared utilizing the modification of Ugi condensation products, according to the synthetic pathway shown in Scheme 1 or Scheme 2 and as detailed in Keating and Armstrong, J. Am. Chem. Soc, 778: 2574-2583 (1996). SCHEME1
  • Appropriately substituted or unsubstituted anthranilic acids 1 or 11, amines 3, aldehydes or ketones 2 can be used to prepare the compounds of the present invention, wherein R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , and R 10 are defined above.
  • the acid compounds of the present invention can be prepared by optional hydrolysis of ester using a base, such as NaOH, in an appropriate solvent, such as methanol/water.
  • a base such as NaOH
  • R 5 is selected as a group other than hydrogen
  • R 5 can be introduced by using R 5 Br in the presence of a base, such as NaH, and a solvent, such as THF, or by using a standard Mitsunobu coupling procedure (Mitsunobu, O., Synthesis, 1, (1981)) such as diethyl azodicarboxylate, and triphenylphosphine in THF.
  • Compound 7 can be converted into compound 8 or 9 by using an appropriate reducing reagent, such as BH 3 « S(Me) 2 , in a solvent such as THF.
  • Compound 10 can be made through reaction of compound 7 with Lawesson's reagent (2,4-bis(4-methoxyphenyl)- 1 ,3-dithia-2,4-diphosphetane-2,4-disulfide) in a solvent such as THF.
  • Lawesson's reagent 2,4-bis(4-methoxyphenyl)- 1 ,3-dithia-2,4-diphosphetane-2,4-disulfide
  • the residue was purified using pre-packed silica cartridges (methylene chloride to 10 % ethyl acetate in methylene chloride). The pure ester was then concentrated back down in vacuo, dissolved in methanol (1.5 mL), and 10% sodium hydroxide (0J5 mL) was added. The reaction mixture was shaken overnight at ambient temperature. The solution was then concentrated in vacuo and acidified with hydrochloric acid (IM). The precipitates were extracted with ethyl acetate, separated and the organics were concentrated in vacuo. The residue was purified using pre-packed silica cartridges (8 % ethyl acetate in methylene chloride to 10 % methanol in methylene chloride) to give the title compounds (0.015-0.050 g).
  • the isolated ester was dissolved in methanol (1 mL) and sodium hydroxide (IM, 0.2 mL) was added and the reaction mixture was shaken at ambient temperature overnight.
  • the reaction was concentrated in vacuo, water (0.5 mL) was added, followed by acidification with hydrochloric acid (IM, 0.3 mL).
  • the resulting precipitate was extracted with ethyl acetate (1 mL) and separated.
  • the organics were dried in vacuo and the residues purified using a preparative plate chromatography (silica gel, 8 % methanol in methylene chloride, bottom band) to give the title compounds (0.012-0.030 g).
  • Pd(PPh 3 ) 4 (0.04 eq, 0.002 mmol) were placed in a 2 mL vial equipped with a magnetic stir bar. The vial was fitted with a rubber septum then evacuated and backflushed with dry N 2 . Tetrahydrofuran (THF, 0.8 mL) and 2M Na 2 CO 3 (0.2 mL) were added to the vial via syringe. The reaction vessel was capped tightly under a N 2 purge then heated to 50° C for 12 h. After cooling to ambient temperature, the solvent was removed under reduced pressure. The residue was then purified by Sep-Pak (10 g silica gel, methylene chloride to 10 % ethyl acetate in methylene chloride) to give the title compound.
  • Sep-Pak 10 g silica gel, methylene chloride to 10 % ethyl acetate in methylene chloride
  • the 1,4-benzodiazepine carboxylic acid (0.057 mmol) and EDC (1.5 eq., 0.086 mmol, 16.5 mg) were placed in a 4 mL vial equipped with a magnetic stir bar. The vial was fitted with a rubber septum, then evacuated and backflushed with dry N 2 . Dry dichloromethane (2 mL) was added via syringe. Once the solids dissolved, the amine (1.5 eq, 0.086 mmol) and triethylamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: X and Y are independently -C(O)-, CH2- or -C(S)-; R?1, R2, R3, R4, R7, R8, Rb, Rc, Rd¿ and M are defined herein, R5 is hydrogen, alkyl cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl or alkylaminocarbonylalkyl; R6 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; R9 is cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of which is optionally substituted; and R10 is -(CH¿2?)n-CO2R?b¿, -(CH¿2?)m-CO2M, -(CH2)i-OH or -(CH2)j-CONR?cRd¿ n is 0-8, m is 0-8, i is 1-8 and j is 0-8.

Description

SUBSTITUTED 1,4-BENZODIAZEPINES AND USES THEREOF FOR THE TREATMENT OF
CANCER
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention is in the area of novel 1,4-benzodiazepines and salts thereof, their syntheses, and their use as inhibitors of MDM2 and HDM2 oncoproteins.
Related Art
This invention relates to compounds that bind to the human protein HDM2 and interfere with its interaction with other proteins, especially the tumor suppressor protein p53. HDM2 is the expression product of hdm2, an oncogene that is overexpressed in a variety of cancers, especially soft tissue sarcomas (Momand, J., et al, Nucl. Acids Res. 26:3453-3459 (1998)). p53 is a transcription factor that plays a pivotal role in the regulation of the balance between cell proliferation and cell growth arrest/apoptosis. Under normal conditions, the half-life of p53 is very short, and consequently the level of p53 in cells is low. However, in response to cellular DNA damage, cellular stress, or other factors, levels of p53 increase. This increase in p53 levels in turn increases the transcription of a number of genes which induces the cell to either arrest growth or undergo apoptosis (i.e., controlled cell death). The function of p53 is to prevent the uncontrolled proliferation of cells and thus protect the organism from the development of cancer (for a review, see Levine, A.J., Cell SS:323-331 (1997)). p53 is a latent and short-lived transcription factor which is induced by, and is an integration point for, a range of cellular stresses including DNA damage, UN damage, spindle damage, hypoxia, inflammatory cytokines, viral infection, activated oncogenes, and ribonucleotide depletion. Activation of p53 mediates a change in the balance of gene expression such that expression of many genes involved in proliferation is repressed while a range of genes involved in growth arrest (such as p21WAFl and GADD45), repair (such as p53RE) and apoptosis (such as Bax, Killer/DR5 and PIGs) is activated. The biological outcome of p53 activation (whether permanent or transient growth arrest or apoptosis) is dependent on several factors including the type and strength of the inducing stress, and the type of cell or tissue. p53 and MDM2 exist in a negative regulatory feedback loop in which p53 stimulates transcription of the mdm2 gene while MDM2 binds to p53 and targets it for degradation by the 26S proteosome. The key element in the p53 induction process is disruption of the p53-MDM2 complex which permits p53 to accumulate in the nucleus. This mechanism appears to be common to all of the pathways by which p53 becomes activated, although recent evidence has indicated that there is considerable variation in the molecular events by which this is actually achieved. Inactivation of the p53 tumor suppressor is a frequent event in human neoplasia. The inactivation can occur by mutation of the p53 gene or through binding to viral or cellular oncogene proteins, such as the SN40 large T antigen and MDM2. While the mechanism through which wild-type p53 suppresses tumor cell growth is as yet poorly defined, it is clear that one key feature of the growth suppression is the property of p53 to act as a transcription factor (Farmer, G., et al, Nature 358: 83-86 (1992); Funk, W. D. et al, Mol. Cell. Biol. 12: 2866- 2871 (1992); Kern, S. E., et al, Science 256:827-830 (1992)). Currently, considerable effort is being made to identify growth control genes that are regulated by p53 binding to sequence elements near or within these genes. A number of such genes have been identified. In cases such as the muscle creatine kinase gene (Weintraub, H., et al, Proc. Natl Acad. Sci. U.S.A., 55:4570-4571 (1991); Zambetti, G. P., et al, Genes Dev. 6:1143-1152 (1992)) and a GLN retroviral element (Zauberman, A., et al, EMBO J. 72:2799-2808 (1993)), the role these genes might play in the suppression of growth control is unclear. Yet there are other examples, namely mdm2 (Barak, Y., et al. EMBO J. 72:461-468 (1993); Wu, X., et al, Genes
Dev. 7:1126-1132(1993)) GADD 45 (Kastan, M. B., et al, Cell 77:587- 597(1992)) and WAF1 or CTP1 (El-Beiry, W. S., et al, Cell 75:817-825 (1993); Harper, J. W., et al, Cell 75:805-816 (1993)), where their involvement in the regulation of cell growth is better understood. mdm2, a known oncogene, was originally found on mouse double minute chromosomes (Cahilly-Snyder., L., et al, Somatic Cell Mol Genet. 73:235-244 (1987)). Its protein product was subsequently found to form a complex with p53, which was first observed in a rat fibroblast cell line (Clone 6) previously transfected with a temperature sensitive mouse p53 gene (Michalovitz, D., et al, Cell 62:671-680 (1990)). The rat cell line grew well at 37°C but exhibited a Gl arrest when shifted down to 32°C, which was entirely consistent with an observed temperature dependent switch in p53 conformation and activity. However, the p53-MDM2 complex was only observed in abundance at 32°C, at which temperature p53 was predominantly in a functional or "wild-type" form (Barak, Y. et al, EMBO J. 77:2115-2121
(1992) and Momand, J., et al, Cell 69:1231-1245 (1992)). By shifting the rat cell line down to 32°C and blocking de novo protein synthesis it was shown that only "wild-type" p53 induced expression of the mdm2 gene, thereby accounting for the differential abundance of the complex in terms of p53 transcriptional activity (Barak, Y., et al, EMBO J. 72:461-468 (1993)). The explanation was further developed by the identification of a DNA binding site for wild-type p53 within the first intron of the mdm2 gene (Wu, X., et al, Genes Dev. 7:1126-1132 (1993)). Reporter constructs employing this p53 DNA binding site revealed that they were inactivated when wild-type p53 was co-expressed with MDM2. This inhibition of the transcriptional activity of p53 may be caused by MDM2 blocking the activation domain of p53 and/or the DNA binding site. Consequently, it was proposed that mdm2 expression is autoregulated, via the inhibitory effect of MDM2 protein on the transcriptional activity of wild-type p53. This p53-mdm2 autoregulatory feedback loop provided a novel insight as to how cell growth might be regulated by p53. Up to a third of human sarcomas are considered to overcome p53-regulated growth control by amplification of the hdm2 gene (the human homologue of mdm2) (Oliner, J.D., et al, Nature 35S:80-83 (1992)). Hence, the interaction between p53 and HDM2 represents a key potential therapeutic target. One mechanism by which MDM2 can promote tumorogenesis is by its inhibitory action on p53. The tumor suppressor functions of p53 control a pivotal checkpoint in the control of cell cycling (reviewed in Levine, A.J., Cell 88:323- 331 (1997)). p53 is a transcription factor for a number of proteins that cause cell cycle arrest or cell death by apoptosis. The level and transcriptional activity of p53 are increased by damage to cellular DNA. The MDM2 protein inhibits p53 function by binding to an amphipathic N-terminal helix of p53, abrogating the interaction of p53 with other proteins and its transactivation activity. The interaction with MDM2 also targets p53 for ubiquitin dependent protein degradation. MDM2 exhibits p53 independent effects on cell cycling as well, possibly by direct interaction with some of the downstream effectors such as pRB and EF2 (Reviewed in Zhang, R. and Wang, H., Cur. Pharm. Des. 6:393- 416 (2000)).
Blocking HDM2 from binding p53 would be therapeutically useful in restoring cell cycle control to cells that overexpress HDM2 as a front line cancer treatment. More generally, inhibition of HDM2 may increase the effectiveness of chemotherapy and radiation in p53 normal cancers by enhancing apoptosis and growth arrest signaling pathways.
A need continues to exist for potent, small molecules that inhibit the interactions between HDM2 and p53. SUMMARY OF THE INVENTION
A first aspect of the present invention is directed to novel compounds of Formula /.
A second aspect of the present invention is directed to pharmaceutical compositions comprising at least one compound of Formula I, or a salt thereof, and one or more pharmaceutically acceptable excipients.
A third aspect of the present invention is directed to a method of inhibiting the binding of a protein encoded by hdm2 to p53 protein, comprising contacting p53 or one or more proteins encoded by mdm2, with one or more compounds of Formula /.
A fourth aspect of the invention is directed to a method of inducing apoptosis, comprising contacting an animal with a composition comprising a pharmaceutically effective amount of at least one compound of Formula /, or a salt thereof, and one or more pharmaceutically-acceptable excipients. A fifth aspect of the present invention is directed to a method of treating cancer. The method comprises contacting an animal with (a) a pharmaceutically effective amount of an antineoplastic agent and (b) a pharmaceutically effective amount of at least one compound of Formula /, or a salt thereof, and one or more pharmaceutically-acceptable excipients. A sixth aspect of the present invention is directed to a method of treating cancer, comprising contacting an animal with a composition comprising (a) a pharmaceutically effective amount of at least one compound of Formula /, or a salt thereof, (b) one or more agents that induce or cause DNA damage, and (c) one or more pharmaceutically-acceptable excipients. A seventh aspect of the present invention is directed to a method of synthesizing compounds of Formula 1.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
A novel class of small molecules that bind to HDM2 and/or MDM2 has now been discovered. By interfering with HDM2-p53. or MDM2-p53 interactions, these compounds increase the intracellular concentration of p53. These small molecules, therefore, have therapeutic utility in sensitizing tumor cells for chemotherapy. In tumor types particularly sensitive to an increase in functional p53, compounds of this type will be sufficient to induce apoptosis. Compounds of the present invention are also useful in treating tumor types in which HDM2 or MDM2 is overexpressed.
Compounds of the present invention include compounds of Formula I:
Figure imgf000007_0001
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: X and Y are independently -C(O)-, -CH2- or -C(S)-; R1, R2, R3, and R4 are independently hydrogen, halo, alkyl, alkenyl, alkynyl, cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, alkoxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, cyano, amino, alkanoylamino, nitro, hydroxy, carboxy, or alkoxycarbonyl; or R1 and R2, or R2 and R3, or R3 and R4 are taken together to form
-(CH2)U-, where u is 3-6, -CH=CH-CH=CH- or -CH2CH=CHCH2-; R5 is hydrogen, alkyl, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl or alkylaminocarbonylalkyl; R6 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; R7 and R8 are independently hydrogen or alkyl; R9 is cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of which is optionally substituted; and R10 is -(CH2)„— CO2Rb, -(CH2)m— CO2M, -(CH2)i-OH or
-(CH2)j— CONRcRd where
Rb is hydrogen, alkyl, optionally substituted cycloalkyl, or optionally substituted, saturated or partially unsaturated heterocycle;
M is a cation; Rc and Rd are independently hydrogen, alkyl, hydroxyalkyl, carboxyalkyl, aminoalkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, and an optionally substituted, saturated or partially unsaturated heterocycle; and n is 0-8, m is 0-8, i is 1-8 and j is 0-8.
Preferred compounds include compounds of Formula I, or salts thereof, wherein:
R1, R2, R3, and R4 are independently hydrogen, halo,
Figure imgf000008_0001
alkyl, C2-6 alkenyl, C2-6 alkynyl, C3- cycloalkyl, optionally substituted Ce-to aryl, optionally substituted C6.;ιo ar(C1-6)alkyl, optionally substituted heteroaryl, optionally substituted heteroar(C1-6)alkyl, Cχ.β alkoxy, optionally substituted C6-;ιo aryloxy, optionally substituted heteroaryloxy, cyano, amino, alkanoylamino, nitro, hydroxy, carboxy, or -ό alkoxycarbonyl; or R1 and R2, or R2 and R3, or R3 and R4 are taken together to form
-CH=CH-CH=CH- or -CH2CH=CHCH2-;
R5 is hydrogen, Cι_6ι alkyl, C3.7 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted heteroaryl, optionally substituted Cβ-io ar(C!-6)alkyl, optionally substituted heteroar(C1.6)alkyl, carboxy(C1-6)alkyl, Cϊ-ό alkoxycarbonyl, d-ό alkoxycarbonyl(C1-6)alkyl, aminocarbonyl, aminocarbonyl(C1-6)alkyl, or Cι_6 alkylaminocarbonyl(C1-6)alkyl; R6 is C3-7 cycloalkyl, C6-io aryl, heteroaryl, a saturated or partially unsaturated heterocycle, C3-7 cycloalkyl(Ci.6)alkyl, C6-κ) ar(C1.6)alkyl or heteroaryl(C1.6)alkyl, each of which is optionally ring substituted by one or more substituents independently selected from the group consisting of Q.4 alkyl, C2.4 alkenyl, C2. alkynyl, C6-!o aryl, phenoxy, benzyloxy, 5-10 membered heteroaryl, hydroxy, Q-4 alkoxy, Q-4 alkylenedioxy, halo, Q.4 haloalkyl, Q- alkylthio, thio, amino, mono(C1. )alkylamino, di(C1. )alkylamino, and nitro;
R7 is hydrogen or Q-6 alkyl; R8 is hydrogen or Q-6 alkyl;
R9 is C3- cycloalkyl, a saturated or partially unsaturated heterocycle, C6.io aryl, heteroaryl, C3- cycloalkyl(C1-6)alkyl, C6-!o ar(C1.6)alkyl or heteroaryl(Q.6)alkyl, each of which is optionally substituted by one or more substituents independently selected from the group consisting of Q- alkyl, C2- 4 alkenyl, C2-4 alkynyl, C^o aryl, 5-10 membered heteroaryl, hydroxy, -4 alkoxy, -4 alkylenedioxy, carboxy, halo, Q- haloalkyl, trifluoromethoxy, Q- alkylthio, thio, amino, mono(Q-4)alkylamino, di(Q. )alkylamino, and nitro; and
R10 is -(CH2)n— CO2R , -(CH2)m— CO2M, -(CH2)i-OH or -(CH2)j— CONRcRd , where
Rb is hydrogen, Q.6 alkyl, optionally substituted C3-7 cycloalkyl, or an optionally substituted, saturated or partially unsaturated heterocycle; M is a cation; Rc and Rd are independently hydrogen, Q-6 alkyl, Q-6 hydroxyalkyl, Q-6 carboxyalkyl, aminoalkyl, optionally substituted C3-7 cycloalkyl, optionally substituted C6-ιo aryl, optionally substituted C6-10 ar(C1-6)alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl(C1-6)alkyl, or an optionally substituted, saturated or partially unsaturated heterocycle; and n is 0-4, m is 0-4, i is 1-4 and j is 0-4. In one preferred embodiment: R1 and R4 are both hydrogen;
R2 is hydrogen, halo, Q-6 alkyl, Q-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, acetylamino, cyano, amino, Q-6 alkoxy, phenyl, thienyl, furanyl, and pyrrolyl, wherein said phenyl, thienyl and furanyl are optionally substituted by one or more substituents independently selected from the group consisting of halo, Q.4 alkoxy, Q-4 alkyl, amino, methylenedioxy, and ethylenedioxy;
R is hydrogen, Q-6 alkyl, phenyl, or halo; or R2 and R3 are taken together to form -CH=CH-CH=CH~;
R5 is hydrogen; Q-6 alkyl; Q-6 hydroxyalkyl; carboxy(Q-6)alkyl; Q-6 alkylcarbamoyl(Q.6)alkyl; Q-6 alkoxycarbonylamino(C1-6)alkyl; C3-7 cycloalkyl(C1-6)alkyl; C6-10 aryl, optionally substituted by Q-4 alkyl or halo;
C6-!o ar(Ci-4)alkyl optionally substituted by Q- alkyl or halo; and pyridyl(Q-4)alkyl;
R6 is C6-ιo aryl, thienyl, benzothienyl, furanyl, benzofuranyl, indolyl, pyridyl, quinolinyl, C3-7 cycloalkenyl or cubanyl, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halo, Q- alkyl, C2- alkenyl, Q-4 alkoxy, halo(Q.4)alkoxy, trifluoromethyl, trifluoromethoxy, Q- alkylsulfanyl, trifluoromethylsulfanyl, cyano, thienyl, phenyl, halophenyl, trifluoromethylphenyl, phenoxy, benzyloxy and pyrrolidinyl;
R7 is hydrogen or Q-6 alkyl; R8 is hydrogen or Q-6 alkyl; R9 is C3.7 cycloalkyl, C6.ιo aryl, heteroaryl, C3.7 cycloalkyl(C1-6)alkyl,
C6-ιo ar(C1.6)alkyl or heteroaryl(C1-6)alkyl, each of which is optionally substituted on the ring portion; and
R10 is -(CH2)n— CO2Rb or -(CH2)m— CO2M, where Rb is hydrogen, Q-6 alkyl, optionally substituted C3- cycloalkyl, or optionally substituted heterocycloalkyl, M is a cation n and m are independently 0, 1, 2, 3 or 4; or
R10 is-(CH2)i-OH or -(CH2)j— CONRcRd , where Rc and Rd are independently hydrogen, hydroxy, C3. cycloalkyl, Q.6 alkyl, Q-6 hydroxyalkyl, Q-6 carboxyalkyl, Q-6 aminoalkyl, optionally substituted phenyl, or optionally substituted benzyl; and i is 1, 2, 3, or 4, andj is 0, 1, 2, 3 or 4. Preferred compounds include those wherein R1 is hydrogen.
Preferred compounds include those wherein R4 is hydrogen. Useful values of R include hydrogen, halo, Q.4 alkyl, C3-7 cycloalkyl, C2-6 alkenyl, C2.6 alkynyl, acetylamino, Q-6 alkoxy, phenyl, halophenyl, hydroxyphenyl, Q-6 alkoxyphenyl, Q-6 alkylphenyl, aminophenyl, Q-6 alkylenedioxyphenyl, hydroxycarbonylphenyl, thienyl, Q-6 alkylthienyl, furanyl, pyrrolyl, amino, Q-6 hydroxyalkyl and cyano.
Useful values of R also include hydrogen, iodo, fluoro, chloro, bromo, methyl, ethyl, propyl, isopropyl, t-butyl, sec-butyl, cyclopropyl, ethynyl, acetylamino, methoxy, phenyl, 3-chlorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 3-methoxyphenyl, 4-methylphenyl, 3-methylphenyl,
3-isopropylphenyl, 3-aminophenyl, 3,4-methylenedioxyphenyl,
4-hydroxycarbonylphenyl, thien-3-yl, 4-methylthien-2-yl, furan-2-yl, lH-pyrrol-3-yl, amino, 2-hydroxyethyl, hydroxymethyl, furan-3-yl, vinyl and cyano. Preferred compounds include those wherein R2 is halo or phenyl.
More preferred compounds include those wherein R2 is iodo.
Useful values of R3 include hydrogen, phenyl, fluoro, chloro, iodo and methyl. Preferred compounds are those wherein R3 is hydrogen.
Useful values of R5 include hydrogen, Q-6 alkyl, Q-6 hydroxyalkyl, carboxy (Q.6)alkyl, Q-e alkylphenyl, Q.6 alkylbenzyl, phenethyl, phenyl(C1-6)alkyl, naphthyl(Q.6)alkyl, C3-7 cycloalkyl(Q.6)alkyl, pyridyl(C1-6)alkyl, Ci-6 alkoxycarbonylamino(C1-6)alkyl, and Q.6 alkylcarbamoyl(C1.6)alkyl.
Useful values of R5 also include hydrogen, methyl, carboxymethyl, 3-methylbutyl, 2-methylpropyl, isopropyl, 2-methylphenyl, 3-methylphenyl,
4-methylphenyl, phenyl, benzyl, phenethyl, 3-phenylpropyl, naphthalen- 2-ylmethyl, cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, pyrid- 2-ylmethyl, pyrid-3-ylmethyl, pyrid-4-ylmethyl, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, 2-carboxyethyl,
2-t-butoxycarbonylaminoethyl, 2-pyrid-2-ylethyl, methylcarbamoylmethyl and 2,3-dihydroxyρropyl.
Preferred compounds include those wherein R5 is hydrogen. Useful values of R6 include optionally substituted C6-!o aryl. Useful values of R6 also include trifluoromethylphenyl, halophenyl, Q.6 alkylphenyl, Q-6 alkoxyphenyl, halo(Q-4)alkoxyphenyl, naphthyl, benzyloxyphenyl, phenoxyphenyl, dihydrobenzodioxinyl, trifluoromethyl- halophenyl, pyridyl, thienyl, Q-6 alkylthienyl, halothienyl, bithienyl, Q-6 alkylbenzothienyl, (halophenyl)furanyl, quinolinyl, biphenyl, indolyl, (trifluoromethylsulfanyl)phenyl, (trifluoromethylphenyl)furanyl, halo(Q-4)alkoxyphenyl, benzofuranyl, cyanophenyl, halopyridyl, (methylsulfanyl)phenyl, pyrrolidinylphenyl, C -6 alkenyl (C3-7)cycloalkenyl, cubanyl and halocubanyl.
Useful values of R6 also include 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-chlorophenyl,
3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 4-iodophenyl, 4-methylphenyl, 4-ethylphenyl,
4-trifluoromethoxyphenyl, 4-isopropylphenyl, phenyl, 4-methoxy-phenyl, naphthalen-2-yl, 4-tert-butylphenyl, 4-benzyloxyphenyl, 4-phenoxyphenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl, 2,3-dihydrobenzo[l,4]dioxin-6-yl, 4-bromo-2-fluorophenyl, 2-fluoro-4-trifluoromethylphenyl, 3-fluoro- 4-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 4-chloro-
3-fluorophenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, thien-3-yl, 5-methylthien- 2-yl, 3-methylthien-2-yl, 4-bromothien-2-yl, 5-[2,2']bithienyl,
3-methylbenzo[b]thiophen-2-yl, 5-(2-chlorophenyl)-furan-2-yl,
5-(3-chlorophenyl)-furan-2-yl, quinolin-3-yl, biphen-4-yl, indol-2-yl, indol- 3-yl, 4-trifluoromethylsulfanylphenyl, 5-(3-trifluoromethylphenyl)furan-2-yl,
4-( 1 J ,2,2-tetrafluoroethoxy)phenyl, 4-difluoromethoxyphenyl, benzofuran- 2-yl, 4-cyanophenyl, 6-chloropyrid-3-yl, 4-methylsulfanylphenyl, 4-pyrrolidin-l-ylphenyl, 5-chlorothien-2-yl, 4-isopropenylcyclohex-l-enyl and l-chlorocuban-4-yl.
Preferred compounds include those wherein R6 is 4-chlorophenyl, 4-bromophenyl, 4-trifluoromethylphenyl or 4-trifluoromethoxyphenyl. More preferred compounds include those wherein R6 is 4-chlorophenyl.
Useful values of R7 include hydrogen and methyl. Preferred compounds include those wherein R7 is hydrogen.
Useful values of R include hydrogen and methyl. Preferred compounds include those wherein R8 is hydrogen.
Useful values of R9 include optionally substituted C6-ιo aryl and optionally substituted C6-;ιo ar(Q.6)alkyl.
Useful values of R9 also include phenyl, 4-chlorophenyl, 4-chlorobenzyl, benzyl, cyclohexyl, cyclohexylmethyl, 4-hydroxyphenyl, pyridylmethyl, 4-fluorophenyl, 4-trifluoromethylphenyl, 4-iodobenzyl,
4-bromobenzyl, thien-2-yl, thien-2-ylmethyl, naphth-2-ylmethyl, pyrid- 2-ylethyl, 3-methylphenyl, 4-methylphenyl, 4-ethylphenyl, 4-chloro- 3 -fluorophenyl, 2-fluoro-4-trifluoromethylphenyl, 4-hydroxycarbonylphenyl, naphthalen-2-yl, naphthalen-1-yl, 4-iodophenyl, 4-bromophenyl, 3,4-dichlorophenyl, 2-chlorophenyl, 4-tert-butylphenyl, 4-isopropylphenyl,
3-chlorophenyl, 4-trifluoromethoxyphenyl, and 3-hydroxyphenyl, 4-hydroxybenzyl, 4-trifluoromethylbenzyl, naphth-1-ylmethyl, 6-chloropyrid- 3-yl and 6-methylpyrid-3-yl.
Preferred compounds include those wherein R9 is halophenyl or halobenzyl. More preferred compounds include those wherein R9 is phenyl or
4-chlorophenyl.
Useful values of R10 include -COORb and -CH2-COORb, where R is hydrogen or Q.6 alkyl; and -COOM and -CH2-COOM, where M is Na+ or K+. Preferred compounds include those wherein R10 is -COORb or -CH2-
COORb, where Rb is hydrogen, methyl, ethyl, propyl or tert-butyl. Preferred compounds also include those wherein R10 is -COOH or -COOM, where M is Na+ or K+.
Useful values of R10 also include -CH2OH and -CH2CH2OH; and
-CH2-CONRcRd and -CONRcRd, where Rc and Rd are independently hydrogen, methyl, ethyl, propyl, t-butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, aminomethyl, aminoethyl, aminopropyl, carboxymethyl, carboxyethyl, carboxypropyl, cyclopentyl, cyclohexyl, phenyl or benzyl.
Preferred compounds include those wherein R10 is -CH2-CONRcRd or
-CONRcRd, where Rc and Rd are independently hydrogen, methyl, hydroxyethyl, 3-carboxypropyl, l-carboxy-2-methylpropyl, hydroxy,
4-carboxybutyl, 5-carboxypentyl, 2-(methoxycarbonyl)ethyl or
2-(hydroxyguanidino)ethyl.
In each of the above embodiments, X and Y are independently -C(O)-, -CH2- or -C(S)-, more preferably -C(O)- or -C(S)-, most preferably -C(O)-. A second aspect of the present invention is directed to pharmaceutical compositions comprising a) at least one compound of Formula / or a pharmaceutically acceptable salt thereof; and b) one or more pharmaceutically-acceptable excipients. Preferably, the pharmaceutical composition is sterile.
A third aspect of the present invention is directed to a method of inhibiting the binding of a protein encoded by mdm2 to p53 protein, comprising contacting p53 or one or more proteins encoded by mdm2 with one or more compounds of Formula /, wherein R^R10 are defined as above. A fourth aspect of the invention is directed to a method of inducing apoptosis, comprising contacting an animal with a composition comprising a pharmaceutically effective amount of at least one compound of Formula J, or a salt thereof, wherein R^R10 are defined as above, and optionally one or more pharmaceutically-acceptable excipients. A fifth aspect of the present invention is directed to a method of treating cancer, comprising contacting an animal with (a) a pharmaceutically effective amount of an antineoplastic agent, and (b) a pharmaceutically effective amount of at least one compound of Formula /, or a salt thereof, wherein R1- R10, are defined as above, and optionally one or more pharmaceutically-acceptable excipients, in combination with (a), (b), or (a) and (b).
A sixth aspect of the present invention is directed to a method of treating cancer, comprising contacting an animal with a composition comprising (a) a pharmaceutically effective amount of at least one compound of Formula J, or a salt thereof, (b) one or more agents that induce or cause DNA damage, and optionally (c) one or more pharmaceutically-acceptable excipients.
A seventh aspect of the present invention is directed to a method of making compounds of Formula /.
Compounds within the scope of the invention are described in the Examples. Examples of preferred compounds include:
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid;
2-[7-bromo-3-(4-chloro-phenyl)-2,5-dioxo~l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-3-(4-chloro-phenyl)-propionic acid; 2-(4-chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetamide ;
[7-chloro-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -(4-chloro-phenyl)-acetic acid;
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-ethynyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid;
[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -p-tolyl-acetic acid;
(4-chloro-3 -fluoro-phenyl)- [3 -(4-chloro-phenyl)-7-iodo-2,5 -dioxo- l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid; (4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-ethyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid; (4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-isopropyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid;
(4-bromo-phenyl)-[3-(4-chloro-phenyl)-7-isopropyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e] [ 1 ,4]diazepin-4-yl]-acetic acid; [3-(4-chloro-3-fluoro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid;
[3-(4-chlorophenyl)-7-phenyl-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenylacetic acid;
[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -(4-fluoro-phenyl)-acetic acid;
[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -(4-trifluoromethyl-phenyl)-acetic acid;
(4-chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)- l,2,3,5-tetrahydrobenzo[e][l,4] diazepin-4-yl]-acetic acid; (4-chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethyl-phenyl)-
1 ,2,3 ,5-tetrahydrobenzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid;
[3-(4-bromo-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -(4-chloro-phenyl)-acetic acid;
[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-isopropyl-phenyl)-acetic acid;
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-cyano-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e] [ 1 ,4]diazepin-4-yl]-acetic acid;
3-(4-chloro-phenyl)-4-(3-hydroxy-l-phenyl-propyl)-7-iodo-3,4- dihydro-lH-benzo[e][l,4]diazepine-2,5-dione; 2-(4-chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e] [1 ,4]diazepin-4-yl]-N-hydroxy-acetamide;
[7-bromo-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -(4-chloro-phenyl)-acetic acid;
[8-chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo- 1,2,3, 5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid; 5-{2-(4-chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo- l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetylamino}-pentanoic acid;
3-{2-(4-chloro-phenyl)-2-[3-(4-chloro-ρhenyl)-7-iodo-2,5-dioxo- l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetylamino}-propionic acid; 5-[4-[carboxy-(4-chloro-phenyl)-methyl]-3-(4-chloro-phenyl)-7-iodo-
2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][l,4]diazepin-l-yl]-pentanoic acid; and pharmaceutically acceptable salts thereof.
Additional examples of preferred compounds include:
(4-chlorophenyl)-[3-(4-chlorophenyl)-7-iodo-5-oxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]acetic acid;
3-(4-chloro-phenyl)-3-[3-(4-chloro-phenyl)-7-iodo-5-oxo-l,2,3,5- tetrahydro-benzo[e] [1 ,4]diazepin-4-yl]-propionic acid;
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-5-oxo-2-thioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diaze pin-4-yl] -acetic acid; 3 -(4-chloro-phenyl)-4- [ 1 -(4-chloro-phenyl)-2-hydroxy-ethyl] -7-iodo-
1 ,3,4,5-tetrahydro-benzo[e] [ 1 ,4]diazepin-2-one;
3-(4-chloro-phenyl)-4-[l-(4-chloro-phenyl)-2-hydroxy-ethyl]-7-iodo- l,2,3,4-tetrahydro-benzo[e][l,4]diazepin-5-one; and pharmaceutically-acceptable salts thereof. The invention disclosed herein is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result for example from the oxidation, reduction, hydrolysis, amidation, esterification and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof. Such products typically are identified by preparing a radiolabeled compound of the invention, administering it parenterally in a detectable dose to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur and isolating its conversion products from the urine, blood or other biological samples. Some of the compounds disclosed herein may contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms. The present invention is also meant to encompass all such possible forms as well as their racemic and resolved forms and mixtures thereof. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended to include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present invention as well.
As used herein, the term "stereoisomers" is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another
(diastereomers).
The term "chiral center" refers to a carbon atom to which four different groups are attached, or a sulfur atom to which three different groups are attached, where the sulfur atom and its attached groups form a sulfoxide, sulfinic ester, sulfonium salt or sulfite.
The term "enantiomer" or "enantiomeric" refers to a molecule that is nonsuperimposable on its mirror image and hence optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image rotates the plane of polarized light in the opposite direction.
The term "racemic" refers to a mixture of equal parts of enantiomers and which is optically inactive.
The term "resolution" refers to the separation or concentration or depletion of one of the two enantiomeric forms of a molecule. The phrase
"enantiomeric excess" refers to a mixture wherein one enantiomer is present is a greater concentration than its mirror image molecule.
The compounds of Formula / may also be solvated, especially hydrated. Hydration may occur during manufacturing of the compounds or compositions comprising the compounds, or the hydration may occur over time due to the hygroscopic nature of the compounds. Certain compounds within the scope of Formula J are derivatives referred to as "prodrugs." The expression "prodrug" denotes a derivative of a known direct acting drug, which derivative has enhanced delivery characteristics and therapeutic value as compared to the drug, and is transformed into the active drug by an enzymatic or chemical process.
Prodrugs are derivatives of the compounds of the invention which have metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. For example, ester derivatives of compounds of this invention are often active in vivo, but not in vitro. Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but the acid derivative form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine. Simple aliphatic or aromatic esters derived from acidic groups pendent on the compounds of this invention are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters. Useful prodrugs are those where Rb is alkyl, alkenyl, alkynyl, or arylalkyl.
When any variable occurs more than one time in any constituent or in Formula /, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
Definitions
The term "alkyl" as employed herein by itself or as part of another group refers to both straight and branched chain radicals of up to 10 carbons, unless the chain length is otherwise limited, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, or decyl.
The term "alkenyl" is used herein to mean a straight or branched chain radical of 2-10 carbon atoms, unless the chain length is otherwise limited, wherein there is at least one double bond between two of the carbon atoms in the chain, including, but not limited to, ethenyl, 1-propenyl, 2-propenyl, 2- methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like. Preferably, the alkenyl chain is 2 to 8 carbon atoms in length, most preferably from 2 to 4 carbon atoms in length. The term "alkynyl" is used herein to mean a straight or branched chain radical of 2-10 carbon atoms, unless the chain length is otherwise limited, wherein there is at least one triple bond between two of the carbon atoms in the chain, including, but not limited to, ethynyl, 1-propynyl, 2-propynyl, and the like. Preferably, the alkynyl chain is 2 to 8 carbon atoms in length, most preferably from 2 to 4 carbon atoms in length.
In all instances herein where there is an alkenyl or alkynyl moiety as a substituent group, the unsaturated linkage, i.e., the vinyl or ethenyl linkage, is preferably not directly attached to a nitrogen, oxygen or sulfur moiety.
The term "alkoxy" or "alkyloxy" refers to any of the above alkyl groups linked to an oxygen atom. Typical examples are methoxy, ethoxy, isopropyloxy, sec- butyloxy, and t-butyloxy.
The term "aryl" as employed herein by itself or as part of another group refers to monocyclic or bicyclic aromatic groups containing from 6 to 12 carbons in the ring portion, preferably 6-10 carbons in the ring portion. Typical examples include phenyl, biphenyl, naphthyl or tetrahydronaphthyl.
The term "aralkyl" or "arylalkyl" as employed herein by itself or as part of another group refers to Q-6 alkyl groups as discussed above having an aryl substituent, such as benzyl, phenylethyl or 2-naphthylmethyl.
The term "heteroaryl" as employed herein refers to groups having 5 to 14 ring atoms; 6, 10 or 14 pi electrons shared in a cyclic array; and containing carbon atoms and 1, 2, 3, or 4 oxygen, nitrogen or sulfur heteroatoms (where examples of heteroaryl groups are: thienyl, benzo[b]thienyl, naphtho[2,3- b]thienyl, thianthrenyl, furyl, pyranyl, isobenzofuranyl, benzoxazolyl, chromenyl, xanthenyl, phenoxathiinyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl, pteridinyl, 4αH- carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl, phenoxazinyl, and tetrazolyl groups). The phrase "saturated or partially unsaturated heterocycle" as employed herein, by itself or as part of another group, refers to a saturated or partially unsaturated ring system having 5 to 14 ring atoms selected from carbon atoms and 1, 2, 3, or 4 oxygen, nitrogen, or sulfur heteroatoms. Typical saturated examples include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidyl, piperazinyl, quinuclidinyl, morpholinyl, and dioxacyclohexyl. Typical partially unsaturated examples include pyrrolinyl, imidazolinyl, pyrazolinyl, dihydropyridinyl, tetrahydropyridinyl, and dihydropyranyl. Either of these systems can be optionally fused to a benzene ring. The terms "heteroarylalkyl" or "heteroaralkyl" as employed herein both refer to a heteroaryl group attached to an alkyl group. Typical examples include 2-(3-pyridyl)ethyl, 3-(2-furyl)-.z-propyl, 3-(3-thienyl)-/ι-propyl, and 4-( 1 -isoquinolinyl)-π-butyl .
The term "cycloalkyl" as employed herein by itself or as part of another group refers to cycloalkyl groups containing 3 to 9 carbon atoms.
Typical examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and cyclononyl.
The term "cycloalkylalkyl" or "cycloalkyl(alkyl)" as employed herein, by itself or as part of another group, refers to a cycloalkyl group attached to an alkyl group. Typical examples are 2-cyclopentylethyl, cyclohexylmethyl, cyclopentylmethyl, 3-cyclohexyl-n-propyl, and 5-cyclobutyl-π-pentyl. The term "cycloalkenyl" as employed herein, by itself or as part of another group, refers to cycloalkenyl groups containing 3 to 9 carbon atoms and 1 to 3 carbon-carbon double bonds. Typical examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cyclooctenyl, cyclooctadienyl, cyclooctatrienyl, cyclononenyl, and cyclononadienyl.
The term "halogen" or "halo" as employed herein by itself or as part of another group refers to chlorine, bromine, fluorine or iodine.
The term "monoalkylamine" or "monoalkylamino" as employed herein by itself or as part of another group refers to the group NH2 wherein one hydrogen has been replaced by an alkyl group, as defined above.
The term "dialkylamine" or "dialkylamino" as employed herein by itself or as part of another group refers to the group NH wherein both hydrogens have been replaced by alkyl groups, as defined above. The term "hydroxyalkyl" as employed herein refers to any of the above alkyl groups wherein one or more hydrogens thereof are substituted by one or more hydroxyl moieties.
The term "haloalkyl" as employed herein refers to any of the above alkyl groups wherein one or more hydrogens thereof are substituted by one or more halo moieties. Typical examples include fluoromethyl, difluoromethyl, trifluoromethyl, trichloroethyl, trifluoroethyl, fluoropropyl, and bromobutyl.
The term "carboxyalkyl" as employed herein refers to any of the above alkyl groups wherein one or more hydrogens thereof are substituted by one or more carboxylic acid moieties. The term "heteroatom" is used herein to mean an oxygen atom ("O"), a sulfur atom ("S") or a nitrogen atom ("N"). It will be recognized that when the heteroatom is nitrogen, it may form an NRaRb moiety, wherein Ra and Rb are, independently from one another, hydrogen or Q to C8 alkyl, or together with the nitrogen to which they are bound form a saturated or unsaturated 5-, 6-, or 7-membered ring. The phrase "optionally substituted" when not explicitly defined refers to a group or groups being optionally substituted with one or more substituents independently selected from the group consisting of hydroxy, nitro, trifluoromethyl, halogen, Q.6 alkyl, Q-6 haloalkyl, Q-6 alkoxy, Q-6 alkylenedioxy, Q-6 aminoalkyl, Q.6 hydroxyalkyl, C2-4 alkenyl, C2-4 alkynyl,
C6-io aryl, phenoxy, benzyloxy, 5-10 membered heteroaryl, Q-6 aminoalkoxy, amino, mono(Q-4)alkylamino, di(Q-4)alkylamino, C2.6 alkylcarbonylamino, C2-6 alkoxycarbonylamino, Q-6 alkoxycarbonyl, C2-6 alkoxycarbonylalkyl, carboxy, C2-6 hydroxyalkoxy, (C1-6)alkoxy(C2-6)alkoxy, mono(C1.4)alkylamino(C2-6)alkoxy, di(Q-4)alkylamino(C2-6)alkoxy C2-io mono(carboxyalkyl)amino, bis(C2_ιo carboxyalkyl)amino, C2-6 carboxyalkoxy, C2-6 carboxyalkyl, carboxyalkylamino, guanidinoalkyl, hydroxyguanidinoalkyl, cyano, trifluoromethoxy, or perfluoroethoxy.
Preferred optional substituents include one or more substituents independently selected from the group consisting of nitro, hydroxy, carboxy,
Q-4 alkoxy, -4 alkyl, halo, Q-4 haloalkyl, Q-4 alkylthio, thio, amino,
Figure imgf000023_0001
and di(Q-4)alkylamino.
"mdm2" is used herein to mean the murine double minute 2 gene, and homologous genes found in other animals. "MDM2" is used herein to mean a protein obtained as a result of expression of the mdm2 oncogene. Within the meaning of this term, it will be understood that MDM2 encompasses all proteins encoded by mdm2, mutants thereof, alternative splice proteins thereof, and phosphorylated proteins thereof. Additionally, as used herein, it will be understood that the term "MDM2" includes MDM2 homologues of other animals (e.g. , HDM2).
"hdm2" is used herein to mean the human gene which is homologous to the mouse mdm2.
"HDM2" is used herein to mean a protein obtained as a result of expression of the hdm2 oncogene. Within the meaning of this term, it will be understood that HDM2 encompasses all proteins encoded by the hdm2, mutants thereof, alternative splice proteins thereof, and phosphorylated proteins thereof.
The phrase "antineoplastic agent" is used herein to mean any agent that is used to treat or prevent cancer or other conditions comprising uncontrolled proliferation and growth of cells. Antineoplastic agents include anticancer agents.
The phrase "contacting one or more proteins" is used herein to mean placing a compound of the present invention in a solution with one or more proteins of interest. A compound of Formula J and one or more proteins of interest may be in solution together in an aqueous solution, non-aqueous solution, or combination of an aqueous solution and non-aqueous solution. Other proteins may be present in solution along with the compound of Formula J and the protein of interest. Other inorganic or organic molecules may be present in the solution. Such inorganic and organic molecules include, but are not limited to, NaCl, HEPES, and octyl glucoside. The solution may be within an animal cell or outside of an animal cell.
The phrase "inhibiting the binding" is used herein to mean preventing or reducing the direct or indirect association of one or more molecules, peptides, proteins, enzymes, or receptors; or preventing or reducing the normal activity of one or more molecules, peptides, proteins, enzymes, or receptors.
The phrase "inducing apoptosis" is used herein to mean causing directly or indirectly a cell of animal origin to undergo apoptosis, a process of controlled, or programmed, cellular death.
The phrase "HDM2 inhibitor" is used herein to describe an agent which inhibits the function of HDM2 in the assay described in Example 217.
The pharmaceutically-acceptable salts of the compounds of Formula J (in the form of water- or oil-soluble or dispersible products) include the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, > hydrobromide, hydroiodide,
2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen- containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides like benzyl and phenethyl bromides and others. Preferred acids for forming acid addition salts include HCl, acetic acid, trifluoroacetic acid and fumaric acid.
Compositions and Methods of Use
Compositions of the present invention include pharmaceutical compositions comprising a compound of Formula /, wherein R'-R10 are defined above, and one or more pharmaceutically acceptable excipients.
Preferred compositions of the present invention are pharmaceutical compositions comprising a compound selected from a preferred group of compounds of Formula J as defined above, and one or more pharmaceutically acceptable excipients.
The pharmaceutical compositions of the invention can be administered to any animal that can experience the beneficial effects of the compounds of the invention. Foremost among such animals are humans, although the invention is not intended to be so limited. The pharmaceutical compositions of the present invention can be administered by any means that achieve their intended purpose. For example, administration can be by subcutaneous, intravenous, intramuscular, intraperitoneal, buccal, or ocular routes, rectally, parenterally, intrasystemically, intravaginally, topically (as by powders, ointments, drops or transdermal patch), or as an oral or nasal spray. Alternatively, or concurrently, administration can be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. In addition to the pharmacologically active compounds, the new pharmaceutical preparations can contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically.
The pharmaceutical preparations of the present invention are manufactured in a manner that is, itself, known, for example, by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
Suitable excipients are, in particular, fillers such as saccharides, for example, lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, as well as binders, such as, starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents can be added, such as, the above-mentioned starches and also carboxymethyl-starch, cross- linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as, sodium alginate. Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as, magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings that, if desired, are resistant to gastric juices. For this purpose, concentrated saccharide solutions can be used, which can contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol, and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations, such as, acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used. Dye stuffs or pigments can be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as, glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules that may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as, fatty oils or liquid paraffin. In addition, stabilizers may be added.
Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water- soluble salts, alkaline solutions and cyclodextrin inclusion complexes. Especially preferred alkaline salts are ammonium salts prepared, for example, with Tris, choline hydroxide, Bis-Tris propane, N-methylglucamine, or arginine. One or more modified or unmodified cyclodextrins can be employed to stabilize and increase the water solubility of compounds of the present invention. Useful cyclodextrins for this purpose are disclosed in U.S. Patent Νos. 4,727,064, 4,764,604, and 5,024,998.
In addition, suspensions of the active compounds as appropriate oily injection suspensions can be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400 (the compounds are soluble in PEG-400). Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof. Topical administration includes administration to the skin or mucosa, including surfaces of the lung and eye. Compositions for topical administration, including those for inhalation, may be prepared as a dry powder which may be pressurized or non-pressurized. In nonpressurized powder compositions, the active ingredients in finely divided form may be used in admixture with a larger-sized pharmaceutically acceptable inert carrier comprising particles having a size, for example, of up to 100 micrometers in diameter. Suitable inert carriers include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers. Alternatively, the composition may be pressurized and contain a compressed gas, such as nitrogen or a liquefied gas propellant. The liquefied propellant medium and indeed the total composition are preferably such that the active ingredients do not dissolve therein to any substantial extent. The pressurized composition may also contain a surface-active agent. The surface- active agent may be a liquid or solid non-ionic surface-active agent or may be a solid anionic surface-active agent. It is preferred to use the solid anionic surface-active agent in the form of a sodium salt.
A further form of topical administration is to the eye. The compounds and compositions of the present invention are delivered in a pharmaceutically acceptable ophthalmic vehicle, such that the compounds are maintained in contact with the ocular surface for a sufficient time period to allow the compounds to penetrate the corneal and internal regions of the eye, as for example the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/ciliary, lens, choroid/retina and sclera. The pharmaceutically acceptable ophthalmic vehicle may, for example, be an ointment, vegetable oil or an encapsulating material.
Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the drugs.
The compositions of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the compounds of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art (see, for example, Prescott, Ed., Meth. Cell Biol. 14:33 (1976)).
Compounds of the present invention may be used alone or in combination with one or more additional antineoplastic agents. When a compound of the present invention is used along with one or more additional antineoplastic agents, the compound of the present invention may be formulated with the other antineoplastic agent or agents so that a pharmaceutical composition comprising a compound of Formula / and one or more additional antineoplastic agents is administered to an animal. Alternatively, the compound of Formula / can be administered as a separate pharmaceutical composition from the composition comprising the one or more additional antineoplastic agents. Antineoplastic agents that may be used in combination with the compounds of the present invention include compounds selected from the following compounds and classes of antineoplastic agents: 1. fluoropyrimidines, such as 5-FU (5-fluorouracil),
Fluorodeoxyuridine, Ftorafur, 5'-deoxyfluorouridine, UFT, and S-l Capecitabine;
2. pyrimidine nucleosides, such as Deoxycytidine, Cytosine Arabinoside, Cytarabine, Azacitidine, 5-Azacytosine, Gencitabine, and 5-Azacytosine-Arabinoside;
3. purines, such as 6-Mercaptopurine, Thioguanine, Azathioprine, Allopurinol, Cladribine, Fludarabine, Pentostatin, and 2-Chloroadenosine;
4. platinum analogues, such as Cisplatin, Carboplatin, Oxaliplatin, Tetraplatin, Platinum-DACH, Ormaplatin, and CI-973, JM-216; 5. anthracyclines/anthracenediones, such as Doxorubicin,
Daunorubicin, Epirubicin, Idarubicin, and Mitoxantrone;
6. epipodophyllotoxins, such as Etoposide, and Teniposide;
7. camptothecins, such as Irinotecan, Topotecan, 9-Amino Camptothecin, 10,H-Methylenedioxy Camptothecin, 9-Nitro Camptothecin, and TAS 103; 8. hormones and hormonal analogues, such as diethylstilbestrol, Tamoxifen, Toremefine, Tolmudex, Thymitaq, flutamide, fluoxymesterone, bicalutamide, Finasteride, estradiol, Trioxifene, dexamethasone, leuproelin acetate, estramustine, Droloxifene, medroxyprogesterone, megesterol acetate, aminoglutethimide, testolactone, testosterone, diethylstilbestrol, and hydroxyprogesterone;
9. enzymes, proteins and antibodies, such as Asparaginase, Interleukins, Interferons, Leuprolide, and Pegaspargase;
10. vinca alkaloids, such as Nincristine, Ninblastine, Ninorelbine, and Nindesine;
11. taxanes, such as Paclitaxel, Taxotere and Docetaxel. Antineoplastic agents that may be used in combination with compounds of the invention also include compounds selected from the following Mechanism-Based Classes: 1. Antihormonals-See classification for Hormones and Hormonal
Analogs above, Anastrozole, Goserelin, and Aminoglutethimide;
2. Antifolates, such as methotrexate, leucovorin, aminopterin, trimetrexate, Trimethoprim, pyritrexim, pyrimethamine, Edatrexate, and
MDAM; 3. Antimicrotubule Agents, such as Taxanes, Ninca Alkaloids, and Ninorelbine;
4. Alkylating Agents (Classical and Non-Classical), such as Nitrogen Mustards (Mechlorethamine, Chlorambucil, Melphalan, Uracil Mustard), Oxazaphosphorines (Ifosfamide, Cyclophosphamide, Perfosfamide, Trophosphamide), Alkylsulfonates (Busulfan), Nitrosoureas (Carmustine,
Lomustine, Streptozocin), Thiotepa, and Dacarbazine;
5. Antimetabolites, such as Purines, pyrimidines and nucleoside analogs, listed above;
6. Antibiotics, such as Anthracyclines/Anthracenediones, Bleomycin, Dactinomycin, Mitomycin, Plicamycin, Pentostatin, and
Streptozocin; 7. Topoisomerase Inhibitors, such as Camptothecins (Topo I), Epipodophyllotoxins, AMSA, NP-16 and Ellipticines (Topo II);
8. Antivirals, such as AZT, acyclovir, penciclovir, famcyclovir, didehydrodideoxythymidine, dideoxycytidine, -SddC, ganciclovir, dideoxyinosine, and viral-specific protease inhibitors;
9. Miscellaneous Cytotoxic Agents, such as Hydroxyurea, Mitotane, Fusion Toxins, PZA, Bryostatin, Retinoids, Butyric Acid and derivatives, Pentosan, Fumagillin, Mitoxantrone, Bone Marrow Growth Factors, and Procarbazine. Compounds of the present invention are useful for the treatment of uncontrolled proliferation of cells and/or cancer. The compounds of the present invention may produce beneficial cytostatic and/or cytotoxic effects. The cytostatic effects include the inhibition of further cell growth and/or cell division. The cytotoxic effects include the induction of cell death by mechanisms that include apoptosis and cellular necrosis. Specifically, the compounds of the present invention are useful in treating the following cancers: breast cancer, ovarian cancer, cervical carcinoma, endometrial carcinoma, choriocarcinoma, soft tissue sarcomas, osteosarcomas, rhabdomyosarcomas, leiomyomas, leiomyosarcomas, head and neck cancers, lung and bronchogenic carcinomas, brain tumors, neuroblastomas, esophogeal cancer, colorectal adenocarcinomas, bladder cancer, urothelial cancers, leukemia, lymphoma, malignant melanomas, oral squamous carcinoma, hepatoblastoma, glioblastoma, astrocytoma, medulloblastoma, Ewing's sarcoma, lipoma, liposarcoma, malignant fibroblast histoma, malignant Schwannoma, testicular cancers, thyroid cancers, Wilms' tumor, pancreatic cancers, colorectal adenocarcinoma, tongue carcinoma, gastric carcinoma, and nasopharyngeal cancers. Preferably, the present invention is used to treat the cancers selected from the group consisting of breast cancer, choriocarcinoma, soft tissue sarcomas, osteosarcomas, rhabdomyosarcomas, lipoma and liposarcoma. The cancers and diseases listed above are merely meant to be illustrative and are by no means meant to be a limiting or exhaustive list. Additionally, the compounds and compositions described herein are useful to treat any undesired or detrimental condition that results from the
HDM2 protein or the MDM2 protein inhibiting the function of p53 or other cellular proteins that induce apoptosis, induce cellular death, or regulate the cellular cycle.
The compounds of the present invention are also useful at inhibiting the interaction between p53 and HDMX and/or MDMX. MDMX, also known as MDM4, is a cellular protein involved in the regulation of the cell cycle. For example, see Riemenschneider et al, Cancer Res. 59(24):6091-6 (1999). The compounds of the present invention are also useful for the treatment and prevention of inflammatory conditions. The compounds of the present invention can be administered as anti-inflammatory agents that reduce the degree of or eliminate inflammation of tissues.
The compounds of the present invention are also useful for the treatment of autoimmune diseases and conditions. The compounds of the present invention can be administered to reduce or eliminate the symptoms of an autoimmune disease. Autoimmune diseases include any disease in which an animal's immune system reacts adversely to a self-antigen. A self-antigen is any antigen that is normally found in the animal's body. Representative autoimmune diseases include Hashimoto's thyroiditis, Grave's disease, multiple sclerosis, pernicious anemia, Addison's disease, insulin-dependent diabetes mellitus, rheumatoid arthritis, systemic lupus erythematosus (SLE or lupus), dermatomyositis, Crohn's disease, Wegener's granulomatosis, Anti- Glomerular Basement Membrane Disease, Antiphospholipid Syndrome, Dermatitis Herpetiformis, Allergic Encephalomyelitis, Glomerulonephritis,
Membranous Glomerulonephritis, Goodpasture Syndrome, Lambert-Eaton, Myasthenic Syndrome, Myasthenia Gravis, Bullous Pemphigoid, Polyendocrinopathies, Reiter's Disease, and Stiff-Man Syndrome. Preferably, the present invention is used to treat rheumatoid arthritis or systemic lupus erythematosus. Inhibitors of the interaction of HDM2 and/or MDM2 and p53 are also useful for treating cancer, inhibiting cell growth/replication, and inducing cellular apoptosis and necrosis, when administered along with agents that cause or induce DNA damage (see Chen et al. Proc. Nail. Acad. Sci. USA 95:195-200 (1998)). Compounds of the present invention may be used to treat cancer, inhibit cell growth/replication, and induce cellular apoptosis and necrosis, by administering a compound of the present invention along with agents that cause or induce DNA damage. Agents that induce DNA damage include radiation and chemical agents. The radiation can be administered either internally or externally. Chemical agents include any compounds or elements that cause or induce damage to DNA.
The compounds of the present invention may be administered in an effective amount within the dosage range of about 0.01 mg/kg to about 300 mg/kg, preferably between 1.0 mg/kg to 100 mg/kg body weight. Compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
Preparation of Compounds
The present invention is also concerned with the syntheses of substituted l,4-benzodiazepin-2,5-dione carboxylic acids. The compounds of the present invention can be prepared utilizing the modification of Ugi condensation products, according to the synthetic pathway shown in Scheme 1 or Scheme 2 and as detailed in Keating and Armstrong, J. Am. Chem. Soc, 778: 2574-2583 (1996). SCHEME1
Figure imgf000035_0001
SCHEME 2
Figure imgf000036_0001
Appropriately substituted or unsubstituted anthranilic acids 1 or 11, amines 3, aldehydes or ketones 2 can be used to prepare the compounds of the present invention, wherein R1, R2, R3, R4, R6, R7, R8, R9, and R10 are defined above. The acid compounds of the present invention can be prepared by optional hydrolysis of ester using a base, such as NaOH, in an appropriate solvent, such as methanol/water. In Scheme 2, the standard Suzuki (Miyaura, N; Yanagi, T.; Suzuki, A., Synth. Commun., 11: 513 (1981)) cross coupling condition can be used to introduce R2 (from compound 12 to 6). While R5 is selected as a group other than hydrogen, R5 can be introduced by using R5Br in the presence of a base, such as NaH, and a solvent, such as THF, or by using a standard Mitsunobu coupling procedure (Mitsunobu, O., Synthesis, 1, (1981)) such as diethyl azodicarboxylate, and triphenylphosphine in THF. Compound 7 can be converted into compound 8 or 9 by using an appropriate reducing reagent, such as BH3 «S(Me)2, in a solvent such as THF. Compound 10 can be made through reaction of compound 7 with Lawesson's reagent (2,4-bis(4-methoxyphenyl)- 1 ,3-dithia-2,4-diphosphetane-2,4-disulfide) in a solvent such as THF. The following examples illustrate, but do not limit, the compounds, methods and compositions of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the invention.
EXAMPLES
The compounds in the examples below were synthesized by the following general procedures.
General procedure for the synthesis of non-commercially available anthranilic acids
A solution of the appropriate aniline (50.0 mmol) in acetic acid (30.0 mL) was heated to 45° C. Bromine (55.5 mmol, 2.8 mL) was then added dropwise at a rate to keep the temperature between 50-55° C. The temperature was held at 50° C for 1.5 h. The reaction was allowed to cool to ambient temperature and was poured into ice with stirring. Sodium bisulfite (1.0 g) was added and stirred for 30 min. The solution was extracted with ethyl acetate (2 x 50.0 mL). The combined organic extracts were washed with saturated sodium bicarbonate, brine, dried over sodium sulfate, filtered and concentrated in vacuo to give a dark oil. The oil was purified by flash chromatography (silica gel, 5-10 % ethyl acetate in hexanes) to give the aryl bromide as a light brown oil.
A solution of the aryl bromide (12.0 mmol) in N,N-dimethylformamide (8.0 mL) was stirred at ambient temperature. Copper cyanide (15.0 mmol, 1.3 g) was added and the reaction was heated to 155° C for 4 h. The reaction was allowed to cool and poured into a solution of ethylene diamine (0J mL) in water (130.0 mL) and stirred for 30 min. The solution was extracted with ethyl acetate (2 x 70.0 mL). The organic extracts were combined and washed with saturated ammonium chloride and brine, dried with sodium sulfate and concentrated in vacuo. The residue was then purified by flash chromatography (silica gel, 10 % ethyl acetate in hexane) to give the aryl cyanide as a orange oil.
To a solution of the aryl cyanide (1.5 mmol) in acetic acid (2.0 mL) was added 50 % sulfuric acid (6.0 mL), The reaction was heated to reflux for 2.5 h. The reaction was allowed to cool to ambient temperature and poured into ice (50.0 g). The solution was neutralized with potassium hydroxide (6M) and extracted with ethyl acetate (2 x 40.0 mL). The combined organics were washed with brine and dried with sodium sulfate, filtered and dried in vacuo to a solid. The solid was purified by flash chromatography (silica gel, 15 % ethyl acetate in methylene chloride to 8 % methanol in methylene chloride) to give the anthranilic acid as a white solid.
To a solution of the anthranilic acid (4.2 mmol) in 1,4-dioxane (20.0 mL) and 10 % sodium hydroxide (5.0 mL) was added di-tertbutyl-dicarbonate (12.0 mmol). The reaction was stirred at ambient temperature for 3 days. The reaction was then concentrated in vacuo and poured into water (25.0 mL) and ethyl acetate (50.0 mL). It was then acidified with cold 10 % citric acid. The organic layers were washed with brine and dried with sodium sulfate and filtered. The organics were concentrated in vacuo to a solid and triturated with hexane. The solids were filtered, and washed with hexane and dried under high vacuum to give the title compound as a white solid. General procedure for the synthesis of benzodiazepine compounds
A solution of the aldehyde (0.20 mmol) and amino ester (0.20 mol) in methanol (2.0 mL) were shaken at ambient temperature for 30 min. To this solution was added a solution of cyclohexene-1-isonitrile (0.21 mmol) in hexanes, followed by the anthranilic acid (0.20 mmol). The solution was then shaken for 3 days at ambient temperature. The reaction was cooled in a ice bath and acetyl chloride (0.2 mL) was added slowly. The solution was then shaken for an additional 3 h and concentrated in vacuo. The residue was purified using pre-packed silica cartridges (methylene chloride to 10 % ethyl acetate in methylene chloride). The pure ester was then concentrated back down in vacuo, dissolved in methanol (1.5 mL), and 10% sodium hydroxide (0J5 mL) was added. The reaction mixture was shaken overnight at ambient temperature. The solution was then concentrated in vacuo and acidified with hydrochloric acid (IM). The precipitates were extracted with ethyl acetate, separated and the organics were concentrated in vacuo. The residue was purified using pre-packed silica cartridges (8 % ethyl acetate in methylene chloride to 10 % methanol in methylene chloride) to give the title compounds (0.015-0.050 g).
General procedure for the alkylation of benzodiazepine compounds
To a solution of the benzodiazepine (0J mmol) and alcohol (0.2 mmol) in tetrahydrofuran (1.0 mL) was added triphenylphosphine (0.2 mmol, 0.052 g) in tetrahydrofuran (1.0 mL). The solution was shaken 5 minutes then diisopropyl azodicarboxylate (0.2 mmol, 0.040 mL) was added, and the mixture was shaken at ambient temperature overnight. The reaction was concentrated in vacuo. The residue was purified by preparative plate chromatography (silica gel, 20% ethyl acetate in methylene chloride, bottom band). The isolated ester was dissolved in methanol (1 mL) and sodium hydroxide (IM, 0.2 mL) was added and the reaction mixture was shaken at ambient temperature overnight. The reaction was concentrated in vacuo, water (0.5 mL) was added, followed by acidification with hydrochloric acid (IM, 0.3 mL). The resulting precipitate was extracted with ethyl acetate (1 mL) and separated. The organics were dried in vacuo and the residues purified using a preparative plate chromatography (silica gel, 8 % methanol in methylene chloride, bottom band) to give the title compounds (0.012-0.030 g).
General procedure for the boronic acid cross coupling of benzodiazepine compounds
Benzodiazepine (0.05 mmol), boronic acid (3 eq, 0J5 mmol), and
Pd(PPh3)4 (0.04 eq, 0.002 mmol) were placed in a 2 mL vial equipped with a magnetic stir bar. The vial was fitted with a rubber septum then evacuated and backflushed with dry N2. Tetrahydrofuran (THF, 0.8 mL) and 2M Na2CO3 (0.2 mL) were added to the vial via syringe. The reaction vessel was capped tightly under a N2 purge then heated to 50° C for 12 h. After cooling to ambient temperature, the solvent was removed under reduced pressure. The residue was then purified by Sep-Pak (10 g silica gel, methylene chloride to 10 % ethyl acetate in methylene chloride) to give the title compound.
General procedure for the reduction of 1,4-benzodiazepines
1) The benzodiazepine ester (0.070 mmol) was placed in a 4 mL vial equipped with a magnetic stir bar. The vial was fitted with a rubber septum then evacuated and backflushed with N2. Borane-dimethylsulfide (4 eq., 0.28 mmol, 0J4 mL of 2M THF solution) was added via syringe. The reaction was stirred at ambient temperature for 15 hours. The solvent was removed under reduced pressure then the residue was dissolved in ethyl acetate. The organic phase was washed with IM NaOH then the aqueous phase was extracted twice with ethyl acetate. The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and the solvent removed under reduced pressure. The mono- and di-reduced products were separated by column chromatography on silica gel, eluting with 10% ethyl acetate in hexanes to give the title compound.
2) The benzodiazepine acid (0.023 mmol) was placed in a 4 mL vial equipped with a magnetic stir bar. The vial was fitted with a rubber septum then evacuated and backflushed with N2. Dry THF (1 mL) and borane- dimethylsulfide (4 eq., 0.093 mmol, 46 μL of 2M THF solution) were successively added via syringe and microsyringe, respectively. The reaction was stirred at ambient temperature for 16 hours then additional borane- dimethylsulfide (8 eq., 0J86 mmol, 92 μL of 2M THF solution) was added to the reaction. The reaction was stirred at ambient temperature for an additional
4 hours then the solvent was removed under reduced pressure. The residue was purified by column chromatography using a 5 g silica gel SEP-pak column, eluting with 20% ethyl acetate in dichloromethane. The amide reduction products were further separated by preparative TLC on a 1000 micron silica gel plate, developed with 20% ethyl acetate in hexanes to give the title compound.
General procedure for the preparation of 1,4-benzodiazepine amides
The 1,4-benzodiazepine carboxylic acid (0.057 mmol) and EDC (1.5 eq., 0.086 mmol, 16.5 mg) were placed in a 4 mL vial equipped with a magnetic stir bar. The vial was fitted with a rubber septum, then evacuated and backflushed with dry N2. Dry dichloromethane (2 mL) was added via syringe. Once the solids dissolved, the amine (1.5 eq, 0.086 mmol) and triethylamine
(2.5 eq., 0J43 mmol, 20 μL) were successively added via microsyringe. The reaction was stirred at ambient temperature for 2 hours then the volatiles were removed under reduced pressure. The crude product was purified by column chromatography using a 5 g silica gel SEP-pak column eluting with 50% ethyl acetate in dichloromethane. EXAMPLE 1
[7-Iodo-2,5-dioxo-3-(4-trifluoromethylphenyl)-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]phenylacetic acid
1H NMR (400MHz, DMSO-d6): 6 10.68 (s, 0.4H), 10.52 (s, 0.6H),
7.79 (s, OAK), 1.12 (s, 0.6H), 7.52-7.22 (m, 9H), 7.00 (m, IH), 6.63 (d, J = 8.4 Hz, 0.4H), 6.53 (d, J = 8.4 Hz, 0.6H) 6.36 (s, IH), 5.96 (s, 0.6H), 5.28 (s, 0.4H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H16F3N2O : 580.0; Found: 580.9(M+H).
EXAMPLE 2
[3-(4-Chlorophenyl)-7-iodo-2,5-dioxo- 1 ,2,3 ,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]phenylacetic acid
1H NMR (400MHz, DMSO-de): δ 10.74 (s, 0.6H), 10.56 (s, 0.4H), 7.78-6.89 (m, 1 IH), 6.64 (d, J = 8.7 Hz, 0.6H), 6.56 (d, J = 8.7 Hz, 0.4H), 6.30
(br s, IH), 5.65 (s, 0.4H), 5.14 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H16N2O4ICl: 546.0; Found: 546.8(M+H).
EXAMPLE 3
[3-(4-ethyl-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.57 (s, 0.5H), 10.40 (s, 0.5H), 7.78-6.54 (m, 12H), 6.35 (s, 0.5H), 6.31 (s, 0.5H), 5.89(s, 0.5H), 5.18 (s, 0.5H), 2.38 (m, 2 H), 1.00 (m, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H21N2O : 540.1; Found: 540.8(M+H). EXAMPLE 4
[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.77 (s, 0.6H), 10.55 (s, 0.4H), 7.69-6.99 (m, 11H), 6.63 (d, J = 8.6 Hz, 0.6H), 6.55 (d, J = 8.6 Hz, 0.4H), 6.31
(br s, IH), 5.63 (s, 0.4H), 5.18 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H16F3N2O5I: 596.0; Found: 596.8(M+H).
EXAMPLE 5
[7-Iodo-3-(4-isopropyl-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.58 (s, 0.6H), 10.40 (s, 0.4H), 7.63-6.54 (m, 12H), 6.30 (br s, 1 H), 5.64(s, 0.4H), 5.08 (s, 0.6H), 2.60 (m, IH), 0.96 (m, 6H). Mass spectrum (LCMS, ESI pos) Calcd. for C26H23N2O : 554.1; Found: 554.9(M+H).
EXAMPLE 6
[2,5-Dioxo-3-(4-trifluoromethyl-phenyl)-l ,2,3 ,5-tetrahydro- benzo[e] [ 1 ,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.70 (s, 0.6H), 10.2 (s, 0.4H), 1.1-
6.9 (m, 13H), 6.42 (s, 0.4H), 6.39 (s, 0.6H), 5.86 (s, 0.4H), 5.30 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H17F3N2O4: 454.1; Found: 455.0(M+H).
EXAMPLE 7
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethyl-phenyl)-l,2,3,5-tetrahydro- benzo [e] [1,4] diazepin-4-yl] -3-phenyl-ρropionic acid 1H NMR (400MHz, DMSO-d6): δ 10.81 (s, 0.6H), 10.56 (s, 0.4H), 7.70-7.10 (m, 11H), 6.55 (m, IH), 5.79 (s, 0.6H), 5.59 (br s, 0.6H), 5.51 (s, 0.4H), 5.31 (br s, 0.4H), 3.35 (m, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H18F3N2O4I: 594.0; Found: 595.0(M+H).
EXAMPLE 8
(7-Iodo-2,5-dioxo-3-phenyl-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl)- phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.69 (s, 0.6H), 10.47 (s, 0.4H),
7J8-6.79 (m, 12H), 6.63 (d, J = 8.3 Hz, 0.6H), 6.54 (d, J = 8.3 Hz, 0.4H), 6.38 (s, 0.6H), 6.34 (s, 0.4H), 5.83 (s, 0.4H), 5.23 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H17N2O4I: 512.0; Found: 513.0(M+H).
EXAMPLE 9
[7-Iodo-2,5-dioxo-3-(3-trifluoromethyl-phenyl)-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.76 (s, 0.6H), 10.53 (s, 0.4H), 7.81-6.90 (m, 11H), 6.61 (d, J = 8.7 Hz, 0.6H), 6.54 (d, J = 8.6 Hz, 0.4H), 6.40 (s, 0.6H), 6.36 (s, 0.4H), 5.78 (s, 0.4H), 5.40 (s, 0.6H). Mass spectrum
(LCMS, ESI pos) Calcd. for C24H16F3N2O4I: 580.0; Found: 580.8(M+H). EXAMPLE 10
(7-Iodo-2,5-dioxo-3-p-tolyl-l,2,3,5-tetrahydrobenzo[e][l,4]diazepin-4-yl)- phenylacetic acid
1H NMR (400MHz, DMSO-d6): δ 10.64 (s, 0.6H), 10.45 (s, 0.4H), 7.78-6.54 (m, 11H), 6.37 (s, 0.6H), 6.30 (s, 0.4H), 5.77 (s, 0.4H), 5.16 (s,
0.6H), 5.12 (s, IH), 2.05 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C2 H19N2O4I: 526.0; Found: 526.8(M+H).
EXAMPLE 11
[7-Iodo-3-(4-methoxy-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.64 (s, 0.6H), 10.44 (s, 0.4H), 7.78-6.54 (m, 12H), 6.37 (s, 0.6H), 6.30 (s, 0.4H), 5.72 (s, 0.4H), 5.16 (s, 0.6H), 3.61 (s, IH), 3.55 (s, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H19N2O5I: 542.0; Found: 542.8(M+H).
EXAMPLE 12
(7-Iodo-3-naphthalen-2-yl-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl)-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.83 (s, 0.75H), 10.72 (s, 0.25H),
8.01-7.00 (m, 14H), 6.62 (d, J = 8.3 Hz, 0.75H), 6.57 (d, J = 8.3 Hz, 0.25H), 6.44 (s, 0.75H), 6.21 (s, 0.25H), 5.52 (s, 0.25H), 5.26 (s, 0.75H). Mass spectrum (LCMS, ESI pos) Calcd. for C27H19N2O4I: 562.0; Found:
562.9(M+H). EXAMPLE 13
[3-(4-tert-Butyl-phenyl)-7-iodo-2,5-dioxo- 1,2,3, 5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.61 (s, 0.6H), 10.41 (s, 0.4H), 7J8-6.54 (m, 12H), 6.32 (s, 0.6H), 6.27 (s, 0.4H), 5.76(s, 0.4H), 5J3 (s,
0.6H), 1.12(s, 3 H), 1.07 (s, 6H). Mass spectrum (LCMS, ESI pos) Calcd. for C27H25N2O4I: 568J; Found: 568.9(M+H).
EXAMPLE 14
[3-(2-Chloro-ρhenyl)-7-iodo-2,5-dioxo- 1,2,3, 5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.66 (s, 0.4H), 10.53 (s, 0.6H), 7.81-6.90 (m, 11H), 6.72 (s, 0.4H), 6.61 (d, J = 8.7 Hz, 0.4H), 6.54 (d, J = 8.6 Hz, 0.6H), 6.36 (s, 0.6H), 5.22 (s, 0.6H), 5J2 (s, 0.4H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H16N2O4Cl: 546.0; Found: 547.8(M+H).
EXAMPLE 15
[3-(3-Chloro-phenyl)-7-iodo-2,5-dioxo- 1,2,3, 5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.74 (s, 0.6H), 10.53 (s, 0.4H), 1.19-6.16 (m, 11H), 6.65 (d, J = 8.7 Hz, 0.6H), 6.56 (d, J = 8.6 Hz, 0.4H), 6.34 (s, 0.6H), 6.31 (s, 0.4H), 5.72 (s, 0.4H), 5.25 (s, 0.6H). Mass spectrum
(LCMS, ESI pos) Calcd. for C23H16N2O4: 546.0; Found: 546.9(M+H). EXAMPLE 16
[3-(4-Benzyloxy-phenyl)-7-iodo-2,5-dioxo- 1,2,3, 5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.66 (s, 0.7H), 10.47 (s, 0.3H), 7.78-6.56 (m, 17H), 6.35 (s, 0.7H), 6.28 (s, 0.3H), 5.66 (s, 0.3H), 5.13 (s,
0.7H), 4.95 (s, 0.5H), 4.89 (s, 1.5H). Mass spectrum (LCMS, ESI pos) Calcd. for C30H23N2O5I: 618.1; Found: 618.8(M+H).
EXAMPLE 17
[7-Iodo-2,5-dioxo-3-(4-phenoxy-phenyl)-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.61 (s, 0.5H), 10.41 (s, 0.5H), 7.80-6.55 (m, 17H), 6.33 (s, 0.5H), 5.88 (s, 0.5H), 5.36 (s, 0.5H), 5.22 (s, 0.5H). Mass spectrum (LCMS, ESI pos) Calcd. for C29H21N2O5I: 604.0; Found: 604.8(M+H).
EXAMPLE 18
[7-Iodo-2,5-dioxo-3-(2-trifluoromethyl-phenyl)-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.72 (s, 0.5H), 10.61 (s, 0.5H), 7.81-6.54 (m, 12H), 6.40 (s, 0.5H), 5.35 (s, 0.5H), 5.29 (s, 0.5H), 5.08 (s, 0.5H). Mass spectrum (LCMS, ESI pos) Calcd. for C24Hi6F3N2O4: 580.0;
Found: 580.9(M+H). EXAMPLE 19
3-(3,4-Dichloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.79 (s, 0.8H), 10.58 (s, 0.2H), 7.81-6.84 (m, lOH), 6.67 (d, J = 8.5 Hz, 0.8H), 6.58 (d, J = 8.5 Hz, 0.2H), 6.33
(s, 0.8H), 6.31 (s, 0.2H), 5.35 (s, 0.2H), 5.24 (s, 0.8H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H15N2O4Cl2: 579.9; Found: 580.8(M+H).
EXAMPLE 20
[3-(3,4-Dimethoxy-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.64 (s, 0.5H), 10.41 (s, 0.5H),
7.81-7.22 (m, 10H), 6.67 (d, J = 8.4 Hz, 0.5H), 6.55 (d, J = 8.5 Hz, 0.5H), 6.42
(s, 0.5H), 6.12 (s, 0.5H), 5.62 (s, 0.5H) 5.30 (s, 0.5H), 3.54 (s, 3H), 3.43 (s,
3H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H21N2O6l: 572.0; Found: 572.8(M+H).
EXAMPLE 21
[3-(2,3-Dihydro-benzo[l,4]dioxin-6-yl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.65 (s, 0.7H), 10.46 (s, 0.3H), 7.78-6.47 (m, 11H), 6.32 (s, 0.8 H), 6.25 (s, 0.8H), 6.23 (s, 0.2H), 5.10 (s,
0.2H), 4.07 (br s, 4H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H19N2O6I: 570.; Found: 570.90 (M+H). EXAMPLE 22
[3-(4-Bromo-2-fluoro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.74 (s, 0.6H), 10.47 (s, 0.4H), 7.81-7.01 (m, 10H), 6.67 (d, J = 8.7 Hz, 0.6H), 6.58 (d, J = 8.6 Hz, 0.4H), 6.26
(s, 0.4H), 6.13 (s, 0.6H) 5.77 (s, 0.4H), 5.14 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H15N2O4BrF: 607.9; Found: 608.8(M+H).
EXAMPLE 23
[3-(2-Fluoro-4-trifluoromethyl-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.76 (s, 0.8H), 10.47 (s, 0.2H), 7.81-6.81 (m, 10H), 6.66 (d, J = 8.4 Hz, 0.8H), 6.56 (d, J = 8.4 Hz, 0.2H), 6.31 (s, 0.2H), 6.16 (s, 0.8H) 6.02 (s, 0.2H), 5.29 (s, 0.8H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H15N2O4F4: 598.0; Found: 598.9(M+H).
EXAMPLE 24
[3-(3-Fluoro-4-trifluoromethyl-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.82 (s, 0.8H), 10.61 (s, 0.2H), 7.81-6.90 (m, 10H), 6.65 (d, J = 8.5 Hz, 0.8H), 6.58 (d, J = 8.5 Hz, 0.2H), 6.31 (s, 0.2H), 6.29 (s, 0.8H) 5.74 (s, 0.2H), 5.29 (s, 0.8H). Mass spectrum
(LCMS, ESI pos) Calcd. for C24H15N2O4F4: 598.0; Found: 598.9(M+H). EXAMPLE 25
[3-(4-Chloro-3-fluoro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.75 (s, 0.8H), 10.57 (s, 0.2H), 7.81-6.60 (m, IIH), 6.27 (bs, IH), 5.67 (s, 0.2H), 5.22 (s, 0.8H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H15N2O4IClF: 564.0; Found: 564.9(M+H).
EXAMPLE 26
[3-(4-Bromo-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.76 (s, 0.6H), 10.57 (s, 0.4H), 7.80-6.82 (m, IIH), 6.64 (d, J = 8.6 Hz, 0.6H), 6.54 (d, J = 8.6 Hz, 0.4H), 6.32 (s, 0.6H), 6.27 (s, 0.4H) 5.58 (s, 0.4H), 5.10 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H16N2O4Br: 589.9; Found: 591.8(M+H).
EXAMPLE 27
[8-Chloro-3-(4-chloro-phenyl)-2,5-dioxo- 1,2,3, 5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.78 (s, 0.8H), 10.58 (s, 0.2H), 7.53-6.83 (m, 12H), 6.34 (s, 0.8H), 6.30 (s, 0.2H), 5.66 (s, 0.2H), 5.14 (s, 0.8H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H16N2O4Cl2: 454.0;
Found: 454.9(M+H). EXAMPLE 28
[7-Chloro-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.79 (s, OJH), 10.58 (s, 0.3H), 7.50-6.77 (m, 12H), 6.34 (s, OJH), 6.31 (s, 0.3H), 5.69 (s, 0.3H), 5J5 (s,
OJH). Mass spectrum (LCMS, ESI pos) Calcd. for C23H16N2O4ICl2: 454.0; Found: 454.9(M+H).
EXAMPLE 29
[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
:H NMR (400MHz, DMSO-d6): δ 10.81 (s, OJH), 10.61 (s, 0.3H), 7.59-6.92 (m, IIH), 6.80 (d, J = 8.6 Hz, OJH), 6.72 (d, J = 8.6 Hz, 0.3H), 6.33 (s, O.IK), 6.29 (s, 0.3H) 5.60 (s, 0.3H), 5J3 (s, OJH). Mass spectrum (LCMS, ESI pos) Calcd. for C23H16N2O4ClBr: 498.0; Found: 499J(M+H).
EXAMPLE 30
[3-(4-Chloro-phenyl)-7-methoxy-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.52 (s, OJH), 10.33 (s, 0.3H),
7.50-6.81 (m, IIH), 6.75 (d, j = 8.9 Hz, OJH), 6.68 (d, J = 8.9 Hz, 0.3H), 6.32 (s, 0.1K), 6.29 (s, 0.3H) 5.47 (s, 0.3H), 5J1 (s, OJH), 3.64 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H19N2O5Cl: 450J; Found:
450.9(M+H). EX AMPLE 31
[3-(4-Chloro-phenyl)-7-methyl-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.59 (s, 0.6H), 10.39 (s, 0.4H), 7.50-6.85 (m, IIH), 6J2 (d, J = 8.1 Hz, 0.7H), 6.65 (d, J = 8.1 Hz, 0.3H), 6.33
(s, 0.7H), 6.29 (s, 0.3H) 5.55 (s, 0.3H), 5.14 (s, OJH), 2.14 (s, 2H), 2.13 (s,
IH). Mass spectrum (LCMS, ESI pos) Calcd. for C24H19N2O4Cl: 434.1;
Found: 435.0(M+H).
EXAMPLE 32
[3-(4-Chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro-naphtho[2,3- e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-de): δ 10.87 (s, 0.6H), 10.71 (s, 0.4H), 8.21-6.98 (m, 12H), 6.38 (s, 0.6H), 6.32 (s, 0.4H) 5.52 (s, 0.4H), 5.20 (s, 0.6H) 2.14 (s, 2H) 2.13 (s, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C27H19N2O4Cl: 470.1; Found: 471.0(M+H).
EXAMPLE 33
[8-Chloro-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.76 (s, 0.9H), 10.55 (s, OJH), 7.53-6.80 (m, 12H), 6.32 (s, IH), 5J8 (s, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C24H16N2O5Cl2F3: 504J; Found: 505.0(M+H). EXAMPLE 34
[7-Chloro-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.81 (s, 0.5H), 10.59 (s,0 .5H), 7.50-7.00 (m, IIH), 6.85 (d, J = 8.8 Hz, 0.5H), 6.77 (d, J = 8.8 Hz, 0.5H), 6.32
(s, IH), 5.67 (s, 0.5H), 5.18 (s, 0.5H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H16N2O5ClF3: 504.1; Found: 504.9(M+H).
EXAMPLE 35
[7-Bromo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.78 (s, 0.9H), 10.56 (s, OJH), 7.58-6.98 (m, IIH), 6J9 (d, J = 8.5 Hz, 0.9H), 6J0 (d, j = 8.5 Hz, OJH), 6.33 (s, IH), 5.75 (s, OJH), 5.20 (s, 0.9H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H16N2θ5BrF3: 548.0; Found: 548.8(M+H).
EXAMPLE 36
[7-Methoxy-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.52 (s, 0.6H), 10.30 (s, 0.4H),
7.52-6.79 (m, IIH), 6J4 (d, J = 8.8 Hz, 0.6H), 6.66 (d, J = 8.8 Hz, 0.4H), 6.33 (s, OAK), 6.30 (s, 0.6H) 5.56 (s, 0.4H), 5J6 (s, 0.6H), 3.62 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H19N2O6F3: 500J; Found:
500.9(M+H). EXAMPLE 37
[7-Methyl-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.60 (s, 0.6H), 10.41 (s, 0.4H), 7.51-7.00 (m, UK), 6.11 (d, J = 8.2 Hz, 0.6H), 6.64 (d, J = 8.2 Hz, 0.4H),
6.30 (s, IH), 5.51 (s, 0.4H), 5.16 (s, 0.6H), 2.11 (s, 2H), 2.10 (s, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C25H19N2O5F3: 484.1; Found:
485.0(M+H).
EXAMPLE 38
[2,5-Dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro-naphtho[2,3- e] [l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-dβ): δ 10.86 (s, 0.8H), 10.51 (s, 0.2H), 7.72-6.90 (m, 15H), 6.37 (s, IH), 5.57 (s, 0.4H), 5.25 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C28H19N2O5F3: 520.1; Found: 521.0(M+H).
EXAMPLE 39
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -3-phenyl-propionic acid
1H NMR (400MHz, DMSO-d6): δ 10.76 (s, 0.6H), 10.51 (s, 0.4H), 1.12-6.95 (m, 1 IH), 6.57 (d, J = 8.9 Hz, 0.4H), 6.54 (d, J = 8.9 Hz, 0.6H), 5.57
(br s, IH), 5.39 (s, 0.6H) 5.28 (s, 0.4H), 3.41 (d, J = 4.2 Hz, 0.8H), 3.37 (d, J =
4.2 Hz, 1.2H). Mass spectrum (LCMS, ESI pos) Calcd. for C2 HιsN2O4Cl:
560.0; Found: 560.8(M+H). EXAMPLE 40
3-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -propionic acid
1H NMR (400MHz, DMSO-d6): δ 10.76 (s, 0.8H), 10.54 (s, 0.2H), 1.12-6.95 (m, 10H), 6.58(d, J = 8.4 Hz, 0.2H), 6.54 (d, J = 8.4 Hz, 0.8H), 5.54
(br s, 1.4H), 5.35 (s, 0.2H), 5.13 (s, 0.4H), 3.41 (d, J = 4.4 Hz, 0.8H), 3.37 (d,
J = 4.4 Hz, 1.2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C24H17N2O4ICl2: 594.0; Found: 594.8 (M+H).
EXAMPLE 41
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-3-(4-hydroxy-phenyl)-propionic acid
1H NMR (400MHz, DMSO-d6): δ 10.74 (s, 0.9H), 10.55 (s, OJH),
9J6 (s, OJH), 9.11 (s, 0.9H), 7.71 (s, 0.2H), 7.62 (d, j = 1.9 Hz, 0.8H), 7.49
(m, IH), 7.15-6.96 (m, 6H), 6.57(m, 3H), 5.63 (br s, 0.8H), 5.46 (br s, 0.8H), 5.21 (br s, 0.4H), 3.25 (m, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C24H18N2O5ICl: 576.0; Found: 576.8(M+H).
EXAMPLE 42
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-3-cyclohexyl-propionic acid
1H NMR (400MHz, DMSO-d6): δ 10.96 (s, 0.9H), 10.84 (s, OJH),
7.76 (d, J = 2.1 Hz, IH), 7.57 (dd, J = 2.2 Hz, 8.4 Hz, IH), 7.23 (d, J = 8.6 Hz, IH), 7.12 (d, J = 8.4 Hz, 2H), 6.61 (d, J = 8.6 Hz, IH), 5.51 (br s, IH), 5.43 (s, IH), 1.87-0.83(m, 13H), 3.23 (d, J = 5.1 Hz, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C2 H2 N2O4Cl: 566.0; Found: 566.9(M+H). EXAMPLE 43
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-3-phenyl-propionic acid
1H NMR (400MHz, DMSO-d6): δ 10.77 (s, 0.8H), 10.52 (s, 0.2H), 1.12-6.95 (m, 1 IH), 6.57 (d, J = 8.6 Hz, 0.2H), 6.52 (d, J = 8.6 Hz, 0.8H), 5.58
(br s, 1.2H), 5.44 (s, 0.4H), 5.29 (s, OAK), 3.42 (d, J = 5.5 Hz, 0.8H), 3.39 (d,
J = 5.5 Hz, 1.2H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H18N2O5IF3:
610.0; Found: 610.9(M+H).
EXAMPLE 44
3-(4-Chloro-phenyl)-2-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-
1 ,2,3 ,5-tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl]-propionic acid
1H NMR (400MHz, DMSO-d6): δ 10.76 (s, 0.8H), 10.54 (s, 0.2H),
1.12-6.95 (m, 10H), 6.57(d, J = 8.6 Hz, 0.2H), 6.52 (d, J = 8.6 Hz, 0.8H), 5.59
(br s, 1.4H), 5.54 (s, 0.2H), 5.40 (s, 0.2H), 5.16 (s, 0.2H), 3.42 (d, J = 5.2 Hz, 0.8H), 3.39 (d, J = 5.2 Hz, 1.2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C25H17N2O5IF3: 644.0; Found: 644.8(M+H).
EXAMPLE 45
3-(4-Hydroxy-phenyl)-2-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)- 1 ,2,3 ,5-tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -propionic acid
1H NMR (400MHz, DMSO-d6): δ 10.76 (s, IH), 9.15 (s, IH), 7.60 (d,
J = 1.6 Hz, 4H), 7.48 (dd, J = 1.9 Hz, 8.4 Hz, 3H), 7.05 (m, 3H), 6.59 (d, J = 8.5 Hz, 0.6H), 6.54 (d, J = 8.5 Hz, 0.4H), 5.53 (br, s, 2H), 3.28 (m, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H18N2O6IF3: 626.0; Found: 626.9(M+H). EXAMPLE 46
3-Cyclohexyl-2-[7-iodo-2,5-dioxo-3-(4Jrifluoromethoxy-phenyl)-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -propionic acid
1H NMR (400MHz, DMSO-d6): δ 10.94 (s, 0.9H), 10.84 (s, OJH), 7.71 (d, J = 1.9 Hz, IH), 7.54 (dd, J = 2.1 Hz, 8.4 Hz, IH), 7.24 (d, J = 8.4 Hz,
2H), 7.14 (d, J = 8.4 Hz, 2H), 6.59 (d, J = 8.6 Hz, IH), 5.51 (br s, 2H), 1.87-
0.83 (m, 13H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H24N2O5IF3:
616J; Found: 616.9(M+H).
EXAMPLE 47
[l-Benzyl-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [1,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 7.62-6.97 (m, 17H), 6.22 (s, 0.6H), 6J9 (s, 0.4H), 5.65 (br s, IH), 5.40 (m, IH), 4.80 (m, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C30H22N2O4IC1: 636.0; Found: 636.9(M+H).
EXAMPLE 48
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo- 1 -phenethyl- 1 ,2,3 ,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, CDC13): δ 7.71 (s, IH), 7.56 (m, 2H), 7.31 (m, 8H), 7.05 (m, 5H), 6.89 (s, IH), 6.20 (s, IH), 5.85 (s, 0.4H), 5.31 (s, 0.6H), 4.23 (m, IH), 3.85 (m, IH), 2.85 (m, 0.5H), 2.62 (m, 1.5H). Mass spectrum
(LCMS, ESI pos) Calcd. for C31H24N2O4Cl: 650.0; Found: 650.9(M+H). EXAMPLE 49
[3-(4-Chloro-phenyl)-7-iodo-l-isobutyl-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 7.68 (m, IH), 7.59 (m, IH), 7.51 (d, J = 6.5 Hz, IH), 7.39 (m, 5H), 7.12 (m, IH), 6.95 (m, 3H), 6.26 (s, 0.6H), 6.13
(s, 0.4H), 5.57 (s, 0.6H), 5.34 (s, 0.4H), 4.10 (m, 2H), 1.60 (m, IH), 0.65 (m,
6H). Mass spectrum (LCMS, ESI pos) Calcd. for C27H24N2O4ICl: 602.0;
Found: 602.9(M+H).
EXAMPLE 50
[3-(4-Chloro-phenyl)-7-iodo-l-(3-methyl-butyl)-2,5-dioxo-l,2,3,5Jetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 7.68 (m, IH), 7.53 (m, 2H), 7.30 (m,
4H), 7.06 (m, 3H), 6.87 (m, IH), 6.26 (s, IH), 6.04 (m, 1.6H), 5.35 (s, 0.4H),
4.07 (m, IH), 3.44 (m, IH), 1.40 (m, IH), 1.24 (m, IH), 1.13 (m, IH), 0.75 (m, 6H). Mass spectrum (LCMS, ESI pos) Calcd. for C28H26N2O4Cl: 616.1;
Found: 616.9(M+H).
EXAMPLE 51
[3-(4-Chloro-ρhenyl)-l-cyclobutylmethyl-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-de): δ 7.65 (m, IH), 7.58 (m, IH), 7.49 (m,
2H), 7.40 (m, 4H), 7.11 (m, 2H), 6.95 (m, 2H), 6.23 (s, OJH), 6.10 (s, 0.7H), 5.56 (s, 0.3H), 5.33 (s, 0.3H), 4.18 (m, IH), 3.52 (m, IH), 2.19 (m, IH), 1.68 (m, 4H), 1.40 (m, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for C28H24N2O4ICl: 614.0; Found: 614.9(M+H). EXAMPLE 52
[3-(4-Chloro-phenyl)-l-cyclopentylmethyl-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 7.66 (m, IH), 7.53 (m, 3H), 7.38 (s, IH), 7.25 (s, 4H), 7.02 (m, 3H), 6.85 (m, IH), 6.34 (s, OJH), 6J0 (br s, IH),
5.44 (s, 0.3H), 4.02 (m, 1.3H), 3.48 (m, OJH), 1.34 (m, 6H), 0J7 (m, 2H).
Mass spectrum (LCMS, ESI pos) Calcd. for C29H26N2O4Cl: 628J; Found:
628.9(M+H).
EXAMPLE 53
[3-(4-Chloro-phenyl)-l-cyclohexylmethyl-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-de): δ 7.64 (m, IH), 7.53 (m, 3H), 7.35 (s,
IH), 7.27 (s, 4H), 7.05 (m, 2H), 6.85 (m, IH), 6.34 (s, OJH), 6.06 (br s, IH), 5.47 (s, 0.3H), 4.98 (m, OJH), 3.23 (m, 1.3H), 1.53-0.6 (m, IIH). Mass spectrum (LCMS, ESI pos) Calcd. for C30H28N2O4C1: 642.9; Found:
643.0(M).
EXAMPLE 54
[3-(4-Chloro-phenyl)-7-iodo-l-(2-methyl-benzyl)-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 7.68 (s, 0.4H), 7.60 (s, 0.6H), 7.51 (d, J = 7.4 Hz, IH), 7.44 (m, IH), 7.38 (s, IH), 7.26 (m, 4H), 7.05 (m, 6H), 6.87 (m, 2H), 6.29 (s, O.IK), 6.11 (s, IH), 5.55 (s, 0.3H), 5.34 (d, J = 15.8 Hz, 0.3H), 5.27 (d, J = 15.8 Hz, O.IK), 4.93 (d, j = 15.8 Hz, 0.3H), 4.68 (d, J = 15.8 Hz, OJH), 2.20 (s, IH), 1.98 (s, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for C31H24N2O4ICl: 650.0; Found: 650.9(M+H).
EXAMPLE 55
[3-(4-Chloro-phenyl)-7Jodo-l-(3-methyl-benzyl)-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 7.62 (s, 0.4H), 7.59 (s, 0.6H), 7.52 (d, J = 7.0 Hz, IH), 7.45 (m, 3H), 7.26 (m, 3H), 7.09 (m, 5H), 6.90 (m, 3H), 6.74 (s, 0.6H), 6.34 (s, 0.4H), 6.17 (m, IH), 5.53 (d, J = 15.6 Hz, 0.4H), 5.27 (d, J = 15.6 Hz, 0.6H), 4.83 (d, j = 15.6 Hz, OAK), 4.64 (d, J = 15.6 Hz, 0.6H), 2.18 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C31H24N2O4ICl:
650.0; Found: 650.9(M+H).
EXAMPLE 56
[3-(4-Chloro-phenyl)-7-iodo-l-(4-methyl-benzyl)-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 7.57 (m, IH), 7.43 (m, 3H), 7.31 (m,
4H), 7.10 (m, 3H), 6.99 (m, 3H), 6.84 (m, 2H), 6.35 (s, .4H), 6.19 (s, IH), 5.55 (d, J = 15.1 Hz, 0.4H), 5.42 (s, 0.6H), 5.27 (d, j = 15.1 Hz, 0.6H), 4.77 (d, j = 15.1 Hz, OAK), 4.59 (d, j = 15.1 Hz, 0.6H), 2.20 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C31H24N2O ICI: 650.0; Found: 650.9(M+H).
EXAMPLE 57
[3-(4-Chloro-phenyl)-7-iodo-l-naphthalen-2-ylmethyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 7.79 (m, 4H), 7.58 (m, 2H), 7.46 (m, 4H), 7.31 (m, 2H), 7.15 (s, 2H), 7.05 (m, IH), 6.90 (m, IH), 6.36 (m, 0.6H), 6.23 (s, IH), 5.76 (d, J = 15.8 Hz, 0.4H), 5.47 (d, J = 15.8 Hz, 0.6H), 5.44 (s, 0.4H), 5.00 (d, J = 15.8 Hz, 0.4H), 4.84 (d, J = 15.8 Hz, 0.6H), 2.20 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C34H24N2O4Cl: 686.0; Found: 686.9(M+H).
EXAMPLE 58
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo- 1 -pyridin-2-ylmethyl- 1 ,2,3 ,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 8.48 (m, IH), 7.73 (m, 2H), 7.65 (m, 2H), 7.53 (m, 4H), 7.34 (m, 4H), 7.09 (m, 2H), 6.90 (m, IH), 6.32 (s, 0.6H), 6.20 (s, IH), 5.89 (br s, 0.4H), 5.36-4.89 (m, 2H). Mass spectrum (LCMS,
ESI pos) Calcd. for C29H21N3O4ICl: 637.0; Found: 638.0(M+H).
EXAMPLE 59
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l-pyridin-3-ylmethyl-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-dβ): δ 8.40 (m, IH), 7.52 (m, 3H), 7.27 (m,
4H), 7.11 (m, 4H), 6.96 (m, 2H), 6.82 (m, 2H), 6.33 (s, 0.6H), 6.24 (s, 0.4H), 6.15 (s, 0.6H), 5.69 (m, 0.4H), 5.35 (s, 0.6H), 5.31 (m, 0.4H), 4.85 (m, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C29H21N3O4Cl: 637.0; Found: 638.1(M+H).
EXAMPLE 60
[3-(4-Chloro-phenyl)-7Jodo-2,5-dioxo-l-pyridin-4-ylmethyl-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-de): δ 8.41 (br s, IH), 7.64 (m, IH), 7.48 (m, 4H), 7.32 (m, 4H), 7.11 (m, 3H), 6.91 (m, 3H), 6.34 (s, 0.6H), 6.23 (s, 0.4H), 6J6 (s, 0.4H), 5.60 (d, j = 15.5 Hz, 0.4H), 5.38 (s, 0.6H), 5.26 (d, J = 15.5 Hz, 0.6H), 4.90 (d, j = 15.5 Hz, 0.4H), 4.77 (d, J = 15.5 Hz, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C29H21N3O4ICl: 637.0; Found: 638.1(M+H).
EXAMPLE 61
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1, 4] diazepin-4-yl] -acetic acid methyl ester
1H NMR (400MHz, CDC13): δ 8.04 (m, 1.7H), 7.87 (m, 0.3H), 7.50 (s,
IH), 7.42-7.10 (m, 6H), 7.00 (m, IH), 6.83 (s, 0.8H), 6.73 (d, j = 8.4 Hz, 1.2H), 6.44 (d, J = 8.4 Hz, 0.8H), 6.37 (d, J = 8.4 Hz, 0.2H), 5.34 (m, 0.2H),
5.28 (s, 0.8H), 3.84 (s, 0.6H), 3.83 (s, 2.4H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H17N2O4Cl2: 594.0; Found: 594.8(M+H).
EXAMPLE 62
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.64 (s, 0.6H), 10.53 (s, 0.4H),
7.81 (s, 0.6H) 7.73 (s, 0.4H), 7.52-7.15 (m, 4H), 7.07 (d, J = 7.9 Hz, 3H), 6.81
(m, 2H), 6.63 (d, j = 8.6 Hz, 0.6H), 6.54 (d, J = 8.6 Hz, 0.4H), 6.25 (m, IH),
5.81 (br s, 0.4H), 5.22 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H15N2O4ICl2: 579.9; Found: 580.8(M+H). EXAMPLE 63
[3-(4-Chloro-phenyl)-7-iodo-l-methyl-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 7.63 (m, 2H), 7.49 (m, IH), 7.29 (m, 4H), 7.09 (s, 2H), 7.00 (d, J = 1.1 Hz, IH), 6.82 (m, IH), 6.72 (m, IH), 6.28
(m, IH), 5.92 (s, 0.5H) 5.31 (s, 0.5H), 3.12 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H18N2O4ICl: 560.0; Found: 560.9(M+H).
EXAMPLE 64
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l-(3-phenyl-propyl)-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-de): δ 7.70 (m, IH), 7.49 (m, 3H), 7.17 (m,
IIH), 6.80 (s, 2H), 6.36 (m, 0.6H), 6.15 (s, 0.4H), 6.01 (s, 0.6H), 5.31 (s,
0.4H), 4.50 (m, IH), 4.34 (m, IH), 2.31 (m, IH), 2.24 (m, IH), 1.58, (m, IH),
1.45 (m, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C32H26N2O4CI: 664.1; Found: 665.2(M+H).
EXAMPLE 65
2-{2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetylamino } -3 -methyl-butyric acid
1H NMR (400 MHz, DMSO-d6): δ 7.80-7.75 (m, IH), 7.58-7.40 (m,
5H), 1.11-1.11 (m, 2H), 6.97 (d, J = 8.0 Hz, IH), 6.92 (d, J = 8.0 Hz, IH),
6.67-6.52 (m, 2H), 5.15 (s, 0.5 H) 4.94 (s, 0.5H), 4.07-3.95 (m, IH), 2.05 (s,
IH), 0.84 (d, J = 6 Hz, 3H), 0.79-0.71 (m, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for CzsHzΛI^Os: 679.01; Found: 679.69 (M+H). EXAMPLE 66
3-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -3 -phenyl-propionic acid
1H NMR (400MHz, DMSO-de): δ 10.90 (s, 0.8H), 10.71 (s, 0.2H), 7.81 (s, IH) 7.66 (m, IH), 7.61-7.53 (m, 3H), 7.42-7.27 (m, 4H), 6.99 (d, J =
8.8 Hz, 1.6 H), 6.61 (d, J = 8.7 Hz, 0.4H), 6.50 (m, 2H), 5.24 (s, IH), 3.18 (m,
2H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H18N2O4Cl: 560.0;
Found: 560.9(M+H).
EXAMPLE 67
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l ,2,3 ,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -N-methyl-2-phenyl-acetamide
1H NMR (400MHz, CDC13): δ 8.06 (d, J = 2.1 Hz, 0.8H), 8.02 (m,
0.6H), 7.98 (s, 0.6H), 7.50-7.30 (m, 6H), 716-7.07 (m, 4H), 6.50 (m, IH), 6.34
(d, J = 8.4 Hz, IH), 5.96 (m, 0.5H), 5.61 (s, 0.5H), 2.91 (s, 1.5H), 2.90 (s, 1.5H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H19N3O3ICl: 559.0;
Found: 559.9(M+H).
EXAMPLE 68
(7-Iodo-2,5-dioxo-3-pyridin-2-yl-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4- yl)-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.60 (s, 0.6H), 10.52 (s, 0.4H),
8.56 (m, 0.4H), 8.46 (m, 0.6H), 8.06 (s, 0.4H), 7.85 (m, IH), 7.76 (dd, I = 2.2 Hz, 8.2 Hz, IH), 7.61 (m, 0.6H), 7.51 (m, IH), 7.40 (m, 2H), 7.30 (m, IH), 7.10 (m, 2H), 6.70 (m, 2H), 6.63 (d, J = 8.6 Hz, 0.6H), 6.56 (d, I = 8.6 Hz, 0.4H), 5.67 (s, 0.4H), 5.58 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C22H16N3O4I: 513.0; Found: 514.0(M+H). EXAMPLE 69
(7-Iodo-2,5-dioxo-3-pyridin-3-yl- 1 ,2,3 ,5-tetrahydro-benzo[e] [ 1 ,4] diazepin-4- yl)-phenyl-acetic acid
1H NMR (400MHz, DMSO-de): δ 10.72 (s, 0.5H), 10.56 (s, 0.5H), 8.33 (m, IH), 8.35-7.00 (m, 10H), 6.63 (d, J = 8.6 Hz, 0.6H), 6.56 (d, J = 8.6
Hz, 0.4H), 6.35 (s, IH), 5.82 (s, 0.4H), 5.30(s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C22H16N3O4I: 513.0; Found: 514.1(M+H).
EXAMPLE 70
(7-Iodo-2,5-dioxo-3-thiophen-3-yl-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin- 4-yl)-phenyl- acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.59 (s, 0.9H), 10.43 (s, OJH), 7.78 (s, IH), 7.54 ( , 3H), 7.35 (m, 4H), 715 (m, IH), 6J2 (m, IH), 6.38 (s, IH), 6.30 (s, IH), 5J5 (s, OJH), 5J2 (s, 0.9H). Mass spectrum (LCMS, ESI pos) Calcd. for C21H15N2O4IS: 518.0; Found: 518.9(M+H).
EXAMPLE 71
[7-Iodo-3-(5-methyl-thiophen-2-yl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.56 (s, IH), 7.83 (s, IH), 7.61 (m, IH), 7.45 (m, 2H), 7.33 (m, 3H), 6J6 (d, J = 8.6 Hz, IH), 6.33 (s, IH), 6.23 (m, IH), 6.02 (s, IH), 5.24 (s, IH), 2.11 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C22H17N2O4S: 532.0; Found: 532.9(M+H). EXAMPLE 72
[7-Iodo-3-(3-methyl-thiophen-2-yl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.54 (s, IH), 7.99 (s, IH), 7.68 (m, IH), 7.34 (m, 4H), 7.00 (m, IH), 6J7 (m, , IH), 6.39 (m, IH), 6.27 (s, IH),
6.02 (s, IH), 5.36 (s, IH), 1.69 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C22H17N2θ4IS: 532.0; Found: 532.8(M+H).
EXAMPLE 73
[3-(4-Bromo-thiophen-2-yl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.71 (s, OJH), 10.57 (s, 0.3H), 7.83 (d, J = 2.2 Hz, OJH), 7.77 (d, J = 2.2 Hz, 0.3H), 7.65 (m, IH), 7.47 (d, j = 7.0 Hz, 2H), 7.33 (m, 4H), 7.00 (m, IH), 6.78 (d, J = 8.6 Hz, OJH), 6.68 (d, j = 8.6 Hz, 0.3H), 6.36 (s, OJH), 6.24 (s, 0.3H), 5.87 (s, 0.3H), 5.32 (s, OJH). Mass spectrum (LCMS, ESI pos) Calcd. for C21H14N2O4ISBr: 595.9; Found:
596.8(M+H).
EXAMPLE 74
(3-[2,2']Bithiophenyl-5-yl-7-iodo-2,5-dioxo-l,2,3,5Jetrahydro- benzo[e][l,4]diazepin-4-yl)-phenyl-acetic acid
1H NMR (400MHz, DMSO-dg): δ 10.73 (s, 0.8H), 10.57 (s, 0.2H),
7.86 (d, J = 2.0 Hz, 0.8H), 7.79 (d, J = 2.0 Hz, 0.2H), 7.63 (m, IH), 7.52 (d, J = 7.4 Hz, 2H), 7.39 (m, 5H), 7.01 (m, IH), 6J9 (m, 2H), 6.40 (s, IH), 6.27 (m, IH), 5.88 (s, 0.2H), 5.30 (s, 0.8H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H17N2O4S2: 600.0; Found: 601.9(M+H). EXAMPLE 75
[7-Iodo-3-(3-methyl-benzo[b]thiophen-2-yl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.74 (s, 0.5H), 10.56 (s, 0.5H), 8.00 (s, IH), 7.69 (m, 2H), 7.46 (m, 2H), 7.26 (m, 4H), 6.94 (m, IH), 6J7 (m,
IH), 6J0 (s, 0.5H), 6.63 (d, J = 8.6 Hz, IH), 6.28 (s, 0.5H), 5.60 (s, 0.5H),
5.48 (s, 0.5H), 1.90 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C26H19N2O4IS: 582.0; Found: 583.9(M+H).
EXAMPLE 76
{ 3-[5-(2-Chloro-phenyl)-furan-2-yl]-7-iodo-2,5-dioxo-l ,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl } -phenyl-acetic acid
1H NMR (400MHz, DMSO-de): δ 10.70 (s, 0.8H), 10.59 (s, 0.2H),
7.90 (d, J = 2.1 Hz, IH), 7.70 (dd, J = 2.1 Hz, 8.3 Hz, 2H), 7.37 (m, 5H), 6.85
(m, 4H), 6.67 (d, J = 3.5 Hz IH), 6.41 (s, IH), 5.62 (s, IH), 5.32 (s, IH.). Mass spectrum (LCMS, ESI pos) Calcd. for C27H18N2O5ICl: 612.0; Found:
613.KM+H).
EXAMPLE 77
{3-[5-(3-Chloro-phenyl)-furan-2-yl]-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl } -phenyl-acetic acid
1H NMR (400MHz, DMSO-de): δ 10.70 (s, IH), 7.91 (d, J = 2.3 Hz,
2H), 7.68 (dd, J = 2.1 Hz, 8.3 Hz, 2H), 7.49 (d, J = 7.2 Hz, 2H), 7.30 (m, 5H), 6.89 (d, J = 8.6 Hz, IH), 6.63 (d, J = 3.5 Hz, IH), 6.44 (s, IH), 5.49 (s, IH), 5.35 (s, IH.). Mass spectrum (LCMS, ESI pos) Calcd. for C27H18N2O5ICl: 612.0; Found: 612.9(M+H). EXAMPLE 78
(7-Iodo-2,5-dioxo-3-quinolin-3-yl-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4- yl)-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.72 (s, 0.8H), 10.61 (s, 0.2H), 9.02 (d, J = 2.0 Hz, 1.5 H), 8.82 (d, J = 2.0 Hz, 0.5H), 8.45 (s, 1.5 H), 8.36 (s,
0.5H), 8.05 (d, J = 8.5 Hz, 1.5H), 7.98 (d, J = 8.5 Hz, 0.5H), 7.84-6.84 ( , 7H), 6.72 (s, 0.8H), 6.62 (d, J = 8.6 Hz, 0.8H), 6.56 (d, J = 8.6 Hz, 0.2H), 6.45 (s, 0.2H), 5.68 (s, 0.2H), 5.10 (s, 0.8H.). Mass spectrum (LCMS, ESI pos) Calcd. for C26H18N3O4I: 563.0; Found: 564.1(M+H).
EXAMPLE 79
[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [1,4] diazepin-4-yl] -(4-chloro-phenyl)-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.79 (s, 0.5H), 10.63 (s, 0.5H),
7.58 (m, IH) 7.52 (d, J = 8.6 Hz IH), 7.41 (m, 4H), 7J7 (m, 3H), 6.98 (m, IH), 6.79 (d, J = 8.6 Hz, 0.5H), 6J2 (d, J = 8.6 Hz, 0.5H), 6.29 (s, 0.5H), 6.24
(s, 0.5H), 5.68 (s, 0.5H), 5.23 (s, 0.5H). Mass spectrum (LCMS, ESI pos)
Calcd. for C23Hi5N2O4BrCl2: 534.0; Found: 534.9(M+H).
EXAMPLE 80
2-[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzofe] [ 1 ,4]diazepin-4-yl]-3-(4-trifluoromethyl-phenyl)-propionic acid
1H NMR (400MHz, DMSO-d6): δ 10.77 (s, 0.8H), 10.51 (s, 0.2H), 7.30-7.20 (m, 6H), 7.35 (m, IH), 7J5 (m, 3H), 6.96 (m, 2H), 6J2 (m, IH), 5.60 (br s, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H17N2O4BrF3Cl: 580.0; Found: 581.0(M+H). EXAMPLE 81
2-[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-3-phenyl-propionic acid
1H NMR (400MHz, DMSO-d6): δ 10.81 (s, 0.8H), 10.56 (s, 0.2H), 7.48 (s, IH) 7.42-7.30 (m, 4H), 7.22 (m, 3H), 7J3 (m, 2H), 6.95 (m, IH), 6.69
(m, IH), 5.54(m, 1.4H), 5.40 (s, 0.3H), 5.30 (br s, 0.3H), 3.40 (m, 1.5H), 3.20
(m, 0.5H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H18N2O4BrCl:
512.0; Found: 513.0(M+H).
EXAMPLE 82
2-[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -3 -(4-chloro-phenyl)-propionic acid
1H NMR (400MHz, DMSO-d6): δ 10.80 (s, 0.8H), 10.58 (s, 0.2H),
7.50 (s, IH), 7.43-7.37 (m, 3H), 7.22-7J2 (m, 4H), 6.92 (m, 2H), 6.69 (m,
IH), 5.57(m, 0.8H), 5.53 (s, 0.8H), 5.37 (s, 0.2H), 5J6 (br s, 0.2H), 3.40 (m, 1.5H), 3.20 (m, 0.5H). Mass spectrum (LCMS, ESI pos) Calcd. for
C24H17N2O4BrCl2: 546.0; Found: 547.0 (M+H).
EXAMPLE 83
2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7Jodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetamide
1H NMR (400MHz, DMSO-d6): δ 10.75 (s, 0.6H), 10.65 (s, 0.4H),
7.77 (m, IH), 7.71 (m, IH), 7.56 (m, IH), 7.52-7.45 (m, 3H), 7.38-7.07 (m, 4H), 6.91 (d, j = 8.4 Hz, IH), 6.64-6.55 (m, IH), 6.41 (s, 0.6H), 5.51 (s, 0.4H), 4.96 (s, 0.6H), 4.70 (s, 0.4H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H16N3θ3lCl2: 579.0; Found: 580.1(M+H). EXAMPLE 84
[7-Chloro-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.77 (s, 0.8H), 10.61 (s, 0.2H),
7.52 (m, IH) 7.46-7.39 (m, 4H), 7.32 (m, 2H), 7J5 (d, J = 9.0 Hz, 2H), 6.97 (m, IH), 6.86 (d, J = 8.4 Hz, 0.6H), 6.78 (d, J = 8.4 Hz, 0.4H), 6.28 (s, 0.4H), 6.23 (s, 0.6H), 5.72 (br s, 0.4H), 5.23 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H15N2O4Cl3: 488.0; Found: 489.0(M+H).
EXAMPLE 85
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-methyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e] [ 1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.53 (s, 0.6H), 10.37 (s, 0.4H), 7.50 (d, J = 8.4 Hz, IH), 7.41-7.29 (m, 4H), 7J7-7.00 (m, 4H), 6.91 (m, IH),
6J2 (d, J = 8.4 Hz, 0.6H), 6.64 (d, J = 8.4 Hz, 0.4H), 6.34 (s, OAK), 6.25 (s,
0.6H), 5.71 (s, 0.4H), 5.25 (s, .6H), 2J4 (s, 2H), 2J2 (s, IH). Mass spectrum
(LCMS, ESI pos) Calcd. for C24H18N2O4Cl2: 468J; Found: 469.0(M+H).
EXAMPLE 86
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5Jetrahydro- naphtho[2,3-e] [1 ,4]diazepin-4-yl]-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.79 (s, 0.6H), 10.64 (s, 0.4H),
8.21 (s, 0.6H), 8J7 (s, 0.4H), 7.88 (m, 3H), 7.69 (m, IH), 7.55 (d, j = 8.4 Hz, IH), 7.49-7.39 (m, 4H), 7.29 (s, IH), 7.21 (m, IH), 7.01 (m, 2H), 6.41 (s, 0.4H), 632 (s, 0.6H), 5.81 (s, 0.4H), 5.32 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C27H18N2O4Cl2: 504.1; Found: 505.0(M+H).
EXAMPLE 87
[8-Chloro-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.73 (s, 0.8H), 10.58 (s, 0.2H), 7.52 (m, 2H), 7.40 (m, IH), 7.14 (m, 4H), 7.00 (m, IH), 6.91 (m, 3H), 6.30 (s, 0.2H), 6.25 (s, 0.8H) 5.76 (s, 0.2H), 5.22 (s, 0.8H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H15N2O4Cl3: 488.0; Found: 489.0(M+H).
EXAMPLE 88
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-ethynyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.83 (s, 0.5H), 10.66 (s, 0.5H),
7.52 (m, 2H) 7.43-7.29 (m, 4H), 7.15 (m, 3H), 6.96 (m, IH), 6.83 (d, J = 8.4 Hz, 0.6H), 6.75 (d, J = 8.4 Hz, 0.4H), 6.29 (s, 0.4H), 6.23 (s, 0.6H), 5.74 (br s, 0.4H), 5.21 (s, 0.6H), 4.16 (s, 0.6H), 4.14 (s, 0.4H). Mass spectrum (LCMS, ESI pos) Calcd. for C23HJ6N2O4C12: 478.0; Found: 479.0(M+H).
EXAMPLE 89
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -p-tolyl-acetic acid 1H NMR (400MHz, DMSO-d6): δ 10.64 (s, 0.8H), 10.46 (s, 0.2H),
7.81 (s, IH), 7.50 (m, 2H), 7.36 (d, I = 7.9 Hz, 2H), 7.20 (m, IH), 7.08 (m,
3H), 6.81 (d, J = 8.4 Hz, IH), 6.63 (d, J = 8.6 Hz, IH), 6.27 (s, IH), 5.83 (br s,
0.2H), 5.16 (s, 0.8H), 2.22 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C2 H18N2O4ICl: 560.0; Found: 561.0(M+H).
EXAMPLE 90
(4-Chloro-3-fluoro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e] [1 ,4]diazepin-4-yl]-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.65 (s, 0.9H), 10.60 (s, OJH),
7J9 (s, IH), 7.52 (m, 3H), 7.35 (m, 2H), 7J3 (m, 2H), 6.95 (d, j = 8.0 Hz, IH), 6.63 (d, J = 8.6 Hz, IH), 6.29 (s, OJH), 6J4 (s, 0.9H), 5.80 (s, OJH), 5.29 (s, 0.9H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H14N2O4Cl2F: 597.9; Found: 598.9(M+H).
EXAMPLE 91
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(2-fluoro-4-trifluoromethyl-phenyl)-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.65 (br s, IH), 7.80 (s, IH), 7.74- 7.53 (m, 5H), 7J2 (d, j = 8.8 Hz, 2H), 6.85 (d, J = 8.1 Hz, IH), 6.63 (d, j =
8.6 Hz, IH), 6.45 (s, IH), 5.60 (s, OJH), 5.24 (s, 0.9H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H14N2O4ClF4: 632.0; Found: 633.0(M+H). EXAMPLE 92
(4-Chloro-phenyl)-[3-(4-chloro-ρhenyl)-7-ethyl-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-acetic acid
1H NMR (400MHz, DMSO-ds): δ 10.50 (s, 0.8H), 10.32 (s, 0.2H),
7.52 (d, J = 8.4 Hz, IH), 7.36 (m, 3H), 7.17-7.03 (m, 4H), 6.83 (d, J = 8.0 Hz, IH), 6.63 (d, J = 8.6 Hz, IH), 6.72 (d, J = 8.4 Hz, IH), 6.37 (s, 0.2H), 6.29 (m, 0.8H), 5.74 (s, 0.2H), 5.26 (s, 0.8H), 2.42 (m, 2H), 1.00 (m, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H2oN2O4Cl2: 482.1; Found: 483.1(M+H).
EXAMPLE 93
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-isopropyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.49 (s, 0.8H), 10.27 (s, 0.2H),
7.53 (d, J = 8.4 Hz, IH) 7.36 (m, 2H), 7J7-7.03 (m, 3H), 6.98 (d, J = 8.4 Hz, IH), 6.78 (d, J = 8.1 Hz, IH), 6.72 (d, J = 8.4 Hz, IH), 6.38 (s, 0.2H), 6.31 (m, 0.8H), 5.76 (s, 0.2H), 5.29 (s, 0.8H), 2.72 (m, IH), 1.02 (m, 6H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H2oN2O4Cl2: 496J; Found: 497J(M+H).
EXAMPLE 94
[7-tert-Butyl-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5Jetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid 1H NMR (400MHz, DMSO-d6): δ 10.45 (s, 0.8H), 10.25 (s, 0.2H), 7.52 (d, J = 8.4 Hz, IH), 7.44 (m, IH), 7.40-7.31 (m, 3H), 7.22-7.03 (m, 3H), 6.98 (d, J = 8.6 Hz, IH), 6.78 (d, J = 8.4 Hz, IH), 6.72 (d, J = 8.6 Hz, IH), 6.37 (s, 0.2H), 6.29 (m, 0.8H), 5.75 (s, 0.2H), 5.27 (s, 0.8H), 1.13 (s, 8H), 1.11 (s, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C27H24N2O4Cl2: 510.1;
Found: 511.1(M+H).
EXAMPLE 95
[3-(4-Chloro-phenyl)-7-ethyl-2,5-dioxo-l ,2,3 ,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.58 (s, IH), 7.48 (d, J = 7.0 Hz, IH), 7.35 (m, 6H), 7.09 (d, J = 8.6 Hz, 2H), 6.92 (d, J = 8.1 Hz, 2H), 6.74 (d, J = 8.1 Hz, IH), 6.32 (s, IH), 5.12 (s, IH), 2.43 (q, J = 1.1 Hz, 2H), 1.00 (t, J = 7.5 Hz, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H21N2O4Cl2: 448.1; Found: 449.1 (M+H).
EXAMPLE 96
[3-(4-Chloro-phenyl)-7-isopropyl-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-dg): δ 10.55 (s, IH), 7.48 (d, J = 7.0 Hz,
2H), 7.35(m, 3H), 7.07 (m, 3H), 6.91 (d, J = 8.4 Hz, 2H), 6.73 (d, J = 8.4 Hz, 2H), 6.31 (s, IH), 5.11 (s, IH), 2.74 (m, IH), 1.03 (d, J = 7.0 Hz, 6H). Mass spectrum (LCMS, ESI pos) Calcd. for C26H23N2O4Cl: 462.1; Found: 463.1(M+H). EXAMPLE 97
[7-tert-Butyl-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.54 (s, IH), 7.50 (d, J = 7.0 Hz,
2H), 7.37 (m, 3H), 7.24 (dd, J = 2.4, 8.6 Hz, 2H), 7.06 (d, J = 8.6 Hz, 2H), 6.90 (d, J = 7.9 Hz, 2H), 6.72 (d, J = 8.6 Hz, IH), 6.32 (s, IH), 5.10 (m, IH), 1.13 (s, 9H). Mass spectrum (LCMS, ESI pos) Calcd. for C27H25N2O4Cl2: 476.2; Found: 477.1(M+H).
EXAMPLE 98
[7-sec-Butyl-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.51 (s, IH), 7.49 (d, J = 7.0 Hz, 2H), 7.36 (m, 4H), 7.20 (m, IH), 7.03 (m, 3H), 6.86 (m, IH), 6.73 (m, IH),
6.31 (s, IH), 5.11 (s, IH), 2.45 (m, IH), 1.44 (m, IH), 1.28 (m, IH), 1.06 (m,
3H), 0.45 (m, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C27H25N2O4CI: 476.2; Found: 477J(M+H).
EXAMPLE 99
[7-sec-Butyl-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [1,4] diazepin-4-yl] -(4-chloro-phenyl)-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.54 (s, IH), 7.53 (d, j = 8.6 Hz,
2H), 7.44 (m, 3H), 7.21-6.99 (m, 5H), 6.71 (m, IH), 6J9 (s, IH), 5.23 (s, IK), 2.44 (m, IH), 1.45 (m, IH), 1.29 (m, IH), 1.05 (m, 3H), 0.45 (m, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C27H24N2O4Cl2: 510.1; Found: 511.1CM+H).
EXAMPLE 100
(4-Bromo-phenyl)-[3-(4-chloro-phenyl)-7-isopropyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e] [ 1 ,4]diazepin-4-yl]-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.53 (s, 0.1K), 10.34 (s, 0.3H), 7.54 (m, 2H), 7.46 (d, J = 8.6 Hz, 2H), 7.36-7.24(m, 2H), 7.09 (m, 3H), 6.96 (m, IH), 6.72 (d, I = 8.4 Hz, 0.7H), 6.64 (d, J = 8.4 Hz, 0.3H), 6.30 (s, 0.3H), 6.17 (s, OJH), 5.65 (s, 0.3H), 5.24 (s, OJH), 2.72 (m, IH), 1.03 (m, 6H).
Mass spectrum (LCMS, ESI pos) Calcd. for C26H22N2O4ClBr: 540.0; Found: 541.0(M+H).
EXAMPLE 101
[3-(4-Bromo-phenyl)-7-isopropyl-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.52 (s, OJH), 10.34 (s, 0.3H), 7.52 (d, I = 8.4 Hz, IH), 7.41 (m, 3H), 7.28-7.21(m, 3H), 7.12-7.03 (m, 2H), 6.91 (m, IH), 6.72 (d, j = 8.6 Hz, OJH), 6.64 (d, J = 8.6 Hz, 0.3H), 6.30 (s, 0.3H), 6.17 (s, OJH), 5.65 (s, 0.3H), 5.24 (s, OJH), 2.73 (m, IH), 1.03 (m,
6H). Mass spectrum (LCMS, ESI pos) Calcd. for C26H22N2O4ClBr: 540.0; Found: 541.0(M+H). EXAMPLE 102
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-cyclopropyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.53 (s, OJH), 10.35 (s, 0.3H),
7.50 (d, J = 8.4 Hz, IH), 7.39 (m, 2H), 7.21-7.09 (m, 4H), 6.92 (m, 3H), 6.70 (d, J = 8.4 Hz, OJH), 6.61 (d, J = 8.4 Hz, 0.3H), 6.31 (s, 0.3H), 6.22 (s, OJH), 5.67 (s, 0.3H), 5.23 (s, OJH), 1.80 (m, IH), 0.86 (m, 2H), 0.5 (m, IH), 0.42 (m, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C26H20N2O4C12: 494J; Found: 495.0(M+H).
EXAMPLE 103
[3-(4-Chloro-phenyl)-7-cyclopropyl-2,5-dioxo- 1 ,2,3 ,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.51 (s, OJH), 10.30 (s, 0.3H),
7.47 (d, J = 7.0 Hz, 2H), 7.38-7.08 (m, 5H), 7.04 (d, j = 8.6 Hz, 2H), 6.88 (m, 2H), 6.70 (d, J = 8.4 Hz, O.IK), 6.61 (d, J = 8.4 Hz, 0.3H), 6.34 (br s, IH), 5.71 (s, 0.3H), 5.16 (s, OJH), 1.79 (m, IH), 0.85 (m, 2H), 0.53 (m, IH), 0.44(m, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C26H21N2O4Cl: 460J; Found: 461.1(M+H).
EXAMPLE 104
[3-(4-Chloro-3-fluoro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.56 (s, 0.9H), 10.36 (s, OJH), 7.50 (m, 3H), 7.34 (m, 2H), 7.17 (m, 2H), 7.05-6.80 (m, 3H), 6.37 (s, IH), 5J9 (s, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C23H14N2O4Cl2F: 597.9; Found: 598.9(M+H).
EXAMPLE 105
(2,5-Dioxo-3-phenyl-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl)-phenyl- acetic acid
1H NMR (400MHz, DMSO-d6): δ 10.79 (s, 0.9H), 10.61 (s, OJH),
7.77 (s, IH), 7.53 (m, 4H), 7.38 (m, 4H), 7.03 (m, 2H), 6.81 (m, 2H), 6.67 (d,
J = 8.6 Hz, 0.9H), 6.58 (d, J = 8.6 Hz, OJH), 6.27 (s, OJH), 6J6 (s, 0.9H), 5.64 (s, OJH), 5.30 (s, 0.9H). Mass spectrum (LCMS, ESI pos) Calcd. for
C23H18N2O: 386J; Found: 387J(M+H).
EXAMPLE 106
[3-(4-Chlorophenyl)-7-phenyl-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenylacetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.60 (s, 0.8H), 10.50 (s, 0.2H),
7.82 (s, IH), 7.52 (m, 4H), 7.41 (m, 2H), 7.33 (m, 5H), 7.02 (d, J = 8.2 Hz,
2H), 6.91 (d, J = 8.3 Hz, IH), 6.82 (m, 2H), 6.39 (bs, IH), 5.25 (bs, IH).
Mass spectrum (LCMS, ESI pos.) Calcd. For C29H21ClN2O4: 496.10. Found: 497.0 (M+H).
EXAMPLE 107
[3-(4-Chlorophenyl)-7-(4-methylphenyl)-2,5-dioxo-l,2,3,5Jetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-phenylacetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.67 (bs, IH), 1.11 (m, IH), 7.49
(m, 3H), 7.41 (m, 4H), 7.25 (m, 4H), 7.06 (m, 2H), 6.90 (d, J = 8.9 Hz, 2H), 6.39 (bs, IH), 5.20 (bs IH), 2.32 (s, 3H). Mass spectrum (LCMS, ESI pos.) Calcd. For C3oH23ClN2O4: 510.10. Found: 511.0 (M+H).
EXAMPLE 108
[3-(4-Chlorophenyl)-7-(3-methylphenyl)-2,5-dioxo-l,2,3,5Jetrahydro- benzo[e][l,4]diazepin-4-yl]-phenylacetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.60 (bs, IH), 7.92 (m, IH), 7.63 (m, 2H), 7.43 (m, 4H), 7.29 (m, 5H), 7.16 (m, IH), 7.04 (m, IH), 6.89 (m, 2H), 6.53 (bs, IH), 5.40 (bs, IH), 2.40 (s, 3H). Mass spectrum (LCMS, ESI pos.) Calcd. For C30H23C1N2O4: 510.10. Found: 511.0 (M+H).
EXAMPLE 109
[3-(4-Chlorophenyl)-7-(4-hydroxyphenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenylacetic acid
1H NMR (400 MHz, DMSO-de): δ 10.73 (bs, 0.85H), 10.56 (s, 0.15H),
9.62 (s, IH), 7.68 (s, IH), 7.52 (m, 3H), 7.36 (m, 4H), 7.17 (m, IH), 7.10 (m, 2H), 6.97 (d, J = 1.1 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 6.81 (d, J = 8.6 Hz, 2H), 6.37 (bs, IH), 5.14 (bs, IH), 2.40. Mass spectrum (LCMS, ESI pos.) Calcd. For C29H21ClN2θ5: 512.15. Found: 513.1 (M+H).
EXAMPLE 110
[3-(4-Chlorophenyl)-7-(4-hydroxycarbonylphenyl)-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -phenylacetic acid 1H NMR (400 MHz, DMSO-d6): δ 13.1 (bs, IH), 10.80 (bs, 0.4H), 10.59 (s, 0.6H), 7.98 (d, J = 6.5 Hz, 2H), 7.85 (d, J = 9.5 Hz, IH), 7.65 (m, 3H), 7.50 (d, J = 8.0 Hz, IH), 7.34 (m, 4H), 7.24 (d, J = 7.2 Hz, IH), 7.14 (d, J = 8.6 Hz, IH), 7.07 (d, J = 1.1 Hz, IH), 6.94 (m, IH), 6.37 (d, J = 14.8 Hz, IH), 5.76 (s, IH). Mass spectrum (LCMS, ESI pos.) Calcd. For
C30H21C1N2O6: 540.16. Found: 541.0 (M+H).
EXAMPLE 111
(4-Chlorophenyl)-[3-(4-chlorophenyl)-7-iodo-5-oxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] acetic acid
1H NMR (400 MHz, d6-DMSO): Major (75%): δ 8.25 (d, J = 2.2 Hz,
IH), 7.22 (d, J = 8.4 Hz, 2H), 7.19 (dd, J = 8.8 Hz, J = 2.2 Hz, IH), 7.08 (d, J = 8.3 Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H), 6.93 (br m, IH), 6.77 (d, J = 7.9 Hz, 2H), 6.27 (d, J = 8.7 Hz, IH), 6.15 (br s, IH), 5.02 (s, IH), 3.89 (br m, 2H). Minor (25%): 7.97 (d, J = 2.1 Hz, IH), 7.43 (d, J = 8.6 Hz, 2H), 7.36 (d, J = 8.5 Hz, IH), 7.14 (d, J = 8.4 Hz, 2H), 7.11 (dd, J = 8.8 Hz, J = 2.2 Hz, 2H),
6.93 (br m, IH), 6.19 (d, J = 8.8 Hz, IH), 6.15 (br s, IH), 5.23 (s, IH), 3.89 (br m, 2H). Mass Spectrum (LCMS, ESI pos.): Calcd. For C23H17Cl2IN2O3: 565.97; found: 566.94 (M+H).
EXAMPLE 112
[3-(4-Chlorophenyl)-2,5-dioxo-8-phenyl- 1,2,3, 5-tetrahydro- benzo[e] [1 ,4] diazepin-4-yl] -phenylacetic acid
1H NMR (400 MHz, d6-DMSO): δ 10.41 (s, IH), 7.73-7.61 (m, IH), 7.57-7.32 (m, 8H), 7.28-7.02 (m, 5H), 6.98 (d, J = 8.7 Hz, IH), 6.72 (d, I = 7.8 Hz, IH), 6.32 (s, IH), 5.29 (s, IH). Mass Spectrum (LCMS, ESI pos.): Calcd. for C29H21ClN2O4: 496.12; found: 497.12 (M+H). EXAMPLE 113
[7-Benzo[l,3]dioxol-5-yl-2,5-dioxo-3-(4-trifluoromethyl-phenyl)-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-phenylacetic acid
1H NMR (400 MHz, d6-DMSO): Major (67%): δ 10.84 (s, IH), 7.65 (d, J = 2.1 Hz, IH), 7.56-7.34 (m, 9H), 7.23 (d, J = 8.1 Hz, IH), 7.05 (s, IH),
6.99-6.93 (m, 2H), 6.86 (d, J = 8.5 Hz, IH), 6.37 (s, IH), 5.20 (s, IH). Minor (33%): 10.69 (s, IH), 7.70 (d, J = 2.1 Hz, IH), 7.56-7.34 (m, 9H), 7.23 (d, J = 8.1 Hz, IH), 7.09 (s, IH), 6.99-6.93 (m, 2H), 6.81 (d, J = 8.3 Hz, IH), 6.34 (s, IH), 5.40 (s, IH). Mass Spectrum (LCMS, ESI pos.): Calcd. for C31H21F3N2θ6: 574.14; found: 574.98 (M+H).
EXAMPLE 114
3-(4-Chloro-phenyl)-3-[3-(4-chloro-phenyl)-7-iodo-5-oxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -propionic acid
1H NMR (400 MHz, DMSO-d6): δ 8.17 (d, I = 2.0 Hz, IH), 7.33 (d, J = 8.8Hz, 2H), 7.19-6.96 (m, 4H), 6.75 (d, J = 8.8Hz, IH), 6.39-6.29 (m, IH),
6.21 (d, J = 8.8 Hz, IH), 4.92 (d, J = 5.2 Hz, IH), 4.08-3.96 (m, IH), 3.46-3.36 (m, 2H), 2.93-2.75 (m, 2H).
Mass spectrum (LCMS, ESI pos) Calcd. for C24Hι9Cl2IN2O3: 579.98; Found 580.8 (M+H).
EXAMPLE 115
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-3-naphthalen-2-yl-propionic acid
1H NMR (400 MHz, DMSO-d6): δ 10.77 (s, 0.7 H), 10.42 (s, 0.3 H), 7.87-7.84 ( , 1.0 H), 7.82-7.68 (m, 3.0 Hz), 7.66-7.62 (m, 0.7 H), 7.58 (bs, 0.3 H), 7.55 (d, J = 2.0 Hz, 1.0 H), 7.51-7.36 (m, 3.0H), 7.20-7.07 (m, 3.0 H), 6.92 (bs, l.OH), 6.56-6.52 (m, 1.0 H), 5.80 (bs, 0.7 H), 5.58 (bs, OJH), 5.44 (bs, 0.3H), 5.38 (bs, 0.3H) 3.62-3.08 (m, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For C28H2oClIN2O4: 610.02 Found: 610.94 (M+H).
EXAMPLE 116
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -3-naphthalen-2-yl-propionic acid
1H NMR (400 MHz, DMSO-dg): δ 10.77 (s, O.IK), 10.44 (s, 0.3H), 7.92-7.55 (m, 5.0 H), 7.56-7.36 (m, 4.0H), 7.31-7.19 (bs, 1.0 H), 7.12-6.96 (m,
2.0H), 6.93-6.82 (m, l.OH), 6.58-6.46 (m, l.OH), 5.80 (bs, 0.7H), 5.67-5.57 (m, OJH), 5.49 (s, 0.3H), 5.43-5.35 (m, 0.3H), 3.71-3.52 (m, l.OH), 3.21-3.08 (m, l.OH). Mass spectrum (LCMS, ESI pos.) Calcd. For C29H20F3IN2O5: 660.04. Found: 660.98 (M+H).
EXAMPLE 117
2-[3-(4-Chloro-phenyl)-7Jodo-2,5-dioxo-l,2,3,5Jetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -3-naphthalen- 1 -yl-propionic acid
1H NMR (400 MHz, DMSO-d6): δ 10.94 (s, OJH), 10.39 (s, 0.3H), 8.32 (d, J = 8.8 Hz, 0.7 H), 8.27-8.15 (m, 0.3H), 7.97-7.83 (m, l.OH), 7.84-
7.73 (m, 0.3H), 1.13-1.65 (m, OJH), 7.62-7.44 (m, 3.0H), 7.40-7.23 (m, 3.0H), 7.22-7.07 (m, 3.0H), 6.64-6.54 (m, l.OH), 5.87 (bs, l.OH), 5.62 (bs, l.OH), 5.36 (bs, 0.6H), 5.20 (bs, 0.4H), 3.89-3.52 (m, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For C28H20ClIN2θ4: 610.02. Found: 610.92 (M+H). EXAMPLE 118
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -3 -naphthalen- 1 -yl-propionic acid
1H NMR (400 MHz, DMSO-d6): δ 10.94 (s, OJH), 10.40 (s, 0.3H),
8.34 (d, J = 8.4 Hz, 0.7H), 8.21 (bs, 0.3H), 7.88 (d, J = 8.0 Hz, l.OH), 7.78 (d, J = 7.2 Hz, 0.3H), 7.69 (d, J = 8.4 Hz, OJH), 7.72-7.68 (m, 5.0H), 7.67-7.22 (m, 4.0H), 7.07 (d, J = 8.4 Hz, l.OH), 7.04-7.00 (m, 0.3H), 6.58 (d, j = 8.8 Hz, OJH), 5.90 (bs, O.IK), 5.70-5.63 (m, OJH), 5.46-5.37 (m, 0.3H), 5.26-5.16 (m, 0.3H), 3.97-3.60 (m, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C29H20F3ΓN2O5: 660.04; Found: 660.99(M+H).
EXAMPLE 119
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-(4-fluoro-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.62 (s, 0.6H), 10.50 (s, OAK), 7.80 (d, J = 2Hz, 0.6H), 7.72 (d, J = 2.4 Hz, OAK), 7.58-7.47 (m, 2.0H), 7.44- 7.32 (m, l.OH), 7.25-7.03 (m, 4.0H), 6.87-6.75 (m, l.OH), 6.64 (d, j = 8.4 Hz, 0.6H), 6.55 (d, J = 8.4 Hz, 0.4H), 6.29 (d, J = 6Hz, l.OH), 5.80 (s, 0.6H), 5.76 (s, 0.4H), 5.22 (l.OH). Mass spectrum (LCMS, ESI pos.) Calcd. For
C23H15C1FΓN2O4: 563.97; Found: 564.84 (M+H). EXAMPLE 120
(4-Fluoro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5- tetrahydrobenzo[e] [1 ,4]diazepin-4-yl]-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.63 (s, OJH), 10.48 (s, 0.3H), 7.75 (d, I = 2 Hz, OJH), 7.67 (d, j = 2Hz, 0.3H), 7.59-7.46 (m, 2.3H), 7.43-
7.36 (m, OJH), 7.29 (d, J = 8.4 Hz, OJH), 7J6-7.06 (m, 2.3H), 7.03-6.97 (d, J = 8.4 Hz, l.OH), 6.93-6.87 (d, J = 8.4 Hz, l.OH), 6.63 (d, J = 8.8 Hz, OJH), 6.53 (d, J = 8.8 Hz, 0.3H), 6.32 (s, 0.3H), 6.28 (s, OJH), 5.83 (s, l.OH), 5J6 (s, 0.3H), 5.25 (s, OJH). Mass spectrum (LCMS, ESI pos.) Calcd. For C2 HιsF4r 2θ5: 614.00; Found: 614.94(M+H).
EXAMPLE 121
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5 tetrahydrobenzo[e][l,4]diazepin-4-yl]-3-(4-iodo-phenyl)-propionic acid
1H NMR (400 MHz, DMSO-d6): δ 10.72 (s, 0.8H), 10.49 (s, 0.2H),
7.68 (s, 0.4H), 7.60-7.49 (m, 2.6H), 7.49-7.43 (m, l.OH), 7.27-7.20 (m, 3.0H), 7J1-7.04 (m, 3.0H), 7.00 (d, J = 8Hz, 0.2H), 6.53 (d, j = 8.8 Hz, 0.8H), 5J3 (s, l.OH), 5.56-5.45 (m, 0.8H), 5.40 (s, 0.2H), 2.95-2.84 (m, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For C25H17F3l2N2O5: 735.92. Found: 736.83 (M+H).
EXAMPLE 122
3-(4-Bromo-phenyl)-2-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)- l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-propionic acid 1H NMR (400 MHz, DMSO-d6): δ 10.70 (s, 0.4H), 10.47 (s, 0.6H), 7.69 (d, J = 2Hz, 0.6H), 7.48 (d, J = 2Hz, 0.4H), 7.51-7.43 (m, l.OH), 7.39- 7.33 (m, 2.0H), 7.29-7.12 (m, 3.0H), 7.09-6.99 (m, 2.0H), 6.60-6.50 (m, l.OH), 5.76 (s, l.OH), 5.53 (bs, 0.6H), 5.39 (s, 0.4H), 5.10 (bs, l.OH), 3.17 (d, J = 5.12 Hz, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C25H17BrF3IN2O5: 687.93. Found: 688.80 (M+H).
EXAMPLE 123
3-(4-Bromo-phenyl)-2-[3-(4-chloro-ρhenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -propionic acid
1H NMR (400 MHz, DMSO-d6): δ 10.73 (s, 0.6H), 10.50 (s, OAK), 7.73 (d, I = 2Hz, 0.4H), 7.60 (d, J = 2Hz, 0.6H), 7.55-7.45 (m, l.OH), 7.41- 7.32 (m, 2.0H), 7.25-7.03 (m, 6.0H), 6.55 (d, J = 8.4 Hz, l.OH), 5.70 (s, 0.6H), 5.55-5.46 (m, 0.6H), 5.35 (s, 0.4H), 5.10 (bs, 0.4H), 3.20-2.84 (m, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For C2 H17BrClIN2θ4: 637.91.
Found: 638.82(M+H).
EXAMPLE 124
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahyαjro- benzo [e] [ 1 ,4] diazepin-4-yl] -3 -thiophen-2-yl-propionic acid
1H NMR (400 MHz, DMSO-d6): δ 10.83 (s, O.IK), 10.59 (s, 0.3H), 7.73 (bs, 0.3H), 1.10-1.66 (m, OJH), 7.60-7.55 (m, 0.3H), 7.51 (dd, J = 2.0 Hz, 8.0 Hz, .IK), 7.32 (d, J = 5.2 Hz, 0.3H), 7.30-7.25 (m, 1.7H), 7.19-7.04 (m, 4.0H), 6.92-6.84 (m, 2.0H), 5.69 (s, OJH), 5.48-5.41 (m, l.OH), 5.19 (bs, 0.3H), 3.56-3.15 (m, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C23H16F3IN2θ5S: 615.98. Found: 616.75 (M+H). EXAMPLE 125
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-trifluoromethyl-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.61 (s, 0.6H), 10.58 (s, 0.4H),
7.80 (d, J = 2.4 Hz, 0.6H), 7.73 (d, J = 2.0 Hz, 0.4H), 1.12-1.62 (m, 3.0H), 7.58-7.50 (m, 2.0H), 7.18 (s, 2.0H), 7.06 (d, J = 8.4 Hz, l.OH), 6.88-6.82 (m, l.OH), 6.63 (d, J = 8.4 Hz, 0.6H), 6.53 (d, J = 8.4 Hz, 0.4H), 6.37 (s, OAK), 6.27 (s, 0.6H), 5.76 (s, 0.4H), 5.28 (s, 0.6H). Mass spectrum (LCMS, ESI pos.) Calcd. For C2 H15ClF3N2O4: 613.97. Found: 614.86 (M+H).
EXAMPLE 126
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-3-thiophen-2-yl-propionic acid
1H NMR (400 MHz, DMSO-d6): δ 10.85 (s, 0.1K), 10.59 (s, 0.3H),
1.15-1.11 (m, l.OH), 1.10-1.66 (m, l.OH), 7.60-7.49 (m, l.OH), 7.32 (d, J = 5.2 Hz, 0.3H), 7.30-7.25 (m, OJH), 7.19-7.03 (m, 3.0H), 6.93-6.84 (m, l.OH), 6.78 (d, J = 8.0 Hz, OJH), 6.65 (d, J = 8.8 Hz, 0.3H), 6.58 (d, J = 8.4 Hz, l.OH), 5.57 (s, OJH), 5.53-5.47 (m, OJH), 5.41 (s, 0.3H), 5.28-5.21 (bs, 0.3H), 3.62-3.54 (m, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C22H16ClIN2O4S: 565.96. Found: 566.90 (M+H), 591.32 (M+Na).
EXAMPLE 127
[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro benzo [e] [ 1 ,4] diazepin-4-yl] -(4-trifluoromethyl-phenyl)-acetic acid 1H NMR (400 MHz, DMSO-d6): δ 10.66 (s, 0.8H), 10.57 (s, 0.2H), 1.19-1.14 (d, J = 2.0 Hz, l.OH), 7.73-7.61 (m, 4.0H), 7.56-7.49 (dd, J = 1.6 Hz, 8.4 Hz, l.OH), 7.03-6.92 (m, 3.0H), 6.62 (d, J = 8.4 Hz, 2.0H), 6.27 (bs, l.OH), 5.93 (s, 0.4H), 5.38 (s, 0.6H). Mass spectrum (LCMS, ESI pos.) Calcd. For C25H15F6iN2O5: 663.99. Found 664.89 (M+H).
EXAMPLE 128
(4-Chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5- tetrahydrobenzo[e][l,4] diazepin-4-yl] -acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.53 (s, 0.6H), 10.49 (s, 0.4H),
7.74 (d, J = 2.3 Hz, 0.6H), 7.66 (d, J = 2.1 Hz, 0.4H), 7.53-7.47 (m, 2.0H), 7.38-7.32 (m, 2.0H), 7.28 (d, J = 8.8 Hz, l.OH), 7.09 (d, J = 8.8 Hz, l.OH), 7.05-6.88 (m, 3.0H), 6.62 (d, J = 8.8 Hz, 0.6H), 6.53 (d, J = 9.6 Hz, 0.4H), 6.28 (s, 0.4H), 6.20 (s, 0.6H), 5.89 (s, OAK), 5.23 (s, 0.6H). Mass spectrum (LCMS, ESI pos.) Calcd. For C24H15ClF3IN2θ5: 629.97. Found 630.89
(M+H).
EXAMPLE 129
(4-Chloro-phenyl)-[7-iodo-2,5-dioxor3-(4-trifluoromethyl-phenyl)-l,2,3,5- tetrahydrobenzo[e] [1 ,4]diazepin-4-yl]-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.60 (s, 0.6H), 10.53 (s, 0.4H), 7.78 (d, J = 2.0 Hz, 0.6H), 7.70 (d, J = 2.0 Hz, 0.4H), 7.56-7.45 (m, 3.0H), 7.43-7.31 ( , 4.0H), 7.10-7.00 (m, l.OH), 6.62 (d, J = 8.8 Hz, l.OH), 6.52 (d, J = 8.8 Hz, 0.6H), 6.31 (s, OAK), 6.24 (s, 0.6H), 6.02-5.96 (m, OAK), 5.31-5.25 (m, l.OH). Mass spectrum (LCMS, ESI pos.) Calcd. For C24H15ClF3IN2O4:
613.97. Found 614.86(M+H). EXAMPLE 130
[3-(4-Bromo-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.60 (s, O.IK), 10.48 (s, 0.3H),
7.80 (d, J = 2.4 Hz, OJH), 7.72 (d, J = 2.0 Hz, 0.3H), 7.56-7.45 (m, 2.0H), 7.40-7.27 (m, 3.0H), 7.25-7.18 (m, l.OH), 7.15-7.09 (m, l.OH), 6.77 (m, l.OH), 6.63 (d, J = 8.8 Hz, 0.3H), 6.54 (d, J = 4.8 Hz, OJH), 6.27 (s, 0.3H), 6.22 (s, OJH), 5.84 (bs, l.OH), 5.16 (s, l.OH). Mass spectrum (LCMS, ESI pos.) Calcd. For C23H15BrClIN2O4: 623.89. Found 626.77 (M+H).
EXAMPLE 131
[3-(4-Bromo-phenyl)-2,5-dioxo-7-phenyl-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.67 (s, OJH), 10.53 (s, 0.3H),
7.82 (d, J = 2.0 Hz, OJH), 7.74 (d, J = 2.0 Hz, 0.3H), 7.58-7.49 (m, 4.0H), 7.47-7.40 (m, 3.0H), 7.38-7.30 (m, 3.0H), 7.29-7.24 (m, l.OH), 7.21-7.14 (m, 2.0H), 6.91 (d, J = 8.4 Hz, l.OH), 6.86-6.79 (m, l.OH), 6.40 (s, 0.3H), 6.34 (s, O.IK), 5.81 (s, 0.3H), 5.26 (s, OJH). Mass spectrum (LCMS, ESI pos.) Calcd. For C29H20BrClN2O4: 574.03. Found 574.90 (M+H).
EXAMPLE 132
(4-Chloro-phenyl)-[2,5-dioxo-7-phenyl-3-(4-trifluoromethyl-phenyl)-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid 1H NMR (400 MHz, DMSO-d6): δ 10.69 (s, 0.5H), 10.55 (s, 0.5H), 7.79-7.68 (m, 2.0H), 7.58-7.29 (m, 11.0H), 7.16 (bs, 2.0H), 6.94-6.85 (m, 0.5H), 6.80 (d, J = 8.4 Hz, 0.5H), 6.40 (bs, 0.5H), 6.30 (bs, 0.5H), 5.95 (bs, 0.5H), 5.33 (bs, 0.5H). Mass spectrum (LCMS, ESI pos.) Calcd. For C3oH2oClF3N2O4: 564.11. Found 565.02 (M+H).
EXAMPLE 133
(4-Chloro-phenyl)-[2,5-dioxo-7-phenyl-3-(4-trifluoromethoxy-phenyl)- 1 ,2,3,5-tetrahydro-benzo[e] [1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.63 (s, 0.4H), 10.50 (s, 0.6H),
7.73 (d, J = 2.4 Hz, 0.4H), 7.66 (d, J = 2.4 Hz, 0.6H), 7.60-7.28 (m, 11.0H), 7.05 (d, J = 8.4 Hz, 2.0H), 6.99 (s, l.OH), 6.90 (d, J = 8.0 Hz, 0.6H), 6.80 (d, J = 8.4 Hz, 0.4H), 6.40 (bs, 0.6H), 6.29 (bs, 0.4H), 5.87 (bs, 0.6H), 5.30 (bs, 0.4H). Mass spectrum (LCMS, ESI pos.) Calcd. For C3oH2oClF3N2O5: 580.10. Found 581.00 (M+H).
EXAMPLE 134
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-2,5-dioxo-7-phenyl-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid
1H NMR (400 MHz, DMSO-dg): δ 10.62 (s, 0.4H), 10.51 (s, 0.6H),
7.81 (d, J = 1.6 Hz, OAK), 1.13 (d, J = 2.4 Hz, 0.6H), 7.59-7.48 (m, 4.0H), 7.47-7.30 (m, 5.0H), 7.23 (d, J = 8.4 Hz, l.OH), 7.13 (d, J = 8.4 Hz, 2.0H), 7.06 (d, J = 8.8 Hz, 2.0H), 6.91 (d, J = 8.0 Hz, l.OH), 6.82 (d, J = 8.4 Hz, l.OH), 6.39 (bs, 0.6H), 6.33 (bs, 0.4H), 5.84 (bs, 0.4H), 5.27 (bs, 0.6H). Mass spectrum (LCMS, ESI pos.) Calcd. For C29H2oCl2N2O4: 530.08. Found
531.01(M+H). EXAMPLE 135
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-thiophen-2-yl-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.62 (s, 0.8H), 10.52 (s, 0.2H),
7.80 (d, J = 2.4 Hz, 0.8H), 7.73 (d, J = 2.4 Hz, 0.2H), 7.56-7.51 (m, l.OH), 7.37 (d, J = 8.4 Hz, l.OH), 1.19-1.15 (m, l.OH), 7.10 (d, J = 8.6 Hz, 2.0H), 6.95-6.91 (m, l.OH), 6.80 (d, J = 8.4 Hz, 2.0H), 6.65 (d, J = 8.6 Hz, 0.8H), 6.58 (d, J = 8.4 Hz, 0.2H), 6.44 (bs, 0.6H), 5.85 (bs, 0.4H), 5.50 (bs, l.OH). Mass spectrum (LCMS, ESI pos.) Calcd. For C21H14ClIN2O4S: 551.94. Found
552.83 (M+H).
EXAMPLE 136
[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -thiophen-2-yl-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.65 (s, 0.8H), 10.52 (s, 0.2H), 7.74 (d, 2.0 Hz, 0.8H), 7.68 (d, J = 2.0 Hz, 0.2H), 7.55-7.49 (m, l.OH), 7.42- 7.37 (m, l.OH), 7.28 (d, J = 8.4 Hz, 0.2H), 7.20 (d, J = 2.8 Hz, 0.8H), 7.13- 6.99 (m, 2.0H), 6.96-6.87 (m, 3.0H), 6.64 (d, J = 8.8 Hz, 0.8H), 6.56 (d, J = 8.8 Hz, 0.2H), 6.44 (bs, 0.8H), 5.88 (bs, 0.2H), 5.55 (bs, l.OH). Mass spectrum
(LCMS, ESI pos.) Calcd. For C22H14F3N2O5S: 601.96. Found 602.81(M+H).
EXAMPLE 137
(3-Biphenyl-4-yl-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin- 4-yl)-(4-chloro-phenyl)-acetic acid 1H NMR (400 MHz, DMSO-d6): δ 10.63 (s, OJH), 10.52 (s, 0.3H),
7.82 (d, J = 2.0 Hz, OJH), 7.74 (d, J = 2.4 Hz, 0.3H), 7.57-7.22 (m, 12.0H),
6.86 (d, J = 7.6 Hz, 2.0H), 6.66 (d, J = 7.6 Hz, OJH), 6.56 (d, j = 8.8 Hz,
0.3H), 6.33 (bs, OJH), 5.95 (bs, 0.3H), 5.29 (bs, l.OH). Mass spectrum (LCMS , ESI pos.) Calcd. For C29H2oCHN2O4: 622.02. Found 622.91 (M+H).
EXAMPLE 138
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5Jetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -(4-ethyl-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.68 (s, 0.8H), 10.51 (s, 0.2H),
7.79 (d, J = 2.0 Hz, 0.8H), 7.73 (d, J = 2.0 Hz, 0.2H), 7.56-7.49 (m, l.OH), 7.39 (d, J = 8.0 Hz, 2.0H), 7.29-7J5 (m, l.OH), 7J2 (d, J = 8.0 Hz, 2.0H), 7.06 (d, J = 8.4 Hz, l.OH), 6.77 (d, J = 8.0 Hz, 2.0H), 6.64 (d, j = 8.4 Hz, 0.8H), 6.55 (d, J = 8.8 Hz, 0.2H), 6.30 (bs, l.OH), 5.82 (bs, 0.2H), 5.21 (bs, 0.8H), 2.62-2.51 (m, 2.0H), 1.21-1.14 (m, 3.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For C25H2oClIN2O4: 574.02. Found 574.94 (M+H).
EXAMPLE 139
[3-(4-Chloro-ρhenyl)-7-iodo-2,5-dioxo-l,2,3,5Jetrahydro- benzo[e][l,4]diazepin-4-yl]-(3,4-dichloro-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-de): δ 10.70 (s, 0.6H), 10.64 (s, 0.4H), 7.79 (d, J = 2.0 Hz, l.OH), 7.81-7J8 (m, l.OH), 7.61-7.46 (m, 2.0H), 7.40-7.31 (m, l.OH), 7J8 (s, l.OH), 7J3 (d, J = 8.4 Hz, l.OH), 7.04-7.00 (m, l.OH), 6.63 (d, J = 8.4 Hz, l.OH), 6.56 (d, J = 8.8 Hz, 0.6H), 6.29 (bs, OAK), 6.12 (bs, 0.6H), 5.80 (bs, 0.4H), 5.32 (bs, l.OH). Mass spectrum (LCMS, ESI pos.)
Calcd. For C23H14Cl3IN2O4: 613.91. Found 614.84 (M+H). EXAMPLE 140
(2-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
H NMR (400 MHz, DMSO-d6): δ 10.61 (s, 0.2H), 10.55 (s, 0.8H),
7.77 (d, J = 2.4 Hz, l.OH), 7.60-7.49 (m, 2.0H), 7.44-7.30 (m, 4.0H), 7.16 (d, J = 8.8 Hz, l.OH), 7.11 (d, J = 8.4 Hz, 0.2H), 6.89 (d, J = 8.0 Hz, 0.8H), 6.61 (d, J = 8.8 Hz, l.OH), 6.55 (d, J = 8.8 Hz, l.OH), 6.29 (bs, l.OH), 5.23 (bs, 0.8H), 5.10 (bs, 0.2H). Mass spectrum (LCMS, ESI pos.) Calcd. For C23H15Cl2IN2O4: 579.95. Found 580.92 (M+H).
EXAMPLE 141
(4-tert-Butyl-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3 ,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.62 (s, O.IK), 10.55 (s, 0.3H),
7.77 (d, J = 2.0 Hz, O.IK), 1.15-1.61 (m, 0.3H), 7.55-7.48 (m, l.OH), 7.39 (d, J = 8.4 Hz, 2.0H), 7.29 (d, J = 8.4 Hz, 2.0H), 7.25-7.14 (m, l.OH), 7.02 (d, J = 8.0 Hz, 2.0H), 6.92 (d, J = 8.0 Hz, 0.3H), 6.73-6.62 (m, 3.0H), 6.54 (d, J = 8.4 Hz, 0.7H), 6.27 (s, l.OH), 5.92 (bs, 0.3H), 5.27 (bs, OJH), 1.27 (s, l.OH), 1.20 (s, 9.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For C zHwCllT^:
602.05. Found 602.99 (M+H).
EXAMPLE 142
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-isopropyl-phenyl)-acetic acid 1H NMR (400 MHz, DMSO-d6): δ 10.69 (s, 0.8H), 10.54 (s, 0.2H),
7.79 (d, J = 2.0 Hz, 0.8H), 7.73 (d, J = 2.0 Hz, 0.2H), 7.57-7.50 (m, l.OH), 7.39 (d, J = 8.0 Hz, 2.0H), 7.27 (d, J = 8.0 Hz, 0.8H), 7.21 (d, J = 8.4 Hz, 0.2H), 7.14 (d, J = 8.0 Hz, 2.0H), 7.03 (d, J = 8.4 Hz, 2.0H), 6.72 (d, J = 8.8 Hz, l.OH), 6.65 (d, J = 8.8 Hz, l.OH), 6.54 (d, J = 8.8 Hz, 0.2H), 6.30 (bs,
0.8H), 5.86 (bs, 0.2H), 5.27 (bs, 0.8H), 2.88-2.76 (m, l.OH), 1.18 (d, J = 8.8 Hz, 1.2H), 1.11 (d, J = 6.8 Hz, 6.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For C26H22CHN2O4: 588.03. Found 588.95 (M+H).
EXAMPLE 143
(3-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
XH NMR (400 MHz, DMSO-d6): δ 10.69 (s, OJH), 10.60 (s, 0.3H),
7.80 (d, J = 2.0 Hz, .IK), 1.13 (d, J = 2.4 Hz 0.3H), 7.57-7.50 (m, 2.0H), 7.49-7.44 (m, OJH), 7.41 (s, 0.3H), 7.35-7.29 (m, 3.0H), 7.18 (s, l.OH), 6.92
(d, J = 8.0 Hz, 2.0H), 6.63 (d, J = 8.8 Hz, OJH), 6.56 (d, J = 8.4 Hz, 0.3H), 6.31 (bs, 0.3H), 6.23 (bs, OJH), 5.84 (bs, 0.3H), 5.26 (bs, O.IK). Mass spectrum (LCMS, ESI pos.) Calcd. For C23H15Cl2IN2θ4: 579.95. Found 581.00 (M+H).
EXAMPLE 144
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5Jetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-trifluoromethoxy-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-de): δ 10.72 (s, 0.8H), 10.59 (s, 0.2H), 7.80 (d, J = 2.0 Hz, 0.8H), 7.74 (d, j = 2.0 Hz, 0.2H), 7.61 (d, J = 8.8 Hz,
2.0H), 7.57-7.48 (m, 2.0H), 7.28 (d, J = 8.4 Hz, 2.0H), 7.18 (s, l.OH), 7.07 (d, J = 8.4 Hz, l.OH), 6.85-6.12 (m, l.OH), 6.65 (d, J = 8.4 Hz, 0.8H), 6.55 (d, J = 8.4 Hz, 0.2H), 6.35 (bs, 0.2H), 6.31 (bs, 0.8H), 5.77 (bs, 0.2H), 5.31 (bs, 0.8H). Mass spectrum (LCMS, ESI pos.) Calcd. For C24H15ClF3IN2θ5: 629.97. Found 630.95 (M+H).
EXAMPLE 145
(4-Bromo-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.69 (s, OJH), 10.56 (s, 0.3H), ' 7.79 (d, J = 2.0 Hz, OJH), 7.73 (d, j = 2.0 Hz, 0.3H), 7.58-7.41(m, 5.0H), 7.32
(d, J = 8.4 Hz, l.OH), 7.23 (s, l.OH), 7.11 (d, j = 8.8 Hz, l.OH), 6.94-6.85 (m, l.OH), 6.64 (d, J = 8.4 Hz, OJH), 6.55 (d, j = 8.0 Hz, 0.3H), 6.29 (bs, 0.3H), 6.23 (bs, O.IK), 5.78 (bs, 0.3H), 5.23 (bs, OJH). Mass spectrum (LCMS, ESI pos.) Calcd. For C23H15BrClIN2O4: 623.89. Found 624.90 (M+H).
EXAMPLE 146
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(3-hydroxy-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-de): δ 10.48 (s, l.OH), 9.50, (s, l.OH), 7.78 (d, J = 2.0 Hz, l.OH), 7.54 (dd, J = 2.0 Hz, 8.0 Hz, l.OH), 7.08 (d, j = 8.4
Hz, 3. OH), 6.91 (s, 2.0H), 6.84-6.76 (m, 2.0H), 6.69-6.59 (m, 2.0H), 6.26 (bs, l.OH), 5.24 (bs, l.OH). Mass spectrum (LCMS, ESI pos.) Calcd. For
C23H16ClIN2θ5: 561.98. Found 562.89 (M+H). EXAMPLE 147
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-hydroxy-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.58 (s, OJH), 10.43 (s, 0.3H),
9.43 (s, OJH), 9.38 (s, 0.3H) 7.76 (d, J = 2.4 Hz, l.OH), 7.70 (d, J = 1.6 Hz, 0.3H), 7.50 (m, OJH), 7.25 (d, j = 8.4 Hz, 2.0H), 7.23-7.11 (m, 3.0H), 7.07 (d, J = 2.4 Hz, l.OH), 6.83-6.76 (m, l.OH), 6.68-6.60 (m, 2.0H), 6.22 (bs, l.OH), 6.17 (bs, 0.3H), 5.14 (bs, OJH). Mass spectrum (LCMS, ESI pos.) Calcd. For C23H16CirN2O5: 561.98. Found 562.80 (M+H).
EXAMPLE 148
(4-Chloro-phenyl)-[3-(4-chloro-3-trifluoromethyl-phenyl)-7-iodo-2,5-dioxo- 1,2,3 ,5-tetrahydro-benzo [e] [1,4] diazepin-4-yl] -acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.80 (s, 0.6H), 10.63 (s, 0.4H),
7.76-7.69 (m, l.OH), 7.61-7.44 (m, 3.0H), 7.40 (s, l.OH), 7.36-7.21 (m, l.OH), 7.17 (d, J = 8.0 Hz, l.OH), 6.67-6.51 (m, 2.0H), 6.38-6.19 (m, l.OH), 5.63 (bs, 0.4H), 5.50 (bs, 0.6H), 5.17 (bs, l.OH). Mass spectrum (LCMS, ESI pos.) Calcd. For 024^4^3^204: 647.93. Found 648.91(M+H).
EXAMPLE 149
[3-(4-Chloro-phenyl)-7Jodo-2,5~dioxo-l,2,3,5Jetrahydro- benzo[e][l,4]diazepin-4-yl]-cyclohexyl-acetic acid
1H NMR (400 MHz, DMSO-dg): δ 10.99 (s, l.OH), 7.74 (d, J = 1.6 Hz, l.OH), 7.57 (dd, J = 2.0 Hz, 8.4 Hz, l.OH), 7.22 (d, J = 8.8 Hz, 2.0H), 6.96 (d, J = 8.4 Hz, 2.0H), 6.62 (d, J = 8.8 Hz, l.OH), 5.90 (bs, l.OH), 5.17-5.10 (m, l.OH), 1.89-0.87 (m, 11.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For C23H22ClIN2O4: 552.03. Found 552.90 (M+H).
EXAMPLE 150
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-8-methyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.63 (s, 0.4H), 10.51 (s, 0.6H), 7.93 (s, 0.4H), 7.85 (s, 0.6H), 7.50 (d, J = 8.8 Hz, l.OH), 7.41-7.31 (m, 3.0H), 7.18 (s, 2.0H), 7.09 (d, J = 8.8 Hz, l.OH), 6.86-6.81 (m, 0.6H), 6.77 (s, 0.4H),
6.68 (s, l.OH), 6.35-6.27 (m, l.OH), 5.78 (bs, 0.6H), 5.25 (bs, 0.4H) 2.18 (s, 1.8H), 2.17 (s, 1.2H). Mass spectram (LCMS, ESI pos.) Calcd. For C24H17Cl2IN2O4: 593.96 (M+H). Found 594.89.
EXAMPLE 151
[3-(4-Chloro-phenyl)-7,8-difluoro-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl- acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 7.6-7.7 (m, 2H), 7.4-7.5 (m, IH), 7.2-7.4 (m, 4H), 6.9-7.0 (m, 2H), 6.6-6.8 (m, 4H), 5.7 (s, 0.13H), 5.4 (s, 0.87H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H15ClF2N2O4: 456.1;
Found: 457.0 (M + H). EXAMPLE 152
[7,8-Difluoro-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3 ,5-tetrahydro- benzo [e][ 1,4] diazeρin-4-y 1] -phenyl-acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 7.6 (m, 2H), 7.2-7.5 (m, 5H), 6.6- 6.9 (m, 6H), 5.8 (s, OJH), 5.4 (s, 0.9H). (LCMS, ESI pos) Calcd. for C24H15F5N2O5: 506.1; Found: 507J (M + H).
EXAMPLE 153
[3-(4-Chloro-phenyl)-7-fluoro-2,5-dioxo-l,2,3,5Jetrahydro- benzofe] [1 ,4]diazepin-4-yl]-phenyl-acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 7.6-7J (m, 2H), 7.2-7.4 (m, 5H), 6.9-7J (m, 2H), 6.6-6.9 (m, 6H), 5.7 (m, OJH), 5.4-5.5 (s, 0.9H). Mass spectram (LCMS, ESI pos) Calcd. for C23H16ClFN2O4: 438.1; Found: 439.0
(M + H).
EXAMPLE 154
[7 -Fluoro-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3 ,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H-NMR (400 MHz, DMSO-de): δ 7.6-7.7 (m, 2H), 7.4-7.5 (m, IK), 7.2-7.4 (m, 5H), 6.9-7.0 (m, 2H), 6.6-6.9 (m, 7H), 5.7 (s, 0.2H), 5.5 (s, 0.8H). ). Mass spectrum (LCMS, ESI pos) Calcd. for C2 H16F4N2O5: 488.1; Found: 489.1 (M + H). EXAMPLE 155
[7-Acetylamino-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 7.4-7.9 (m, 5H), 7.0-7.3 (m, 3H),
6.6-6.9 (m, 7H), 5.4-5.8 (m, IH), 1.9-2.2 (s, 3H). Mass spectram (LCMS, ESI pos) Calcd. for C25H2oClN3O5: 477.1; Found: 478.0 (M + H).
EXAMPLE 156
[7-Acetylamino-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 7.6-7.9 (m, 3H), 7.2-7.5 (m, 5H), 6.6-6.9 (m, 6H), 5.7 (br s, IH), 1.9-2.2 (s, IH). (LCMS, ESI pos) Calcd. for C26H2oF3N3O6: 527.1; Found: 528.1 (M + H).
EXAMPLE 157
[3-(4-Chloro-phenyl)-7-(3-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]- phenyl-acetic acid
1H-NMR (400 MHz, DMSO-ds): δ 7.8-7.9 (s, IH), 7.6-7.7 (m, 2H), 7.2-7.5 (m, 8H), 6.8-6.9 (m, 3H), 6.7-6.8 (m, 3H), 5.4 (s, IH). Mass spectram
(LCMS, ESI pos) Calcd. for
Figure imgf000098_0001
530.1; Found: 531.0 (M + H). EXAMPLE 158
[3-(4-Chloro-ρhenyl)-7-(4-methyl-thiophen-2-yl)-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 7.8 (s, IH), 7.6-7.7 (s, IH), 7.4-7.5
(m, 5H), 7.2-7.4 (m, 2H), 6.6-6.9 (m, 5H), 5.7 (s, 0.4H), 5.4-5.5 (s, 0.6H), 2.2 (3 H, s). Mass spectrum (LCMS, ESI pos) Calcd. for C28H21ClN2O4S: 516.1; Found: 517.0 (M + H).
EXAMPLE 159
[3-(4-Chloro-phenyl)-2,5-dioxo-7-thiophen-3-yl- 1 ,2,3 ,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 7.9 (s, IH), 7.6 (s, IH), 7.4-7.55 (m, 4H), 7.2-7.4 (m, 5H), 7.0-7.1 (m, IH), 6.8-6.9 (m, 2H), 6.7-6.8 (m, 2H), 5.7 (s, 0.5H), 5.4 (s, 0.5H). Mass spectrum (LCMS, ESI pos) Calcd. for
C27H19ClN2O4S: 502.1; Found: 503.0 (M + H).
EXAMPLE 160
[3-(4-Chloro-phenyl)-7-furan-3-yl-2,5-dioxo-l,2,3,5Jetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl- acetic acid methyl ester
1H-NMR (400 MHz, DMSO-d6): δ 7.9 (s, IH), 7.8 (s, IH), 7.4-7.7 (m, 8H), 7.0-7.3 (m, 3H), 6.7-6.9 (m, 3H), 5.3 (s, OAK), 5.2 (s, 0.6HJ, 3.8 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C28H2iClN2O5: 500.0; Found: 501.0 (M + H). EXAMPLE 161
[3-(4-Chloro-phenyl)-7-furan-3-yl-2,5-dioxo- 1,2,3, 5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 7.8-7.9 (m, 2H), 7.6-7.7 (m, IH),
7.2-7.5 (m, 7H), 7.0-7.1 (m, IH), 6.6-6.9 (m, 5H), 5.7 (s, 0.4H), 5.5 (m, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C27H19ClN2O5: 486J; Found: 487.0 (M + H).
EXAMPLE 162
[3J-Bis-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid methyl ester
1H-NMR (400 MHz, DMSO-d6): δ 7.8-7.9 (s, IH), 7.4-7.7 (m, IIH), 7.1-7.2 (m, IH), 6.8-7.0 (m, 4H), 6.7 (m, IH), 5.3 (s, 0.18H), 5.25 (s, 0.82H), 3.8 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C30H22C12N2O4: 544.1; Found: 545.0 (M + H).
EXAMPLE 163
[3,7-Bis-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenyl-acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 7.8-7.9 (m, IH), 7.6-7.7 (m, IH),
7.4-7.5 (m, 4H), 7.2-7.4 (m, 6H), 7.0-7.1 (m, IH), 6.7-6.9 (m, 4H), 5.7 (s, 0.5H), 5.45 (s, 0.5H). Mass spectrum (LCMS, ESI pos) Calcd. for C29H2oCl2N2O4 : 530.1; Found: 531.0 (M + H). EXAMPLE 164
[7-(3-Amino-phenyl)-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-phenyl-acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 7.8-7.9 (m, IH), 7.6-7.7 (s, IH),
7.2-7.5 (m, 5H), 7.0-7.1 (m, 4H), 6.5-6.9 (m, 6H), 5.7 (s, 0.4H), 5.5 (br s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C29H22ClN3O4 : 511.1; Found: 512.1 (M + H).
EXAMPLE 165
[3-(4-Chloro-phenyl)-7-(3-isopropyl-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-y l]-phenyl-acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 7.8-7.9 (m, IH), 7.6-7.7 (m, IH), 7.4-7.5 (m, 3H), 7.2-7.4 (m, 6H), 7.0-7.1 (m, IH), 6.6-6.9 (m, 5H), 5.7 (s, 0.3H), 5.5 (s, O.IK), 2.9-3.0 (m, IH), 1.2-1.3 (m, 6H). Mass spectrum (LCMS,
ESI pos) Calcd. for C32H27ClN2O4 : 538.2; Found: 539.1 (M + H).
EXAMPLE 166
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-5-oxo-2-thioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diaze pin-4-yl] -acetic acid
1H-NMR (400 MHz, DMSO-d6): δ 12.3-12.5 (br s, IH), 7.7-7.8 (m, IH), 7.5-7.6 (m, 2H), 7.2-7.4 (m, 6H), 7.1-7.2 (m, 2H), 6.6-6.8 (m, IH), 6.4 (s, OJH), 6.2 (s, O.IK), 5.7 (m, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H15Cl2lN2O3S : 595.9; Found: 596.9 (M + H). EXAMPLE 167
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-2,5-dioxo-7-vinyl-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400MHz, DMSO-d6): 10.67 (s, 0.6H), 10.52 (s, 0.4H), 7.54- 7.36 (m, 6H), 7.19-7.05 (m, 3H), 6.95 (m, IH), 6.82 (d, J = 8.4Hz, 0.6H), 6.72 (d, I = 8.4Hz, 0.4H), 6.64-6.55 (m, IH), 6.32 (br s, 0.6H), 6.25 (br s, 0.4H), 5.73 (brs, 0.4H), 5.70-5.66 (m, IH), 5.26 (s, 0.6H), 5.19-5.16 (m, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C25H18N2O4Cl2: 480.06; Found: 481.07(M+H).
EXAMPLE 168
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-cyano-2,5-dioxo-l,2,3 ,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400MHz, DMSO-d6): 11.13 (s, OJH), 10.97 (s, 0.3H), 7.88 (m, IH), 7.68 (m, IH), 7.50-7.41 (m, 4H), 7J7 (m, 3H), 7.01 (m, 2H), 6.28 (br s, 0.3H), 6.27 (br s, O.IK), 5.10 (brs, 0.3H), 5.25 (s, OJH). Mass spectram (LCMS, ESI pos) Calcd. for C24H15N3O4Cl2: 479.04; Found: 479.9(M+H).
EXAMPLE 169
[3-(l-Chloro-cuban-4-yl)-7Jodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-dg): 10.64 (s, IH), 8.03 (d, j = 2.2 Hz,
IH), 7.86 (dd, j = 8.4 Hz and J = 2.2 Hz, IH), 7.47 (d, j = 8.7 Hz, 2H), 7.37
(d, I = 8.8 Hz, 2H), 6.88 (d, J = 8.7 Hz, IH), 4.62 (s, IH), 4.16 (s, IH), 3.80- 3.73 (m, 3H), 3.70-3.64 (m, 3H). Mass spectrum (LCMS, ESI pos.): Calcd. for
C25H17Cl2IN2θ4: 605.96; found: 606.99 (M+H). EXAMPLE 170
3-(4-Chloro-phenyl)-4-[l-(4-chloro-phenyl)-2-hydroxy-ethyl]-7-iodo-l,3,4,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-2-one
1H NMR (400 MHz, CDC13): 7.50 (br s, IH), 7.45 (dd, J = 8.3 Hz and J = 2.0 Hz, IH), 7.33 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.8 Hz, 2H), 7.26 (d, J = 8.8 Hz, 2H), 7.23 (d, J = 8.5 Hz, 2H), 7.12 (d, J = 1.9 Hz, IH), 6.49 (d, J = 8.3 Hz, IH), 5.14 (s, IH), 4.08-4.00 (m, IH), 3.95-3.85 (m, 2H), 3.89 (d, J = 14.9 Hz, IH), 3.58 (d, J = 14.8 Hz, IH), 2.02-1.99 (m, IH). Mass spectram (LCMS, ESI pos.): Calcd. for C23H19Cl2IN2θ2: 551.99; found: 552.90 (M+H).
EXAMPLE 171
3-(4-Chloro-phenyl)-4-[ 1 -(4-chloro-phenyl)-2-hydroxy-ethyl]-7-iodo- 1 ,2,3 ,4- tetrahydro-benzo[e] [ 1 ,4] diazepin-5-one
1H NMR (400 MHz, CDC13): 8.52 (d, J = 2.1 Hz, IH), 7.36 (dd, I = 8.6 Hz and J = 2.2 Hz, IH), 7.20-7.14 (m, 4H), 7.08 (d, J = 8.5 Hz, 2H), 6.81 (d, J
= 8.4 Hz, 2H), 6.18 (d, J = 8.6 Hz, IH), 5.48-5.45 (m, IH), 4.73 (d, J = 6.0 Hz, IH), 4.47-4.40 (m, IH), 4.33-4.24 (m, IH), 4.22-4.15 (m, IH), 3.83-3.75 (m, IH), 3.71-3.64 (m, IH), 3.14-3.08 (m, IH). Mass spectrum (LCMS, ESI pos.): Calcd. for C23H19Cl2iN2O2: 551.99; found: 552.84 (M+H).
EXAMPLE 172
3-(4-Chlorophenyl)-4-(2-hydroxy-l-phenyl-ethyl)-7-iodo-3,4-dihydro-lH- benzo[e] [1 ,4]diazepine-2,5-dione
1H NMR (400 MHz, DMSO-d6): 10.82 (br s, IH), 7.80 (d, J = 2.1 Hz, IH), 7.55 (dd, J = 8.5 Hz and J = 2.1 Hz, IH), 7.51 (d, J = 7.4 Hz, 2H), 7.40-
7.26 (m, 3H), 7.03 (d, J = 8.6 Hz, 2H), 6.64-6.58 (m, 3H), 6.13-6.05 (m, IH), 5.17 (s, IH), 5.05 (t, J = 5.0 Hz, IH), 4.11-3.97 (m, 2H). Mass spectrum (LCMS, ESI pos.): Calcd. for C23H18ClIN2O3: 532.01; found: 532.95 (M+H).
EXAMPLE 173
3-(4-Chloro-phenyl)-4-(3-hydroxy- 1 -phenyl-propyl)-7-iodo-3 ,4-dihydro- 1H- benzo[e][l,4]diazepine-2,5-dione
1H NMR (400 MHz, DMSO-d6): 10.94 (s, IH), 7.80 (d, J = 2.1 Hz, IH), 7.59 (d, J = 7.3, 2H), 7.54 (dd, J = 8.5 Hz and J = 2.1 Hz, IH), 7.37 (t, J = 7.4 Hz, 2H), 7.30 (t, J = 7.3 Hz, IH), 6.99 (d, J = 8.6 Hz, 2H), 6.64 (d, I = 8.5 Hz, IH), 6.45 (d, J = 8.7 Hz, 2H), 6.33 (t, J = 1.1 Hz, IH), 5.25 (s, IH), 4.61
(t, J = 4.9 Hz, IH), 3.48-3.39 (m, 2H), 2.28-2.20 (m, 2H). Mass spectram (LCMS, ESI pos.): Calcd. for C24H2oCπN2O3: 546.02; found: 546.91 (M+H).
EXAMPLE 174
2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-N-(2-hydroxy-ethyl)-acetamide
1H NMR (400 MHz, DMSO-d6): 10.73 (s, IH), 8.25 (t, J = 5.6 Hz, IH), 7.78 (d, J = 2.1 Hz, IH), 7.56 (dd, J = 8.5 Hz and J = 2.1 Hz, IH), 7.50- 7.43 (m, 4H), 7.13 (d, J = 8.6 Hz, 2H), 6.91 (d, J = 7.8 Hz, 2H), 6.64 (d, J = 8.5 Hz, IH), 6.48 (s, IH), 5.00 (s, IH), 4.65 (t, J = 5.3 Hz, IH), 3.42-3.37 (m,
2H), 3.29-3.05 (m, 2H). Mass spectrum (LCMS, ESI pos.): Calcd. for C25H2oCi2lN3θ4: 622.99; found: 623.75 (M+H). EXAMPLE 175
3-(4-Chloro-phenyl)-3-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e] [1 ,4]diazepin-4-yl]-propionic acid
1H NMR (400 MHz, DMSO-d6): δlθ.90 (s, IH), 7.81 (d, J = 2.4 Hz, IH), 7.64 (d, J = 8.4 Hz, 2H), 7.56 (dd, J = 8.0Hz, 2.0Hz, IH), 7.41 (d, J = 8.4
Hz, 2H), 7.05 (d, J = 8.4 Hz, 2H), 6.61 (d, J = 8.4 Hz, IH), 6.54 (d, J = 8.8 Hz, 2H), 6.42 (t, J = 8.0 Hz, IH), 5.31 (s, IH), 3.15 (d, J = 7.2 Hz, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C24H17Cl2rN2O4: 593.96; Found 594.90 (M+H).
EXAMPLE 176
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(6-chloro-pyridin-3-yl)-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.64 (s, OJH), 10.61 (s, 0.3H), 8.46 (d, J = 2.4 Hz, 0.7H), 8.34 (d, J = 2.4 Hz, 0.3H), 7.93-7.90 (m, O.IK), 7.81-7.80 (m, 0.3H), 7J8 (d, j = 2 Hz, .IK), 1.11 (d, J = 2.4 Hz, 0.3H), 7.54-
7.51 (m, IH), 7.46-7.41 (m, IH), 7J9-7J3 (m, 2.6H), 7.04-7.02 (m, 1.4H), 6.62 (d, J = 8.8 Hz, OJH), 6.56 (d, J = 8.8 Hz, 0.3H), 6.25 (s, 0.3H), 6.04 (s, OJH), 5.81 (s, 0.3H), 5.40 (s, OJH). Mass spectrum (LCMS, ESI pos) Calcd. for C22H14C12ΓN3O4: 580.94; Found 581.93 (M+H).
EXAMPLE 177
2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -N-hydroxy-acetamide
1H NMR (400 MHz, DMSO-d6): δlθ.83 (s, IH), 7.73 (d, j = 2.0Hz,
IH), 7.76 (dd, j = 8.0 Hz, 2.0 Hz, IH), 7.52-7.45 (m, 3H), 7.20 (d, j = 8.8Hz, 2H), 7.07 (d, j = 8.8Hz, 2H), 6.64 (d, J = 8.4 Hz, IH), 6.20 (s, IH), 5.24 (s, 1H). Mass spectrum (LCMS, ESI neg) Calcd. for C23H16Cl2IN3O4: 594.96; Found 578.9.
EXAMPLE 178
[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.68 (s, IH), 7.60 (d, J = 2.4 Hz,
IH), 7.50 (d, J = 8.4 Hz, 2H), 7.44-7.39 (m, 3H), 7.10 (d, J = 8.8 Hz, 2H),
6.93-6.85 (m, 2H), 6.78 (d, J = 8.8 Hz, IH), 6.24 (s, IH), 5.22 (s,' IH). Mass spectrum (LCMS, ESI pos) Calcd. for C23H15BrCl2N2O4: 531.96; Found 532.90 (M+H).
EXAMPLE 179
[8-Chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.78 (s, IH), 7.98 (s, IH), 7.49 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H), 7.04 (s,
IH), 6.82 (d, J = 8.4 Hz, 2H), 6.26 (s, IH), 5.21 (s, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C23H14Cl3IN2O4: 613.91; Found 614.8 (M+H).
EXAMPLE 180
2-{2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetylamino}-3-methyl-butyric acid
1H NMR (400 MHz, DMSO-d6): δl0.80-10.69 (m, IH), 8.58-8.47 (m, IH), 7.62-7.29 (m, 3H), 7.25-6.83 (m, 5H), 6.80-6.50 (m, 2H), 5.04 (s, 0.5H), 4.86 (s, 0.5H), 4.27-4.08 (m, IH), 2.07-1.97 (m, IH), 0.92-0.81 (m, 6H). Mass spectram (LCMS, ESI pos) Calcd. for C2ΛCI2IN3O5: 679.01; Found 679.66 (M+H).
EXAMPLE 181
3-(4-Chloro-phenyl)-3-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-propionic acid
1H NMR (400 MHz, DMSO-d6): δlθ.88 (s, IH), 7.80 (d, J = 2.4 Hz, IH), 7.59-7.50 (m, 3H), 7.35 (d, J = 8.0Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H), 6.64-6.58 (m, 3H), 6.42-6.36 (m, IH), 5.10 (s, IH), 2.95-2.86 (m, IH), 2.41- 2.34 (m, IH).
EXAMPLE 182
5-{2-(4-Chloro-ρhenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetylamino } -pentanoic acid
1H NMR (400 MHz, DMSO-de): δ 12.00 (s, IH), 10.72 (s, IH), 8.25 (t, J = 5.6 Hz, IH), 7.77 (d, J = 2.0 Hz, IH), 7.60-7.52 (m, IH), 7.50-7.41 (m, 4H), 7.13 (dd, J = 8.0 Hz, 2.0 Hz, 2H), 6.90 (dd, J = 8.0 Hz, 1.2 Hz, 2H), 6.64
(d, J = 8.4 Hz, IH), 6.42 (s, IH), 4.98 (s, IH), 3.22-2.98 (m, 2H), 2.23-2.17 (m, 2H), 1.52-1.34 (m, 4H). Mass spectram (LCMS, ESI pos) Calcd. for C28H24Cl2IN3O5: 679.01; Found 679.86 (M+H).
EXAMPLE 183
3-{2-(4-Chloro-ρhenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4]diazepin-4-yl] -acetylamino } -propionic acid
1H NMR (400 MHz, DMSO-de): δ 10.73 (s, IH), 8.37-8.28 (m, IH), 7.77 (d, J = 2.0 Hz, IH), 7.58-7.53 (m, IH), 7.46-7.42 (m, 4H), 7.13 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 8.4 Hz, 2H), 6.64 (d, J = 8.4 Hz, IH), 6.43 (s, IH), 4.97 (s, IH), 3.17 (d, J = 5.6 Hz, 2H), 2.42-2.38 (m, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for CΛoCWsOs: 650.98; Found 651.68 (M+H).
EXAMPLE 184
(4-Chloro-phenyl)-[7-iodo-2.5-dioxo-3-(4-trifluoromethylsulfanyl-phenyl)- l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid
Mass spectram (LCMS, ESI pos) Calcd. for C24H15ClF3rN2O4S: 645.94; Found 646.96 (M+H).
EXAMPLE 185
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-2,5-dioxo-7-(lH-pyrrol-3-yl)-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid
1H NMR (400 MHz, DMSO-de): δ 10.94 (s, IH), 10.60 (s, IH), 7.66- 7.35 (m, 6H), 7.22-7.03 (m, 5H), 6.19-6.12 (m, 2H), 6.34-6.28 (m, IH), 6.21 (s, IH), 5.25 (s, IH).
Mass spectrum (LCMS, ESI pos) Calcd. for C 7H19Cl2N3O4: 519.08; Found 520.00 (M+H).
EXAMPLE 186
3-[4-[Carboxy-(4-chloro-phenyl)-methyl]-3-(4-chloro-phenyl)-7-iodo-2,5- dioxo-2,3 ,4,5 -tetrahydro-benzo [e] [ 1 ,4] diazepin- 1 -yl] -propionic acid
1H NMR (400 MHz, CD3OD-d6): δ 8.06-7.89 (m, 1.2H), 7.83 (d, J = 8.4 Hz, 0.6H), 7.74-7.68 (m, 0.6H), 7.56 (d, J = 8.0 Hz, IH), 7.47-7.24 (m,
3H), 7.08-6.93 (m, 2H), 6.82-6.57 (m, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for C26H19Cl2IN2θ6: 651.97; Found 652.90 (M+H). EXAMPLE 187
6-{2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7Jodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetylamino}-hexanoic acid
1H NMR (400 MHz, DMSO-d6): δ 11.98 (s, IH), 10.72 (s, IH), 8.29- 8.15 (m, IH), 7.77 (d, J = 2.0 Hz, IH), 7.59-7.53 (m, IH), 7.51-7.42 (m, 4H),
7.13 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 7.6 Hz, 2H), 6.64 (d, J = 8.4 Hz, IH), 6.41 (s, IH), 4.98 (s, IH), 3.20-2.95 (m, 2H), 2.16 (t, J = 7.6 Hz, 2H), 1.53- 1.31 (m, 4H), 1.26-1.15 (m, 2H). Mass spectram (LCMS, ESI pos) Calcd. for C29H26Cl2IN3O5: 693.03; Found 693.82 (M+H).
EXAMPLE 188
[l-(2-tert-Butoxycarbonylamino-ethyl)-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo- l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400 MHz, CD3OD): δ 7.94 (d, J = 2.0 Hz, IH), 7.53 (d, J = 8.4 Hz, 2H), 7.47 (dd, J = 8.4 Hz, 2.0 Hz, IH), 7.29 (d, J = 8.0 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 6.73 (dd, I = 8.0 Hz, 1.6 Hz, 2H), 6.61 (d, J = 8.4 Hz, IH),
6.50 (s, IH), 5.27 (s, IH), 3.55-3.49 (m, 2H), 3.50-3.45 (m, IH), 3.15-3.10 (m, IH). Mass spectram (LCMS, ESI pos) Calcd. for C3oH28Cl2IN3O6: 723.04; Found 723.70 (M+H).
EXAMPLE 189
(4-Chloro-phenyl)-{7-iodo-2,5-dioxo-3-[5-(3-trifluoromethyl-phenyl)-furan-2- yl]-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl}-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 8.03 (s, IH), 7.68-7.56 (m, 4H), 7.57-7.44 (m, 4H), 7.40-7.33 (m, 2H), 6.79 (d, J = 8.4 HzJH), 6.73 (s, IH), 6.48 (d, J = 3.2 Hz, IH), 5.61-5.57 (m, IH), 5.49 (s, IH). Mass spectram (LCMS, ESI pos) Calcd. for C28H17ClF3rN2O5: 679.98; Found 680.77 (M+H). EXAMPLE 190
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l-(2-pyridin-2-yl- ethyl)-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid
Mass spectrum (LCMS, ESI pos) Calcd. for C30H22C12IN3O4: 685.00; Found 686.18 (M+H).
EXAMPLE 191
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-l-methylcarbamoylmethyl- 2,5-dioxo-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid
1H NMR (400 MHz, DMSO-de): δ 7.84-7.81 (m, IH), 7.52-7.46 (m, 3H), 7.33-7.27 (m, 2H), 6.91 (d, J = 8.4 Hz, 2H), 6.80 (d, J = 8.4 Hz, IH), 6.69
(d, J = 8.8 Hz, 2H), 6.57 (s, IH), 5.33 (s, IH), 4.50 (m, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C26H2oCl2rN3O5: 650.98; Found 651.94 (M+H).
EXAMPLE 192
(4-Chloro-phenyl)-[3-(4-difluoromethoxy-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400 MHz, CD3OD): δ 7.93 (d, J = 2.0Hz, 0.6H), 7.89 (d, J = 2.0Hz, 0.4H), 7.59 (d, J = 8.0 Hz, IH), 7.54-7.48 (m, IH), 7.45 (d, J = 8.4 Hz, 0.6H), 7.37-7.30 (m, 2.4H), 7.13-7.05 (m, 0.4H), 6.85 (d, J = 8.4 Hz, 0.6H), 6.82-6.70 (m, 2.3H), 6.68-6.65 (m, 0.6H), 6.64-6.58 (m, IH), 5.70 (s, 0.3H), 5.37 (s, IH). Mass spectram (LCMS, ESI pos) Calcd. for C24H16C1F2ΓN2O5:
611.98; Found 612.80 (M+H). EXAMPLE 193
[l-(2-tert-Butoxycarbonylamino-ethyl)-3-(4~chloro-phenyl)-7-iodo-2,5-dioxo- 1 ,2,3,5-tetrahydro-benzo[e] [1 ,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400 MHz, CD3OD): δ 7.84 (d, J = 2.0 Hz, IH), 7.57-7.45 (m, 3H), 7.37 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 7.00 (d, J = 8.8 Hz,
2H), 6.82 (d. J = 8.8 Hz, IH), 6.56 (s, IH), 5.76 (s, IK), 4.11-3.98 (m, IH),
3.78-3.65 (m, IH), 3.16-3.08 (m, 2H), 1.39 (s, 9H). Mass spectrum (LCMS,
ESI pos) Calcd. for C3oH28Cl2IN3O6: 723.04; Found 745.90 (M+Na)
EXAMPLE 194
(3-Benzofuran-2-yl-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl)-(4-chloro-phenyl)-acetic acid
1H NMR (400 MHz, CD3OD): δ 8.01 (d, J = 1.6 Hz, IH), 7.64 (d, J =
8.8 Hz, 2H), 7.58-7.51 (m, IH), 7.49-7.44 (m, IH), 7.40-7.32 (m, 2H), 7.26-
6.95 (m, 4H), 6.83-6.72 (m, IH), 5.92 (s, OJH), 5.80 (s, 0.3H), 5.64 (s 0.3H), 5.56 (s, O.IK). Mass spectrum (LCMS, ESI pos) Calcd. for C25H16ClIN2O5:
585.98; Found 586.93 (M+H).
EXAMPLE 195
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-l-methyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4]diazepin-4-yl]-acetic acid
1H NMR (400 MHz, CD3OD): δ 7.84 (d, J = 2.0Hz, IH), 7.62-7.54 (m,
3H), 7.34 (d, J = 8.4 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 8.8 Hz, IH), 6.68 (dd, J = 8.8 Hz, 1.2 Hz, 2H), 6.53 (s, IH), 5.38 (s, IH), 3.44 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C24H17Cl2IN2θ4: 593.96; Found 594.95 (M+H). - Ill -
EXAMPLE 196
(4-Chloro-phenyl)-[3-(4-cyano-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-acetic acid
1H NMR (400 MHz, CD3OD): δ 7.91 (d, J = 2.0 Hz, IH), 7.59 (d, J = 8.4 Hz, IH), 7.55-7.42 (m, 3H), 7.39-7.27 (m, 3H), 6.98 (d, J = 8.4 Hz, IH),
6.65 (d, J = 7.6 Hz, IH), 6.59 (d, J = 8.4 Hz, 0.5H), 6.51 (d, J = 8.8 Hz, 0.5H), 5.77 (s, 0.5H), 5.44 (s, 0.5H).
Mass spectram (LCMS, ESI pos) Calcd. for C24H15ClIN3θ4: 570.98; Found 571.80 (M+H).
EXAMPLE 197
[l-Carboxymethyl-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid methyl ester
1H NMR (400 MHz, DMSO-d6): δ 1.13-6.15 (m, IIH), 6.24 (s, IH), 5.42 (s, IH), 4.53-4.25 (m, IH), 4.16-3.86 (m, IH), 3.78 (s, 3H). Mass spectram (LCMS, ESI pos) Calcd. for C26H19Cl2IN2O6: 651.97; Found 652.87
(M+H).
EXAMPLE 198
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-(2-hydroxy-ethyl)-2,5-dioxo- l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.46 (s, IH), 7.62-7.26 (m, 4H),
7.08-6.96 (m, 3H), 6.82-6.66 (m, 3H), 6.30 (s, IH), 5.29 (s, IH), 4.59 (s, IH), 3.45-3.39 (m, 2H), 2.55 (t, J = 8.8 Hz, 2H). Mass spectram (LCMS, ESI pos) Calcd. for C2sH2oCl2N2O5: 498.07; Found 498.95 (M+H). EXAMPLE 199
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-l-(2(R),3-dihydroxy-propyl)-7-iodo- 2,5-dioxo-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid
Mass spectrum (LCMS, ESI pos) Calcd. for C26H21Cl2IN2O6: 653.98; Found 654.81 (M+H).
EXAMPLE 200
(4-Chloro-phenyl)-[3-(6-chloro-pyridin-3-yl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [1,4] diazepin-4-yl] -acetic acid
1H NMR (400 MHz, CD3OD): δ 7.63-7.57 (m, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.00-6.89 (m, 3H), 6.78-6.65 (m, 4H), 5.41 (s, IH).
EXAMPLE 201
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-hydroxymethyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400 MHz, DMSO-d6): δlθ.52 (s, IH), 7.57-7.42 (m, 2H), 7.41-7.23 (m, 3H), 7.22-6.96 (m, 4H), 6.87-6.67 (m, 3H), 6.33 (s, IH), 5.18 (s,
IH), 4.38-4.27 (m, 2H).
Mass spectram (LCMS, ESI pos) Calcd. for C24H18Cl2N2O5: 484.06; Found 485.00 (M+H).
EXAMPLE 202
(4-Chloro-phenyl)-{7-iodo-2,5-dioxo-3-[4-(lJ,2,2-tetrafluoro-ethoxy)- phenyl]-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl}-acetic acid
1H NMR (400 MHz, CD3OD): δ 7.96 (d, j = 2.0 Hz, 0.4H), 7.80 (d, j = 2.0Hz, 0.6H), 7.54-7.47 (m, IH), 7.39 (d, j = 8.4 Hz, 2H), 7.29-7J2 (m, 5H), 7.06 (d, J = 8.4 Hz, 2H), 6.85 (t, J = 8.0 Hz, 1.8H), 6.62 (s, 0.7H), 5.96 (s, 0.6H), 5.79 (s, 0.4H), 5.36-5.28 (m, IH). Mass spectrum (LCMS, ESI pos) Calcd. for C25H16ClF4N2O5: 661.97; Found 662.90 (M+H).
EXAMPLE 203
(4-Chloro-phenyl)-[7-iodo-3-(4-methylsulfanyl-phenyl)-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400 MHz, CD3OD): δ 7.92 (s, OJH), 7.88 (s, 0.3H), 7.58 (d, J = 8.0 Hz, IH), 7.56-7.41 (m, UK), 7.38=7.29 (m, UK), 7.20 (d, J = 8.0 Hz, OJH), 7.08 (d, J = 8.0 HZ, 0.3H), 7.02-6.89 (m, IH), 6.86-6.69 (m, IH), 6.70- 6.63 (m, 1.3H), 6.60 (d, J = 8.8 Hz, O.IK), 6.51 (d, J = 8.8 Hz, 0.3H), 5.70 (s,
0.3H), 5.35 (s, OJH), 2.34 (s, IH), 2.29 (s, 2H). Mass spectram (LCMS, ESI pos) Calcd. for C24H18CHN2O4S: 591.97; Found 592.90 (M+H).
EXAMPLE 204
(4-Chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-pyrrolidin-l-yl-phenyl)-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400 MHz, CD3OD): δ 8J8-8.08 (m, IH), 7.98-7.85 (m, IH), 7.59 (d, J = 1.2Hz, IH), 7.52-7.42 (m, 2H), 7.39-7.28 (m, 3H), 7.06 (d, J = 8.0 Hz, IH), 6.74-6.45 (m, IH), 6.29 (d, j = 8.4 Hz, IH), 6.09 (dd, J = 8.0 Hz, 1.2Hz, IH), 5.66 (s, 0.5H), 5.36 (s, 0.5H), 3J7-3.02 (m, 4H), 1.99-1.87 (m, 4H). Mass spectrum (LCMS, ESI pos) Calcd. for C27H23ClIN3O4: 615.04;
Found 616.07 (M+H). EXAMPLE 205
2-(4-Chloro-ρhenyl)-2-[3-(4-chloro-ρhenyl)-7Jodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-N,N-bis-(2-hydroxy-ethyl)-acetamide
1H NMR (400 MHz, DMSO-d6): δ 8.65 (s, 0.5H), 8.20 (s, 0.5H), 8.00 (d, J = 1,6 Hz, 0.5H), 7.94 (d, J = 2.0Hz, 0.5H), 7.52-7.42 (m, 2.5H), 7.37 (d, J
= 8.8 Hz, IH), 7.24 (dd, J = 5.6 Hz, lh), 7.10-6.99 (m, 2H), 6.95 (s, IH), 6.85 (d, J = 8.0Hz, 0.5H), 6.46-6.35 (m, IH), 5.32 (s, 0.5H), 5.12 (s, 0.5H), 4.04- 3.06 (m, 8H). Mass spectrum (LCMS, ESI pos) Calcd. for C27H24Cl2rN3O5: 667.01; Found 667.85 (M+H).
EXAMPLE 206
(4-Chloro-phenyl)-{7-iodo-2,5-dioxo-3-[4-(lJ,2,2Jetrafluoro-ethoxy)- phenyl]-l ,2,3 ,5-tetrahydro-benzo[e] [ 1 ,4] diazepin-4-yl } -acetic acid
1H NMR (400 MHz, CD3OD): δ 7.83-7.74 (m, OJH), 7.60 (d, J = 8.4 Hz, 0.6H), 7.52-7.45 (m, OJH), 7.42-7.30 (m, 2H), 7.27 (d, I = 8.4 Hz, IH), 7.17 (d, J = 7.6 Hz, 2H), 7.09-6.97 (m, 3H), 6.89-6.78 (m, 2H), 6.63 (s, 0.6H),
6.46 (s, 0.4H), 5.97 (s, 0.5H), 5.60-5.51 (m, 0.6H), 5.37-5.27 (m, 0.1K), 4.66- 4.58 (m, 0.5H). Mass spectrum (LCMS, ESI pos) Calcd. for C25H16ClF4IN2θ5: 661.97; Found 662.89 (M+H).
EXAMPLE 207
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-(6-methyl-pyridin-3-yl)-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.76 (s, IH), 8.53 (d, J = 2.0 Hz, IH), 7.78-7.72 (m, 2H), 7.60-7.53 (m, IH), 7.26-7.16 (m, 3H), 7.10-7.03 (m, 2H), 6.65 (d, J = 8.8 Hz, IH), 6.16 (s, IH), 5.33 (s, IH), 2.42 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H17ClIN3O4: 561.00; Found 562.01 (M+H).
EXAMPLE 208
3-{2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetylamino } -propionic acid methyl ester
1H NMR (400 MHz, DMSO-d6): δ 10.74 (s, IH), 8.35 (t, J = 6.0Hz, IH), 7.77 (d, J = 2.0 Hz, IH), 7.61-7.51 (m, IH), 7.45 (s, 2H), 7.13 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 7.8 Hz 2H), 6.64 (d, J = 7.8 Hz, IH), 6.42 (s, IH), 4.98 (s, IH), 3.56 (s, 3H), 3.48-3.36 (m, IH), 3.31-3.21 (m, IH), 2.48-2.40 (m, 2H).
Mass spectrum (LCMS, ESI pos) Calcd. for C27H22Cl2IN3O5: 665.00; Found 665.70 (M+H).
EXAMPLE 209
[7-Amino-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
1H NMR (400 MHz, DMSO-d6): δ 12.00 (s, IH), 10.20 (s, IH), 7.53-
7.35 (m, 3H), 7.27 (d, J = 8.4 Hz, 0.4H), 7.19-6.96 (m, 2.8H), 6.88-6.66 (m,
1.2H0, 6.54-6.39 (m, 1.4H), 6.10 (s, OJH), 5J8 (s, 0.8H), 5.00 (s, l.OH), 4.42
(s, 0.4H). Mass spectrum (LCMS, ESI pos) Calcd. for C23H17Cl2N3O4: 469.06; Found 470.00 (M+H). EXAMPLE 210
2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-N-(2-hydroxyguanidino-ethyl)- acetamide
1H NMR (400 MHz, DMSO-d6): δ 10.95 (s, IH), 10.75 (s, IH), 8.41
(m, IH), 7.77 (d, I = 2.0 Hz, IH), 7.57 (dd, J = 8.4 Hz, 2.4 Hz, IH), 7.53-7.44 (m, 3H), 7.14 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.4 Hz, 2H), 6.65 (d, J = 8.8 Hz, IH), 6.43 (s, IH), 4.99 (s, IH), 3.80 (t, J = 5.6 Hz, 2H), 3.46-3.36 (m, 4H). Mass spectrum (LCMS, ESI pos) Calcd. for C26H23Cl2LN6O4: 680.02; Found 681.00 (M+H).
EXAMPLE 211
(4-Chloro-phenyl)-[3-(5-chloro-thiophen-2-yl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e] [ 1 ,4]diazepin-4-yl] -acetic acid
1H NMR (400 MHz, CD3OD): δ 7.99-7.89 (m, IH), 7.67-7.51 (m, 2H), 7.44-7.32 (m, 2H), 7.27^6.99 (m, IH), 6.90-6.82 (m, 0.5H), 6.73 (d, J = 8.4Hz,
0.5H), 6.67-6.41 (m, 2H), 6.23-6.18 (m, 0.5H), 5.44-5.38 (m, 0.5H). Mass spectrum (LCMS, ESI pos) Calcd. for C21H13Cl2IN2O4S: 585.90; Found
586.72 (M+H).
EXAMPLE 212
(4-Chloro-phenyl)-[7-iodo-3-(4-isopropenyl-cyclohex-l-enyl)-2,5-dioxo-
1 ,2,3,5-tetrahydro-benzo[e] [1 ,4] diazepin-4-yl] -acetic acid
1H NMR (400 MHz, DMSO-d6): δ 10.31 (s, 0.8H), 10.15 (s, 0.2H), 7.93-7.78 (m, IH), 7.72-7.64 (m, IH), 7.44-7.24 (m, 4H), 6.83-6.73 (m, IH), 6.20-6.11 (m, IH), 5.05-4.93 (m, IH), 4.57-4.44 (m, 2H), 4.35-4.24 (m, IH), 1.71-1.21 (m, 10H). Mass spectrum (LCMS, ESI pos) Calcd. for C26H24CHN2O4: 590.05; Found 591.00 (M+H).
EXAMPLE 213
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-l-(2(S),3-dihydroxy-propyl)-7-iodo- 2,5-dioxo-l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid
1H NMR (400 MHz, CD3OD): δ 7.87-7.80 (m, IH), 7.61-7.45 (m, 3H), 7.38-7.28 (m, 2H), 7.19-6.91 (m, 4H), 6.80-6.71 (m, IH), 6.62 (s, 0.3H), 5.89 (s, 0.6H), 4.30-3.38 (m, 5H). Mass spectram (LCMS, ESI pos) Calcd. for C26H21Cl2IN2O6: 653.98; Found 637.20.
EXAMPLE 214
5-[4-[Carboxy-(4-chloro-phenyl)-methyl]-3-(4-chloro-phenyl)-7-iodo-2,5- dioxo-2,3,4,5-tetrahydro-benzo[e][l,4]diazepin-l-yl]-pentanoic acid
1H NMR (400 MHz, DMSO-d6): δ 7.97-7.91 (m, IH), 7.66 (d, J = 8.4
Hz, IH), 7.46-7.41 (m, 4H), 7.03 (d, J = 8.4 Hz, 2H), 6.73 (d, J = 8.4 Hz, IH), 6.67 (s, IH), 6.64 (d, J = 8.4 Hz, 2H), 5.48 (s, IH), 4.57-4.45 (m, IH), 3.75-
3.65 (m, IH), 2.49-2.39 (m, 2H), 1.75-1.55 (m, 4H). Mass spectrum (LCMS,
ESI pos) Calcd. for
Figure imgf000118_0001
680.00; Found 680.85 (M+H).
EXAMPLE 215
5-{3-(4-Chloro-phenyl)-4-[l-(4-chloro-phenyl)-2-hydroxy-ethyl]-7-iodo-2,5- dioxo-2,3,4,5-tetrahydro-benzo[e][l,4]diazepin-l-yl}-pentanoic acid
1H NMR (400 MHz, DMSO-d6): δ 7.85 (d, J = 2 Hz, IH), 7.61-7.52 (m, 3H), 7.38 (d, J = 8.4 Hz, 2H), 6.97-6.87 (m, 3H), 6.58 (dd, J = 2.0 Hz, 8.0 Hz, 2H), 6.28-6.20 (m, IH), 5.39 (s, IH), 4.36-4.24 (m, 2H), 4.20-4.12 (m, IH), 3.83-3.72 (m, IH), 2.23-2.11 (m, 2H), 1.84-1.65 (m, 2H), 1.64-1.52 (m, 2H). Mass spectram (LCMS, ESI pos) Calcd. for C28H25Cl2IN2θ5: 666.02; Found 666.97 (M+H).
EXAMPLE 216
5-{3-(4-Chloro-phenyl)-4-[(4-chloro-phenyl)-diethylcarbamoyl-methyl]-7- iodo-2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][l,4]diazepin-l-yl}-pentanoic acid
1H NMR (400 MHz, DMSO-d6): δ 7.65 (d, J = 2.4 Hz, IH), 7.62-7.55 (m, 3H), 7.53-7.48 (m, 2H), 7.12-7.06 (m, 2H), 6.94-6.87 (m, 2H), 6.60 (s, IH), 4.89 (s, IH), 4.24-4.14 (m, IH), 3.74-3.63 (m, IH), 3.57-3.47 (m, 2H), 3.17-3.08 (m, 2H), 2.23-2.13 (m, 2H), 1.85-1.73 (m, IH), 1.67-1.58 (m, IH), 1.49-1.40 (m, 2H), 1.10-0.98 (m, 6H). Mass spectrum (LCMS, ESI pos)
Calcd. for C32H32C12ΓN3O5: 735.08; Found 735.82 (M+H).
EXAMPLE 217
Fluorescent peptide assay
The inhibition of MDM2 binding to p53 was measured using a p53 peptide analogue binding to MDM2 residues 17-125. The published crystal structure of this complex (Kussie et al, Science 274:948-953 (1996)) validates this fragment as containing the p53 binding site, and we have solved the x-ray structure of the p53 peptide analogue MPRFMDY EGLN, described to be a peptide inhibitor of the MDM2 p53 interaction (Bottger et al, J. Mol Biol. 269:744-756 (1997)). The assay uses N terminal fluorescein RFMDYWEGL peptide (FI 9mer).
The mdm2 17-125 was produced as a glutathione S transferase fusion as follows: cDNA encoding residues 17-125 were cloned into pGEX4t-3 (Pharmacia) as follows. PCR was performed using ATCC item number 384988 containing partial human mdm2 sequence as template and the following primers: Forward: 5'-CTC TCT CGG ATC CCA GAT TCC AGC TTC GGA ACA AGA G; Reverse: 5'-TAT ATA TCT CGA GTC AGT TCT CAC TCA CAG ATG TAG CTG AG. The PCR product was then digested with BamHI and Xhol (sequence recognition sites underlined in primers), gel purified, and ligated into pGEX4t-3 which had also been digested with BamHI and Xhol. Plasmids were transfected into E. coli X90 strain, grown to an OD of 1.0 in TB 0.2% glucose 100 μg/mL ampicillin and induced with 1 mM
IPTG. Cells were harvested 5 hours post induction, centrifuged, and resuspended in PBS 10 mL/g cell paste. Cells were lysed in an Avestin microfluidizer, centrifuged, and the supernatant bound to a glutathione sepharose 4B resin (Pharmacia). The resin was washed with PBS and the MDM2 17-125 cleaved from the GST by the addition of 2 μg mL thrombin
(Enzyme Research Labs). The cleaved MDM2 was further purified on Sepharose SP Fast Flow resin (Pharmacia), eluting with 20 mM HEPES pH 7.5 150 mM NaCl. Glutathione was added to 5 mM, and the protein stored at -70°C. Test compound was incubated for 15 minutes with 30 nM fluorescein peptide FI 9mer and 120 nM MDM2 17-125 in 50 mM HEPES pH 7.5, 150 mM NaCl, 3 mM octyl glucoside. The polarization of the fluorescein label was thereafter measured by excitation at 485 nm and emission at 530 nm. Polarization was expressed as a percent of a no compound control, using buffer with FI 9mer but without MDM2 as background.
Compounds of the present invention inhibited the binding of p53 to MDM2. The potency of the compounds was measured as IC50, which is a measure of the concentration of the test compound required to inhibit 50% binding between MDM2 and p53. The IC50 values for compounds of the present invention ranged from 0J μM to >100 μM. Table 1 provides representative data for compounds of the invention. Table 1. Inhibition of MDM2 binding to p53
Example No. ICso (μM)
Figure imgf000121_0001
EXAMPLE 218
Tablet Preparation
Tablets containing 25.0, 50.0, and 100.0 mg, respectively, of the compound of Example 1 ("active compound") are prepared as illustrated below:
TABLET FOR DOSES CONTAINING FROM 25-100 MG OF THE ACTIVE COMPOUND
Amount-mg
Active compound 25.0 50.0 100.00
Microcrystalline cellulose 37.25 100.0 200.0
Modified food corn starch 37.25 4.25 8.5
Magnesium stearate 0.50 0.75 1.5
All of the active compound, cellulose, and a portion of the com starch are mixed and granulated to 10% com starch paste. The resulting granulation is sieved, dried and blended with the remainder of the com starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 25.0, 50.0, and 100.0 mg, respectively, of active ingredient per tablet.
EXAMPLE 219
Intravenous Solution Preparation
An intravenous dosage form of the compound of Example 1 ("active compound") is prepared as follows:
Active compound 0.5-10.0 mg
Sodium citrate 5-50 mg
Citric acid 1-15 mg
Sodium chloride 1-8 mg
Water for injection (USP) q.s. to 1 ml
Utilizing the above quantities, the active compound is dissolved at room temperature in a previously prepared solution of sodium chloride, citric acid, and sodium citrate in Water for Injection (USP, see page 1636 of United States Pharmacopeia/National Formulary for 1995, published by United States Pharmacopeial Convention, Inc., Rockville, Maryland (1994). Having now fully described this invention, it will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof. All patents and publications cited herein are fully incorporated by reference herein in their entirety.

Claims

WHAT IS CLAIMED IS:
1. A compound of Formula I:
Figure imgf000123_0001
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: X and Y are independently -C(O)~, -CH2- or -C(S)-;
R1, R2, R3, and R4 are independently hydrogen, halo, alkyl, alkenyl, alkynyl, cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, alkoxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, cyano, amino, alkanoylamino, nitro, hydroxy, carboxy, or alkoxycarbonyl; or R1 and R2, or R2 and R3, or R3 and R4 are taken together to form -(CH2)U-, where u is 3-6, -CH=CH-CH=CH- or -CH2CH=CHCH2-;
R5 is hydrogen, alkyl, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, arninocarbonylalkyl, alkylaminocarbonyl or alkylaminocarbonylalkyl;
R6 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted;
R7 and R8 are independently hydrogen or alkyl; R9 is cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of which is optionally substituted; and R10 is -(CH2)„— CO2Rb, -(CH2)m— CO2M, -(CH2)i-OH or
-(CH )j— CONRcRd where Rb is hydrogen, alkyl, optionally substituted cycloalkyl, or optionally substituted, saturated or partially unsaturated heterocycle;
M is a cation;
Rc and Rd are independently hydrogen, alkyl, hydroxyalkyl, carboxyalkyl, aminoalkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, and an optionally substituted, saturated or partially unsaturated heterocycle; and n is 0-8, m is 0-8, i is 1-8 and j is 0-8.
2. A compound according to claim 1, wherein X and Y are independently selected from the group consisting of -C(S)- and -C(O)-.
3. A compound according to claim 1, wherein:
R1, R2, R3, and R4 are independently hydrogen, halo, -6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C -7 cycloalkyl, optionally substituted Cβ-ιo aryl, optionally substituted Cό-io ar(C1-6)alkyl, optionally substituted heteroaryl, optionally substituted heteroar(Ci-6)alkyl, Ci-6 alkoxy, optionally substituted C6-ιo aryloxy, optionally substituted heteroaryloxy, cyano, amino, alkanoylamino, nitro, hydroxy, carboxy, or -6 alkoxycarbonyl; or R1 and R2, or R2 and R3, or R3 and R4 are taken together to form -CH=CH-CH=CH- or -CH2CH=CHCH2-;
R5 is hydrogen, -6 alkyl, C3-7 cycloalkyl, optionally substituted C6-io aryl, optionally substituted heteroaryl, optionally substituted C6-10 ar(Q-6)alkyl, optionally substituted heteroar(Q-6)alkyl, carboxy(Q-6)alkyl,
Ci-6 alkoxycarbonyl, Q.6 alkoxycarbonyl(Q.6)alkyl, aminocarbonyl, aminocarbonyl(Q-6)alkyl, or -6 alkylaminocarbonyl(Q-6)aιkyl;
R6 is C3-7 cycloalkyl, Cβ-io aryl, heteroaryl, a saturated or partially unsaturated heterocycle, C3- cycloalkyl(Q-6)alkyl, C6-ιo ar(Q-6)alkyl or heteroaryl(C1-6)alkyl, each of which is optionally ring substituted by one or more substituents independently selected from the group consisting of Q.4 alkyl, Q.4 alkenyl, C2- alkynyl, C6-ιo aryl, phenoxy, benzyloxy, 5-10 membered heteroaryl, hydroxy, Q- alkoxy, Q.4 alkylenedioxy, halo, Q- haloalkyl, Q- alkylthio, thio, amino, mono(Q.4)alkylamino, di(Q- )alkylamino, and nitro;
R7 is hydrogen or Q-6 alkyl; R8 is hydrogen or Q.6 alkyl;
R9 is C3- cycloalkyl, a saturated or partially unsaturated heterocycle, Cό-io aryl, heteroaryl, C3- cycloalkyl(C1-6)alkyl, Cό-to ar(Q-6)alkyl or heteroaryl(C1.6)alkyl, each of which is optionally substituted by one or more substituents independently selected from the group consisting of Q.4 alkyl, C2- 4 alkenyl, C2.4 alkynyl, Cό-io aryl, 5-10 membered heteroaryl, hydroxy, Q- alkoxy, Q-4 alkylenedioxy, carboxy, halo, Q-4 haloalkyl, trifluoromethoxy, Q-4 alkylthio, thio, amino, mono(C1.4)alkylamino, di(Q-4)alkylamino, and nitro; and
R10 is -(CH2)n— CO2Rb, -(CH2)m— CO2M, -(CH2)i-OH or -(CH2)j— CONRcRd , where
Rb is hydrogen, Q-e alkyl, optionally substituted C3-7 cycloalkyl, or an optionally substituted, saturated or partially unsaturated heterocycle;
M is a cation;
Rc and Rd are independently hydrogen, Q.6 alkyl, Q-6 hydroxyalkyl, Q-e carboxyalkyl, aminoalkyl, optionally substituted C3- cycloalkyl, optionally substituted Cβ-io aryl, optionally substituted Cό-io ar(C1-6)alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl(Q.6)alkyl, or an optionally substituted, saturated or partially unsaturated heterocycle; and n is 0-4, m is 0-4, i is 1-4 and j is 0-4.
4. A compound of claim 1, wherein:
R1 and R4 are both hydrogen; R2 is hydrogen, halo, Q-6 alkyl, Q.6 hydroxyalkyl, C2.6 alkenyl, C2.6 alkynyl, C3. cycloalkyl, acetylamino, cyano, amino, Q-6 alkoxy, phenyl, thienyl, furanyl, and pyrrolyl, wherein said phenyl, thienyl and furanyl are optionally substituted by one or more substituents independently selected from the group consisting of halo, Q_ alkoxy, Q.4 alkyl, amino, methylenedioxy, and ethylenedioxy;
R3 is hydrogen, Q-6 alkyl, phenyl, or halo; or R2 and R3 are taken together to form -CH=CH-CH=CH-;
R5 is hydrogen; Q-6 alkyl; Q-6 hydroxyalkyl; carboxy(Q-6)alkyl; Q-6 alkylcarbamoyl(Q-6)alkyl; Q-e alkoxycarbonylamino(Q-6)alkyl; C3.7 cycloalkyl(Q-6)alkyl; Cό-io aryl, optionally substituted by Q- alkyl or halo;
Ce-io ar(Q-4)alkyl optionally substituted by Q- alkyl or halo; and pyridyl(Q-4)alkyl;
R6 is Cβ-io aryl, thienyl, benzothienyl, furanyl, benzofuranyl, indolyl, pyridyl, quinolinyl, C3- cycloalkenyl or cubanyl, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halo, Q- alkyl, C2-4 alkenyl, Q- alkoxy, halo(Q- )alkoxy, trifluoromethyl, trifluoromethoxy, Q- alkylsulfanyl, trifluoromethylsulfanyl, cyano, thienyl, phenyl, halophenyl, trifluoromethylphenyl, phenoxy, benzyloxy and pyrrolidinyl;
R7 is hydrogen or Q-6 alkyl;
R8 is hydrogen or Q-6 alkyl;
R9 is C3.7 cycloalkyl, C6-io aryl, heteroaryl, C3.7 cycloalkyl(Q-6)alkyl, Cό-io ar(Cι-6)alkyl or heteroaryl(Ci-6)alkyl, each of which is optionally substituted on the ring portion; and
R10 is -(CH2)n— CO2Rb or -(CH2)m— CO2M, where Rb is hydrogen, Q-6 alkyl, optionally substituted C3.7 cycloalkyl, or optionally substituted heterocycloalkyl, M is a cation n and m are independently 0, 1, 2, 3 or 4; or
R10 is-(CH2)i-OH or -(CH2)j— CONRcRd , where Rc and Rd are independently hydrogen, hydroxy, C3. cycloalkyl, Q-e alkyl, Q-6 hydroxyalkyl, C e carboxyalkyl, Q.6 aminoalkyl, optionally substituted phenyl, or optionally substituted benzyl; and i is 1, 2, 3, or 4, andj is O, 1, 2, 3 or 4.
5. The compound of claim 1, wherein R1 and R4 are both hydrogen.
6. The compound of claim 1, wherein R is hydrogen, halo, Q- alkyl, C3. cycloalkyl, C2_6 alkenyl, -6 alkynyl, acetylamino, Q-6 alkoxy, phenyl, halophenyl, hydroxyphenyl, Q-6 alkoxyphenyl, Q-6 alkylphenyl, aminophenyl, Q.6 alkylenedioxyphenyl, hydroxycarbonylphenyl, thienyl, Q_6 alkylthienyl, furanyl, pyrrolyl, amino, Q-6 hydroxyalkyl or cyano.
7. The compound of claim 1, wherein R is hydrogen, iodo, fluoro, chloro, bromo, methyl, ethyl, propyl, isopropyl, t-butyl, sec-butyl, cyclopropyl, ethynyl, acetylamino, methoxy, phenyl, 3-chlorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 3-methoxyphenyl, 4-methylphenyl, 3-methylphenyl, 3-isopropylphenyl, 3-aminophenyl, 3,4-methylenedioxyphenyl, 4-hydroxycarbonylρhenyl, thien-3-yl,
4-methylthien-2-yl, furan-2-yl, lH-pyrrol-3-yl, amino, 2-hydroxyethyl, hydroxymethyl, furan-3-yl, vinyl or cyano.
The compound of claim 1, wherein R2 is halo or phenyl.
The compound of claim 1, wherein R2 is iodo.
10. The compound of claim 1, wherein R3 is hydrogen, phenyl, fluoro, chloro, iodo or methyl.
11. The compound of claim 1, wherein R is hydrogen.
12. The compound of claim 1, wherein R5 is hydrogen, Q.6 alkyl, Q-e hydroxyalkyl, carboxy(Q_6)alkyl, Ci.6 alkylphenyl, Q_6 alkylbenzyl, phenethyl, phenyl(C1.6)alkyl, naphthyl(Q.6)alkyl, C3. cycloalkyl(C1.6)alkyl, pyridyl(C1-6)alkyl, Q-6 alkoxycarbonylamino(Q-6)alkyl, or Q_6 alkylc arbamoyl(C ι -e)alkyl .
13. The compound of claim 1, wherein R5 is hydrogen, methyl, carboxymethyl, 3-methylbutyl, 2-methylpropyl, isopropyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, phenyl, benzyl, phenethyl, 3-phenylpropyl, naphthalen-2-ylmethyl, cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, pyrid-2-ylmethyl, pyrid-3-ylmethyl, pyrid-4-ylmethyl, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, 2-carboxyethyl, 2-t-butoxycarbonylaminoethyl, 2-pyrid-2-ylethyl, methylcarbamoylmethyl, or 2,3-dihydroxypropyl.
14. The compound of claim 1, wherein R5 is hydrogen.
15. A compound according to claim 1, wherein R6 is optionally substituted C6-ιo aryl.
16. The compound of claim 1, wherein R6 is trifluoromethylphenyl, halophenyl, Q_6 alkylphenyl, Q.6 alkoxyphenyl, halo(Q.4)alkoxyphenyl, naphthyl, benzyloxyphenyl, phenoxyphenyl, dihydrobenzodioxinyl, trifluoromethyl-halophenyl, pyridyl, thienyl, Q-6 alkylthienyl, halothienyl, bithienyl, Q-6 alkylbenzothienyl, (halophenyl)furanyl, quinolinyl, biphenyl, indolyl, (trifluoromethylsulfanyl)phenyl, (trifluoromethylphenyl)furanyl, halo(Q-4)alkoxyphenyl, benzofuranyl, cyanophenyl, halopyridyl, (methylsulfanyl)phenyl, pyrrolidinylphenyl, C2.6 alkenyl(C3-7)cycloalkenyl, cubanyl or halocubanyl.
17. The compound of claim 1, wherein R6 is 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 4-iodophenyl, 4-methylphenyl, 4-ethylphenyl, 4-trifluoromethoxyphenyl, 4-isopropylphenyl, phenyl, 4- methoxy-phenyl, naphthalen-2-yl, 4-tert-butylphenyl, 4-benzyloxyphenyl, 4-phenoxyphenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl,
2,3-dihydrobenzo[l,4]dioxin-6-yl, 4-bromo-2-fluorophenyl, 2-fluoro- 4-trifluoromethylphenyl, 3-fluoro-4-trifluoromethylphenyl, 4-chloro- 3-trifluoromethylphenyl, 4-chloro-3-fluoroρhenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, thien-3-yl, 5-methylthien-2-yl, 3-methylthien-2-yl, 4-bromothien- 2-yl, 5-[2,2']bithienyl, 3-methylbenzo[b]thiophen-2-yl, 5-(2-chlorophenyl)- furan-2-yl, 5-(3-chlorophenyl)-furan-2-yl, quinolin-3-yl, biphen-4-yl, indol-2- yl, indol-3-yl, 4-trifluoromethylsulfanylphenyl, 5-(3-trifluoromethylphenyl)furan-2-yl, 4-(l,l,2,2-tetrafluoroethoxy)phenyl, 4- difluoromethoxyphenyl, benzofuran-2-yl, 4-cyanophenyl, 6-chloropyrid-3-yl, 4-methylsulfanylphenyl, 4-pyrrolidin-l-ylphenyl, 5-chlorothien-2-yl, 4-isopropenylcyclohex-l-enyl or l-chlorocuban-4-yl.
18. The compound of claim 1, wherein R is 4-chlorophenyl,
4-bromophenyl, 4-trifluoromethylphenyl or 4-trifluoromethoxyphenyl.
19. The compound of claim 1, wherein R6 is 4-chlorophenyl.
20. The compound of claim 1, wherein R7 and R8 are independently hydrogen or methyl.
21. The compound of claim 1, wherein R7 and R8 are hydrogen.
22. The compound of claim 1, wherein R9 is optionally substituted
Cό-io aryl or optionally substituted C6-ιo ar(Q-6)alkyl.
23. The compound of claim 1, wherein R9 is phenyl, 4-chlorophenyl, 4-chlorobenzyl, benzyl, cyclohexyl, cyclohexylmethyl, 4-hydroxyphenyl, pyridylmethyl, 4-fluorophenyl, 4-trifluoromethylphenyl, 4-iodobenzyl, 4-bromobenzyl, thien-2-yl, thien-2-ylmethyl, naphth-
2-ylmethyl, pyrid-2-ylethyl, 3-methylphenyl, 4-methylphenyl, 4-ethylphenyl, 4-chloro-3-fluorophenyl, 2-fluoro-4-trifluoromethylphenyl,
4-hydroxycarbonylphenyl, naphthalen-2-yl, naphthalen-1-yl, 4-iodophenyl, 4-bromophenyl, 3,4-dichlorophenyl, 2-chlorophenyl, 4-tert-butylphenyl, 4-isopropylphenyl, 3-chlorophenyl, 4-trifluoromethoxyphenyl,
3-hydroxyphenyl, 4-hydroxybenzyl, 4-trifluoromethylbenzyl, naphth- 1-ylmethyl, 6-chloropyrid-3-yl, or 6-methylpyrid-3-yl.
24. The compound of claim 1, wherein R9 is halophenyl or halobenzyl.
25. The compound of claim 1, wherein R9 is phenyl or 4-chlorophenyl.
26. The compound of claim 1, wherein R10 is -COORb or -CH2-
COORb, where Rb is hydrogen or Q-6 alkyl; or R10 is -COOM, or -CH2- COOM, where M is Na+ or K+.
27. The compound of claim 1, wherein R10 is -COORb or -CH2- COORb, where R is hydrogen, methyl, ethyl, propyl or tert-butyl.
28. The compound of claim 1, wherein R10 is -COOH or -COOM, where M is Na+ or K+.
29. The compound of claim 1, wherein R10 is -CH2OH or
-CH2CH2OH, or -CH2-CONRcRd or -CONRcRd, where Rc and Rd are independently hydrogen, methyl, ethyl, propyl, t-butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, aminomethyl, aminoethyl, aminopropyl, carboxymethyl, carboxyethyl, carboxypropyl, cyclopentyl, cyclohexyl, phenyl or benzyl.
30. The compound of claim 1, wherein R10 is -CH2-CONRcRd or -CONRcRd, where Rc and Rd are independently hydrogen, methyl, hydroxyethyl, 3-carboxypropyl, l-carboxy-2-methylpropyl, hydroxy, 4-carboxybutyl, 5-carboxypentyl, 2-(methoxycarbonyl)ethyl or 2-(hydroxyguanidino)ethyl.
31. The compound of claim 1, wherein said compound is selected from the group consisting of:
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid;
2-[7-bromo-3-(4-chloro-phenyl)-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -3-(4-chloro-phenyl)-propionic acid;
2-(4-chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetamide ; [7-chloro-3-(4-chloro-ρhenyl)-2,5-dioxo- 1 ,2,3 ,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -(4-chloro-phenyl)-acetic acid;
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-ethynyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -acetic acid;
[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-p-tolyl-acetic acid;
(4-chloro-3-fluoro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo- l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid;
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-ethyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e] [1 ,4]diazepin-4-yl]-acetic acid; (4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-isopropyl-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e] [ 1 ,4] diazepin-4-yl] -acetic acid; (4-bromo-phenyl)-[3-(4-chloro-phenyl)-7 -isopropyl-2,5-dioxo-l,2,3 ,5- tetrahydro-benzo [e] [1 ,4] diazepin-4-yl] -acetic acid;
[3-(4-chloro-3-fluoro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid; [3-(4-chlorophenyl)-7-phenyl-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -phenylacetic acid;
[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e][l,4]diazepin-4-yl]-(4-fluoro-phenyl)-acetic acid;
[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -(4-trifluoromethyl-phenyl)-acetic acid;
(4-chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)- l,2,3,5-tetrahydrobenzo[e][l,4] diazepin-4-yl] -acetic acid;
(4-chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethyl-phenyl)- l,2,3,5-tetrahydrobenzo[e][l,4]diazepin-4-yl]-acetic acid; [3-(4-bromo-phenyl)-7-iodo-2,5-dioxo-l ,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -(4-chloro-phenyl)-acetic acid;
[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l ,2,3 ,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] -(4-isopropyl-phenyl)-acetic acid;
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-cyano-2,5-dioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetic acid;
3-(4-chloro-phenyl)-4-(3-hydroxy- 1 -phenyl-propyl)-7-iodo-3 ,4- dihydro-lH-benzo[e][l,4]diazepine-2,5-dione;
2-(4-chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -N-hydroxy-acetamide ; [7-bromo-3-(4-chloro-phenyl)-2,5-dioxo- 1,2,3, 5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid;
[8-chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-l,2,3,5-tetrahydro- benzo[e] [1 ,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid;
5-{2-(4-chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo- l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetylamino}-pentanoic acid; 3-{2-(4-chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo- l,2,3,5-tetrahydro-benzo[e][l,4]diazepin-4-yl]-acetylamino}-propionic acid; 5-[4-[carboxy-(4-chloro-phenyl)-methyl]-3-(4-chloro-phenyl)-7-iodo- 2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][l,4]diazepin-l-yl]-pentanoic acid; and pharmaceutically-acceptable salts thereof.
32. The compound of claim 1, wherein said compound is selected from the group consisting of:
(4-chlorophenyl)-[3-(4-chlorophenyl)-7-iodo-5-oxo-l,2,3,5-tetrahydro- benzo [e] [ 1 ,4] diazepin-4-yl] acetic acid;
3-(4-chloro-phenyl)-3-[3-(4-chloro-ρhenyl)-7-iodo-5-oxo-l,2,3,5- tetrahydro-benzo [e] [ 1 ,4] diazepin-4-yl] -propionic acid;
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-5-oxo-2-thioxo-l,2,3,5- tetrahydro-benzo[e][l,4]diaze pin-4-yl] -acetic acid; 3-(4-chloro-phenyl)-4-[l-(4-chloro-phenyl)-2-hydroxy-ethyl]-7-iodo-
1 ,3 ,4,5-tetrahydro-benzo[e] [1 ,4]diazepin-2-one;
3-(4-chloro-phenyl)-4-[l-(4-chloro-phenyl)-2-hydroxy-ethyl]-7-iodo- 1,2,3 ,4-tetrahydro-benzo[e][l,4]diazepin-5-one; and pharmaceutically-acceptable salts thereof.
33. A compound according to any of claims 1-32, in the form of a hydrochloride, acetate, trifluoroacetate or fumarate salt.
34. A pharmaceutical composition, comprising: (a) a compound of any one of claims 1-33, or a salt, hydrate or prodrug thereof; and
(b) one or more pharmaceutically-acceptable excipients.
35. The composition of claim 34, wherein the composition is sterile.
36. The composition of claim 34, further comprising:
(c) at least one additional substance selected from the group consisting of synergists, stabilizing substances, antineoplastic agents, anticancer agents, and cytostatic agents.
37. The composition of claim 34, wherein said compound is present in an amount between about 0.5 and about 100 milligrams.
38. The composition of claim 34, suitable for administration by a subcutaneous, intravenous, intramuscular, intraperitoneal, buccal, or ocular route, rectally, parenterally, instrasystemically, intravaginally, topically, orally, or as an oral or nasal spray.
39. The composition of claim 34, suitable for parenteral administration, wherein said compound is present in an amount between about
0.5 and about 100 milligrams.
40. The composition of claim 34, suitable for parenteral administration, wherein said compound is present in an amount between about 0.5 and about 10 milligrams.
41. The composition of claim 34, suitable for oral administration, wherein said compound is present in an amount between about 0.5 and about 100 milligrams.
42. The composition of claim 34, suitable for oral administration, wherein said compound is present in an amount between about 25 and about 100 milligrams.
43. A method of inhibiting the binding of p53 to a protein encoded by hdm2, comprising contacting p53 or one or more proteins encoded by hdm2, with one or more compounds of any of claims 1-33, or a salt, hydrate or prodrug thereof.
44. A method of treating a condition that results from the inhibition of one or more functions of a cellular protein that induces apoptosis, induces cellular death, or regulates the cell cycle by an HDM2 protein, comprising administering to a patient in need of such treatment a pharmaceutically- effective amount of a compound of any of claims 1-33.
45. A method of inducing apoptosis, comprising contacting an animal with a composition comprising a pharmaceutically-effective amount of at least one compound of any of claims 1-33, or a salt, hydrate or prodrug thereof.
46. The method according to claim 45, wherein said composition further comprises at least one pharmaceutically-acceptable excipient.
47. A method of preventing or treating cancer or a condition that results from the uncontrolled proliferation of cells, comprising contacting an animal with (a) a composition comprising a pharmaceutically-effective amount of an antineoplastic agent, and (b) a compound of any of claims 1-33.
48. The method of claim 47, wherein said cancer or condition is selected from the group consisting of breast cancer, ovarian cancer, cervical carcinoma, endometrial carcinoma, choriocarcinoma, soft tissue sarcomas, osteosarcomas, rhabdomyosarcomas, leiomyomas, leiomyosarcomas, head and neck cancers, lung and bronchogenic carcinomas, brain tumors, neuroblastomas, esophogeal cancer, colorectal adenocarcinomas, bladder cancer, urothelial cancers, leukemia, lymphoma, malignant melanomas, oral squamous carcinoma, hepatoblastoma, glioblastoma, astrocytoma, medulloblastoma, Ewing's sarcoma, lipoma, liposarcoma, malignant fibroblast histoma, malignant Schwannoma, testicular cancers, thyroid cancers, Wilms' tumor, pancreatic cancers, colorectal adenocarcinoma, tongue carcinoma, gastric carcinoma, and nasopharyngeal cancers.
49. The method of claim 47, wherein said cancer or condition is selected from the group consisting of breast cancer, choriocarcinoma, soft tissue sarcomas, osteosarcomas, rhabdomyosarcomas, lipoma and liposarcoma.
50. A method of treating an inflammatory condition, comprising administering to a patient in need of such treatment a pharmaceutically- effective amount of a compound of any of claims 1-33.
51. A method of treating an autoimmune disease or condition, comprising administering to a patient in need of such treatment a pharmaceutically-effective amount of a compound of any of claims 1-33.
52. The method of claim 51, wherein said autoimmune disease or condition is selected from the group consisting of Hashimoto's thyroiditis,
Grave's disease, multiple sclerosis, pernicious anemia, Addison's disease, insulin-dependent diabetes mellitus, rheumatoid arthritis, systemic lupus erythematosus (SLE or lupus), and dermatomyositis, Crohn's disease, Wegener's granulomatosis, Anti-Glomerular Basement Membrane Disease, Antiphospholipid Syndrome, Dermatitis Herpetiformis, Allergic
Encephalomyelitis, Glomerulonephritis, Membranous Glomerulonephritis, Goodpasture Syndrome, Lambert-Eaton, Myasthenic Syndrome, Myasthenia Gravis, Bullous Pemphigoid, Polyendocrinopathies, Reiter's Disease and Stiff- Man Syndrome.
53. The method of claim 51, wherein said autoimmune disease or condition is rheumatoid arthritis or systemic lupus erythematosus.
54. The method according to any of claims 43-53, wherein said effective amount is between about 1.0 and about 100 milligrams per kilogram per day.
PCT/US2002/036208 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer WO2003041715A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
AU2002340464A AU2002340464B2 (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
HU0402003A HUP0402003A3 (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines, pharmaceutical compositions containing them and uses thereof
EP02778828A EP1443937B1 (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
SI200230733T SI1443937T1 (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
IL16169202A IL161692A0 (en) 2001-11-13 2002-11-13 14-benzodiazepine derivatives and pharmaceutical compositions containing the same
UA20040604569A UA76798C2 (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and use thereof for the treatment of cancer, pharmaceutical composition (variants) based thereon and method for treatment of diseases (variants)
NZ532463A NZ532463A (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
JP2003543602A JP4497921B2 (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and their use for the treatment of cancer
DE60227185T DE60227185D1 (en) 2001-11-13 2002-11-13 SUBSTITUTED 1,4-BENZODIAZEPINE AND ITS APPLICATION IN CANCER TREATMENT
DK02778828T DK1443937T3 (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines as well as their use in treating cancer
CA002466055A CA2466055A1 (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
BR0214048-9A BR0214048A (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and their uses for cancer treatment
MXPA04004500A MXPA04004500A (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer.
HR20040415A HRP20040415A2 (en) 2001-11-13 2004-05-07 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
NO20042146A NO20042146L (en) 2001-11-13 2004-05-25 Substituted 1,4-benzodiazepines and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33123501P 2001-11-13 2001-11-13
US60/331,235 2001-11-13

Publications (1)

Publication Number Publication Date
WO2003041715A1 true WO2003041715A1 (en) 2003-05-22

Family

ID=23293137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036208 WO2003041715A1 (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer

Country Status (26)

Country Link
US (2) US7067512B2 (en)
EP (1) EP1443937B1 (en)
JP (1) JP4497921B2 (en)
KR (1) KR20050044413A (en)
CN (1) CN1596114A (en)
AT (1) ATE398453T1 (en)
AU (1) AU2002340464B2 (en)
BR (1) BR0214048A (en)
CA (1) CA2466055A1 (en)
CY (1) CY1108352T1 (en)
DE (1) DE60227185D1 (en)
DK (1) DK1443937T3 (en)
ES (1) ES2309209T3 (en)
HR (1) HRP20040415A2 (en)
HU (1) HUP0402003A3 (en)
IL (1) IL161692A0 (en)
MX (1) MXPA04004500A (en)
NO (1) NO20042146L (en)
NZ (1) NZ532463A (en)
PL (1) PL370176A1 (en)
PT (1) PT1443937E (en)
RU (1) RU2004118243A (en)
SI (1) SI1443937T1 (en)
UA (1) UA76798C2 (en)
WO (1) WO2003041715A1 (en)
ZA (1) ZA200403082B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1712235A2 (en) * 2005-03-04 2006-10-18 Ortho-McNeil Pharmaceutical, Inc. Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction
JP2007521306A (en) * 2003-07-02 2007-08-02 コーラス ファーマ，インコーポレイティド Aztreonam L-lysine and process for preparing the same
WO2008072655A1 (en) 2006-12-14 2008-06-19 Daiichi Sankyo Company, Limited Imidazothiazole derivatives
WO2008122115A1 (en) * 2007-04-09 2008-10-16 Methylgene Inc. Inhibitors of histone deacetylase
US7572783B2 (en) 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
WO2009151069A1 (en) 2008-06-12 2009-12-17 第一三共株式会社 Imidazothiazole derivative having 4,7-diazaspiro[2.5]octane ring structure
US7834016B2 (en) 2004-09-22 2010-11-16 Janssen Pharmaceutica Nv Inhibitors of the interaction between MDM2 and p53
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
US9381238B2 (en) 2010-11-05 2016-07-05 University Of Dundee Method for improving the production of influenza viruses and vaccine seeds
WO2018138673A1 (en) * 2017-01-25 2018-08-02 Sorrento Therapeutics, Inc. Cell penetrating peptide inhibitors of p53-mdm2 interaction

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197893A1 (en) * 2002-10-16 2004-10-07 Carsten Schubert HDM2-inhibitor complexes and uses thereof
US7186713B2 (en) 2003-01-21 2007-03-06 Ecopia Biosciences, Inc. Farnesyl dibenzodiazepinones and methods of treating cancer using same
US7358241B2 (en) * 2003-01-21 2008-04-15 Thallion Pharmaceuticals, Inc. Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
CA2579971C (en) 2004-09-28 2018-02-13 Janssen Pharmaceutica N.V. A bacterial atp synthase binding domain
US7763604B2 (en) * 2005-05-16 2010-07-27 Thallion Pharma Ceuticals, Inc. Methods for administration of a farnesyl dibenzodiazepinone
CA2628193C (en) * 2005-11-01 2012-08-14 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
EP2001868B1 (en) 2006-03-22 2013-07-17 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
CA2644649C (en) 2006-03-22 2014-06-17 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
US8470785B2 (en) 2006-07-28 2013-06-25 St. Jude Children's Research Hospital Method for treating ocular cancer
WO2008014216A1 (en) 2006-07-28 2008-01-31 St. Jude Children's Research Hospital Method for treating ocular cancer
MX2009011923A (en) * 2007-05-10 2009-11-18 Amr Technology Inc Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin.
WO2008144981A1 (en) 2007-05-25 2008-12-04 Topharman Shanghai Co., Ltd. Methods and intermediates for preparing 4-acetyl-2,3,4,5-tetrahydro-1h-1,4-benzodiazepine
CN107021895A (en) * 2007-06-12 2017-08-08 尔察祯有限公司 Antiseptic
TW200922557A (en) 2007-08-06 2009-06-01 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53
ES2494366T3 (en) * 2008-02-22 2014-09-15 Otsuka Pharmaceutical Co., Ltd. Benzodiazepine compound and pharmaceutical composition
AR075235A1 (en) 2009-02-04 2011-03-16 Janssen Pharmaceutica Nv DERIVATIVES OF INDOL AS ANTICANCER AGENTS.
CN102321034B (en) * 2011-06-07 2014-08-13 中国人民解放军第二军医大学 Sulfobenzodiazepine compound and application thereof used as medicament
CN105693634B (en) * 2016-03-17 2018-12-11 清华大学 Compound and application thereof
WO2017214359A1 (en) * 2016-06-10 2017-12-14 Venenum Biodesign Llc Novel clostridium difficile toxin inhibitors
CN110317294B (en) * 2018-03-30 2021-06-18 长春理工大学 Triphenylamine temperature-sensitive fluorescent polymer and preparation method thereof
CN111995576A (en) * 2020-08-31 2020-11-27 三峡大学 Process for preparing polysubstituted nitrogen-containing heterocyclic compound
WO2023174374A1 (en) * 2022-03-16 2023-09-21 江苏恒瑞医药股份有限公司 Fused heterocyclic compound, and preparation method therefor and medical use thereof
CN117263873A (en) * 2022-06-15 2023-12-22 复旦大学 1, 4-benzodiazepine compounds and application thereof in preparation of antitumor drugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
WO2001010799A1 (en) * 1999-08-04 2001-02-15 Aventis Pharmaceutical Products Inc. Methods for preparing n-[(aliphatic or aromatic)carbonyl)]-2-aminoacetamide compounds and for cyclizing such compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
US5389631A (en) 1991-10-29 1995-02-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5441952A (en) 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
AU2446295A (en) 1994-04-15 1995-11-10 Glaxo Inc. A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
DE19653645A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
IL137571A0 (en) 1998-01-29 2001-07-24 Aventis Pharm Prod Inc Method for preparing an n-[(aliphatic or aromatic)carboxyl]-2-aminoacetamide compound and a cyclyzed compound
AU3894800A (en) 1999-03-23 2000-10-09 Axys Pharmaceuticals, Inc. Solid phase synthesis of benzodiazepine diones
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
ATE258439T1 (en) 1999-04-30 2004-02-15 Univ Michigan USE OF BENZODIAZEPINES TO TREAT APOPTOSIS-INDUCED AUTOIMMUNE DISEASES
WO2001004103A1 (en) 1999-07-13 2001-01-18 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
US6600016B1 (en) * 1999-08-24 2003-07-29 Advanced Syntech Llc Multifunctionalized solid support resins for synthesis of combinatorial libraries and method for using the same
AU2882801A (en) * 2000-01-28 2001-08-07 Kaken Pharmaceutical Co., Ltd. Azepine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
WO2001010799A1 (en) * 1999-08-04 2001-02-15 Aventis Pharmaceutical Products Inc. Methods for preparing n-[(aliphatic or aromatic)carbonyl)]-2-aminoacetamide compounds and for cyclizing such compounds

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4741487B2 (en) * 2003-07-02 2011-08-03 コーラス ファーマ，インコーポレイティド Aztreonam L-lysine and process for preparing the same
JP2007521306A (en) * 2003-07-02 2007-08-02 コーラス ファーマ，インコーポレイティド Aztreonam L-lysine and process for preparing the same
US7572783B2 (en) 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
US8404683B2 (en) 2004-09-22 2013-03-26 Janssen Pharmaceutical N.V. Inhibitors of the interaction between MDM2 and P53
US7834016B2 (en) 2004-09-22 2010-11-16 Janssen Pharmaceutica Nv Inhibitors of the interaction between MDM2 and p53
EP1712235A3 (en) * 2005-03-04 2007-03-21 Ortho-McNeil Pharmaceutical, Inc. Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction
EP1712235A2 (en) * 2005-03-04 2006-10-18 Ortho-McNeil Pharmaceutical, Inc. Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction
WO2008072655A1 (en) 2006-12-14 2008-06-19 Daiichi Sankyo Company, Limited Imidazothiazole derivatives
WO2008122115A1 (en) * 2007-04-09 2008-10-16 Methylgene Inc. Inhibitors of histone deacetylase
AU2008235212B2 (en) * 2007-04-09 2014-01-16 Methylgene Inc. Inhibitors of histone deacetylase
US9096565B2 (en) 2007-04-09 2015-08-04 Methylgene Inc. Inhibitors of histone deacetylase
WO2009151069A1 (en) 2008-06-12 2009-12-17 第一三共株式会社 Imidazothiazole derivative having 4,7-diazaspiro[2.5]octane ring structure
US9381238B2 (en) 2010-11-05 2016-07-05 University Of Dundee Method for improving the production of influenza viruses and vaccine seeds
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2018138673A1 (en) * 2017-01-25 2018-08-02 Sorrento Therapeutics, Inc. Cell penetrating peptide inhibitors of p53-mdm2 interaction
US10583193B2 (en) 2017-01-25 2020-03-10 Sorrento Therapeutics, Inc. Cell penetrating peptide inhibitors of p53-MDM2 interaction

Also Published As

Publication number Publication date
KR20050044413A (en) 2005-05-12
US7067512B2 (en) 2006-06-27
DK1443937T3 (en) 2008-10-20
SI1443937T1 (en) 2009-02-28
NZ532463A (en) 2007-02-23
MXPA04004500A (en) 2004-08-11
HUP0402003A2 (en) 2005-02-28
PT1443937E (en) 2008-09-23
HRP20040415A2 (en) 2005-04-30
PL370176A1 (en) 2005-05-16
JP4497921B2 (en) 2010-07-07
ATE398453T1 (en) 2008-07-15
CY1108352T1 (en) 2014-02-12
IL161692A0 (en) 2004-09-27
NO20042146L (en) 2004-08-11
US20060148792A1 (en) 2006-07-06
ES2309209T3 (en) 2008-12-16
RU2004118243A (en) 2006-01-10
EP1443937A1 (en) 2004-08-11
CA2466055A1 (en) 2003-05-22
EP1443937B1 (en) 2008-06-18
AU2002340464B2 (en) 2008-03-13
DE60227185D1 (en) 2008-07-31
HUP0402003A3 (en) 2005-06-28
CN1596114A (en) 2005-03-16
JP2005509005A (en) 2005-04-07
UA76798C2 (en) 2006-09-15
BR0214048A (en) 2004-10-13
ZA200403082B (en) 2005-04-22
US20030109518A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
EP1443937B1 (en) Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
AU2002340464A1 (en) Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
WO2003095625A2 (en) Method for cytoprotection through mdm2 and hdm2 inhibition
CN100357278C (en) Substituted triazole diamine derivatives as kinase inhibitors
US20050227932A1 (en) Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US20060235007A1 (en) Substituted 1,4-diazepines and uses thereof
JP2007525457A (en) Substituted 1,4-diazepines and uses thereof
JPH11508888A (en) Piperazine derivatives as therapeutics
EP2096111A1 (en) Pyrazoles and use thereof as drugs
US20040127502A1 (en) Use of GAL3 antagonist for treatment of depression
EP2140862A2 (en) Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods
US20040110821A1 (en) GAL3 receptor antagonists for the treatment of affective disorders
AU2002249872B2 (en) Substituted triazole diamine derivatives as kinase inhibitors
AU2002249872A1 (en) Substituted triazole diamine derivatives as kinase inhibitors
UA81271C2 (en) 2-pyridone derivatives as inhibitors of neutrophile elastase, process for the preparation thereof and pharmaceutical composition based thereon
EP1712550A2 (en) Substituted triazole diamine derivatives as kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004/03082

Country of ref document: ZA

Ref document number: 200403082

Country of ref document: ZA

Ref document number: 532463

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 563/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 161692

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2466055

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: P20040415A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004500

Country of ref document: MX

Ref document number: 2003543602

Country of ref document: JP

Ref document number: 1020047007168

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002778828

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002340464

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20028239156

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 04055324

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: 2002778828

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1-2004-500683

Country of ref document: PH